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PREFACE
GENERAL INTRODUCTION 
AND OUTLINE OF THIS THESIS
0
INTRODUCTION
One of the persisting key research issues in the design of drug delivery systems is how to achieve
significant cytoplasmic delivery of drug molecules. Many small drug molecules are readily taken up
into cells by passive diffusion across cell membranes, but a growing number of pharmacologically
active agents derived from the emerging field of biotechnology such as proteins, peptides and
nucleic acids cannot easily pass biological membranes due to their unfavorable physicochemical
characteristics.Therefore, these biotherapeutics rely on delivery systems that allow translocation
over cellular membranes.
Many different drug delivery systems have been investigated for cytosolic drug delivery [1-5]. From
these drug delivery systems liposomes have attracted considerable attention [4,6-8]. Liposomes are
spherical vesicles, consisting of one (unilamellar) or more (multilamellar) concentric bilayers
enclosing one or more aqueous compartments. Both the aqueous spaces and the lipidic bilayers of
liposomes can accommodate drug molecules allowing entrapment of both hydrophilic and
hydrophobic compounds.The composition of the lipid bilayers can be manipulated to influence the
physicochemical characteristics of the liposomes (e.g. surface charge, sensitivity to pH changes, and
bilayer rigidity) [9,10].
For selective drug delivery, liposomes have been targeted to specific cell types by conjugating
ligands to the surface of liposomes that recognize specific molecules on target cells [11-16].The
most widely used molecules for targeting liposomes have been monoclonal antibodies as these
molecules often have high affinity and specificity for the cell surface antigens against which they
have been raised. As an example, antibody-targeted liposomes, also referred to as
immunoliposomes, have been used for the selective drug delivery to cancer cells by targeting to
tumor-associated antigens [17-20]. However, specific binding of liposomes to target cells is not
enough. After target cell binding, the entrapped drugs must be able to reach the cellular interior,
often the cytoplasm of target cells. Previous work from our group described in two theses [21,22]
has demonstrated that immunoliposomes directed against cell-surface epitopes that were
preferentially expressed by certain types of carcinoma cells specifically bound to ovarian carcinoma
(OVCAR-3) cells both in vitro and in vivo. However, despite efficient tumor cell binding, no
therapeutic advantages were observed in vivo when anticancer agents were entrapped in these
immunoliposomes.The reason for lack of therapeutic benefit is most likely due to inefficient
intracellular delivery of immunoliposome-entrapped drug after tumor cell binding. Clearly –as
exemplified with our own findings– there is a strong need for drug delivery systems that guarantee
efficient delivery of drugs from cell-bound immunoliposomes into the cytoplasm of target cells.
Cytosolic delivery of immunoliposome-entrapped drugs may be obtained in different ways as
illustrated in Figure 1.Two of these potential routes, extracellular release of drugs from cell-surface
bound immunoliposomes and selective transfer of lipophilic drugs, are only applicable to drug
molecules which intrinsically are able to cross cell membranes. Another route, which is
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independent of the capacity of entrapped drug to cross cell membranes and therefore applicable to
a broader spectrum of drugs, is fusion of the liposomal membrane with the plasma membrane of
target cells after binding of the immunoliposomes to specific receptors on the cell surface.
However, fusion between plasma membranes and liposomal membranes is very unlikely to happen
spontaneously and therefore relies on molecules that can disrupt or penetrate the plasma
membrane. Incorporation of viral fusion proteins that allow fusion of liposomes at neutral pH with
the plasma membranes of target cells seems to be an attractive option [23,24] but appears to be
difficult to realize in a targeted context [25-27]. Moreover, a major impediment of direct plasma
membrane penetration is that it may harness the integrity of the plasma membrane thereby
disturbing the electrochemical potential generated by the asymmetric distribution of ions across the
plasma membrane. Perforation of endosomal membranes to obtain cytosolic drug delivery is
thought to be less injurious to cells and hence will be less cytotoxic than perforating the plasma
membrane.
Immunoliposomes may also deliver their drug contents into the cytosol of target cells via the route
of receptor-mediated endocytosis [28-31]. Receptor-mediated endocytosis is a process utilized by
cells for the uptake of specific substances such as iron, lipids, proteins and peptides [32,33].
Internalization is initiated by binding of the ligand to its receptor, which provokes receptor
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Figure 1 — Schematic representation of potential ways by which targeted immunoliposomes can achieve cytosolic drug
delivery. 1. Extracellular release of drug, followed by subsequent active or passive transport into the cell. 2. Selective transfer
of lipophilic compounds from the liposomal bilayer to the plasma membrane. 3. Fusion of the liposomal membrane with the
plasma membrane. 4. Receptor-mediated endocytosis of immunoliposomes with subsequent cytosolic release of liberated drug
molecules by passive diffusion out of the endosomes or via low pH-induced endosomal membrane destabilization or fusion.
1 - extracellular
content release
2 - transfer of
lipophilic
compounds
4 - liposome
internalization
3 - membrane
fusion
intracellular 
fusion
nucleus
clustering and subsequent activation of signal transduction pathways that induce endocytosis of the
receptor with its bound ligand by coated pits.The cargo (i.e. the receptor-bound ligand) is,
dependent on the receptor type, processed via different pathways in different intracellular
organelles.The cargo may be recycled (e.g. transferrin), degraded (e.g. LDL and growth factors),
transported to the secretory pathway (e.g. bacterial toxins), or, in a pathway specific for polarized
cells, transcytosed to the contralateral side (e.g. immunoglobulins). Many reports have
demonstrated that immunoliposomes are taken up by receptor-mediated endocytosis provided that
the receptor allows internalization and that liposomes are small enough (<150 nm) [34-40].
Unfortunately, following receptor-mediated endocytosis of the immunoliposome-drug-receptor
complex, the complex enters into an acidic endosomal compartment and eventually into an acidic
lysosomal compartment where immunoliposomes and often also the entrapped drugs will be
degraded [37,41-43].Therefore, mechanisms that allow endosomal escape of liposome-entrapped
drugs into the cytoplasm are often required for effective drug delivery. As illustrated in Figure 1,
low-pH induced membrane fusion between internalized liposomes and endosomes is an attractive
option to achieve cytosolic drug delivery after receptor-mediated endocytosis.
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Figure 2, panel A — Schematic representation of a cross-section through an influenza virus A particle. The influenza virus
particle consists of a lipid envelope containing the viral spike proteins hemagglutinin (HA) and neuraminidase (NA).
Homotrimers of HA form one rod-like spike. The matrix protein covers the internal layer of the lipid envelope, which engulfs
the nucleocapsids of the virion. Panel B — schematic representation of the quaternary structure of influenza virus HA
monomer at neutral pH. The protein is composed of two disulfide-linked subunits, HA1 and HA2. HA1 forms the head of the
spike and contains the sialic acid binding pocket. HA2, which forms the stem of the spike, contains the fusion peptide domain
at its N-terminus. This peptide domain is thought to play an important role in the membrane fusion mechanism.
A B
ENDOSOMAL ESCAPE
In developing immunoliposomes that are able to fuse with endosomal membranes, much can be
learned from viruses. Several enveloped viruses enter cells by a process of receptor-mediated
endocytosis, routing the viral particles into the endosomes and eventually lysosomes [44-46].The
low pH within the endosomes triggers the fusion of viral envelopes with the endosomal membrane,
thereby releasing the viral nucleocapsids into the cytoplasm of host cells. Both the adhesion of virus
particles to the host cell membrane, which triggers internalization, and the low-pH induced fusion
reaction are mediated by viral spike glycoproteins [47,48]. One of the best-characterized viral
fusion proteins is undoubtedly the influenza virus hemagglutinin (HA) (Figure 2) [49-52].Trimers
of HA make up the rod-like spikes, which abundantly cover the viral envelope (approximately 500
spikes per virus particle). A HA monomer, whose quaternary structure has been elucidated by X-
ray crystallography [53], is built up of two disulfide-linked subunits, HA1 and HA2 (Figure 2). HA1
forms the head of the spike and contains the sialic acid binding pocket and most of the major
antigenic determinants. HA2 forms the membrane-anchored stem region that contains a stretch of
20 hydrophobic amino acids (the so-called fusion peptide) at its N-terminal end, which is buried
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Figure 3 — Schematic representation of the structural changes in HA2 induced at acidic pH. Equivalent regions of HA2 at
neutral and acidic pH are indicated with the same letter. Regions of α-helix are indicated by cylinders, and β-structure is
shown as arrows. The first β-strand of HA1, which is disulphide-linked to β-strand F of HA2, is labeled 1. Structures are
aligned on the C region, which is unaffected by the conformational change. The location of the N-terminal fusion peptide
domain is indicated with a black triangle. Adapted from Skehel et al. [55].
neutral pH
low pH
fusion peptide
fusion peptide
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within the trimers approximately 3.5 nm from the viral membrane. Upon exposure to low pH
within the endosomes, a conformational change occurs in the HA-protein causing dissociation of
the globular heads and transposition of the fusion peptide (Figure 3) [54-57].The fusion peptide
comes in close proximity of the target membrane and, due to its hydrophobicity, will insert into the
target membrane [58,59].The fusion peptide plays an important role in the fusion process, as it is
the part of the protein that destabilizes the target membrane and presumably also the viral
membrane. Although much research has been performed on the fusion mechanism of influenza
virus, the exact mechanisms underlying the fusion process are still not completely understood.
Synthetic analogs of the N-terminal fusogenic peptide of the influenza virus HA2 subunit have been
shown to destabilize and/or fuse membranes of liposomes exclusively at low pH [60-63].They are
hydrophobic peptides rich in glycine and alanine residues alternated with several acidic amino acids.
Upon exposure to low pH the acidic amino acids become protonated with loss of repulsive forces
between the negatively charged side groups (Figure 4).This allows the fusogenic peptides to adopt
an α-helix where the smaller hydrophobic glycine residues are all located at one side of the helix
and the larger hydrophobic residues on the other side (Figure 4).This so-called glyasymmetry
seems to be important for oblique or “sided” insertion of peptides into membranes [64]. It is
thought that oblique insertion of fusion peptides into the membrane increases the negative
curvature strain of the lipid bilayer and facilitates local bilayer rearrangements [65]. Most of the
synthetic analogs of the influenza virus fusion peptide were able to destabilize bilayers at low pH
causing leakage of liposome-entrapped solutes. In addition, some of them were able to induce lipid
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Figure 4 — Conformation of the N-terminal fusogenic peptide of influenza virus hemagglutinin subunit HA2 at pH 7 and pH
5. At pH 7 the glutamic acid and aspartic acid side chains are negatively charged. This electrostatic repulsion is thought to
prevent α-helix formation. At pH 5, the fusogenic peptide is thought to adopt an α-helical conformation as determined by CD-
measurements. Within the α-helix, glycine residues are located at one side of the helix whereas the larger, more hydrophobic
amino acids are located at the opposite side. Adapted from Oberhauser et al. [69].
pH 7.4 pH 5.0
mixing and/or aqueous contents mixing between liposomes, which is indicative for fusion [66-68].
Moreover, synthetic analogs of the influenza virus fusion peptide have been successfully used to
enhance the endosomal escape of polylyisine/DNA complexes [62,69-71] and DNA from liposomes
[72]. However, it should be mentioned that in no case the efficiency of intracellular delivery
achieved with these synthetic peptides equals the efficiency of naturally evolved translocation or
fusion mechanisms of viruses. Nevertheless, synthetic pH-dependent fusion peptides offer an
attractive opportunity to enhance cytosolic delivery of drugs by facilitating endosomal escape of
compounds following their endocytic uptake.
AIMS AND OUTLINE OF THE THESIS
The principal aim of the research described in this thesis is to develop targeted liposome systems
able to mediate cytosolic drug delivery into tumor cells.The research is focused on both antibody-
mediated targeting of liposomes to tumor-associated cell surface receptors that results in receptor-
mediated endocytosis of the immunoliposomes and on the subsequent cytosolic delivery of their
contents via endosomal escape mechanisms. In particular, fusion mechanisms are exploited to
realize endosomal escape.The molecules delivered via this approach (DTA, plasmid DNA) are
representative molecules of the growing class of biotherapeutics that have poor membrane
permeability characteristics.
A detailed overview of the literature dealing with immunoliposome-mediated targeting of
anticancer agents to tumor cells is given in chapter 1. Besides summarizing the current status of
the in vivo application of immunoliposomes in tumor models, new developments on the utilization
of immunoliposomes for the treatment of cancer are highlighted.
Chapter 2 deals with antibody-mediated targeting of liposomes to intercellular adhesion molecule-
1 (ICAM-1) on bronchial epithelial cells. Specific attention is given to the issue of internalization
and the impact on drug delivery to sites of inflammation.
The appendix to chapter 2 extends the internalizing receptor-targeting concept to ovarian
carcinoma cells, as the latter cells are the main target cells in this thesis. Several receptors
expressed by OVCAR-3 cells are evaluated regarding their usefulness for inducing internalization of
immunoliposomes.
In chapters 3 and 4 the influenza virus HA protein is central to the development of antibody-
targeted fusogenic liposomes. Reconstituted envelopes of influenza virus particles (virosomes)
containing HA have been successfully used for the delivery of proteins and genes into the cytosol of
cells. However, as cellular uptake of these virosomes is mediated by the interaction of HA with
sialic acid residues, which are ubiquitous on the surface of many cell types, specific targeting of
influenza virosomes has been problematic. In chapter 3 a 2-step strategy is followed to target or
re-direct influenza virosomes towards ovarian carcinoma cells.The first step involves incorporation
of the hydrophilic polymer poly(ethylene glycol) (PEG) conjugated to phospholipids into the
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membrane of influenza virosomes.The surface-exposed PEG layer should prevent HA from
interacting with sialic acid residues on target cell membranes. Second, the PEG-layer is meant to
function as a spacer to which specific antibodies can be conjugated for targeting purposes.
As the conventional method of influenza virosome preparation, which is used in chapter 3, does not
allow efficient encapsulation of hydrophilic drug molecules into the virosomes a different method
to prepare HA-containing liposomes (i.e. virosomes) compatible with high encapsulation efficiencies
is explored in chapter 4.
The use of the dimeric fusion peptide (diINF-7) to enhance endosomal escape of the bacterial toxin
fragment DTA after receptor-mediated endocytosis of DTA-containing immunoliposomes is
investigated in chapter 5. diINF-7 is a synthetic analogue of the N-terminal fusion peptide domain
of the influenza virus.To ascertain effective concentrations of this fusion peptide in the endosomes
the diINF-7 peptides are co-encapsulated with DTA into liposomes targeted towards an
internalizing receptor on OVCAR-3 cells.
Chapter 6 is devoted to the issue of targeted delivery of plasmid DNA to ovarian cancer cells.The
non-viral gene carrier poly(2-(dimethylethylamino)ethyl methacrylate) (p(DMAEMA)), which has
been developed in our department, has been shown to efficiently condense plasmid DNA into small
positively charged particles. In vitro these so-called polyplexes are internalized by cells due to
electrostatic interactions with cell membranes, which eventually results in gene expression.
p(DMAEMA)-based polyplexes have two major disadvantages when used for the delivery of genes
to tumor cells. First, they are difficult to target to specific cell types due to the predominant
electrostatic interaction with cell membranes, even if specific ligands have been attached. Second,
intraperitoneal administration of polyplexes in mice bearing OVCAR-3 cells in the peritoneal cavity
resulted in loss of transfection activity. Evidence has been collected pointing to inactivation by
polyanions such as hyaluronic acid present in the intraperitoneal tumor ascitic fluid. Attempts are
made to solve these problems by coating polyplexes with anionic lipids using a detergent-removal
method followed by conjugation of a tumor-specific antibody to achieve tumor cell targeting.
The last chapter of this thesis, chapter 7, provides a summary and general discussion of the
results. Suggestions for future research are given as well.
16
re
fe
re
nc
e 
lis
t
REFERENCE LIST
1 Gharat, L., Taneja, R., Weerapreeyakul, N., Rege, B., Polli, J., and Chikhale, P.J. (2001): Targeted drug delivery systems 6:
Intracellular bioreductive activation, uptake and transport of an anticancer drug delivery system across intestinal 
Caco-2 cell monolayers. Int.J.Pharm., 219:1-10.
2 Rapoport, N.Y., Herron, J.N., Pitt, W.G., and Pitina, L. (1999): Micellar delivery of doxorubicin and its paramagnetic
analog, ruboxyl, to HL-60 cells: effect of micelle structure and ultrasound on the intracellular drug uptake.
J.Control.Release, 58:153-162.
3 Duncan, R., Rejmanova, P., Kopecek, J., and Lloyd, J.B. (1981): Pinocytic uptake and intracellular degradation of N-(2-
hydroxypropyl)methacrylamide copolymers. A potential drug delivery system. Biochim.Biophys.Acta, 678:143-150.
4 Gerasimov, O.V., Boomer, J.A., Qualls, M.M., and Thompson, D.H. (1999): Cytosolic drug delivery using pH- and light-
sensitive liposomes. Adv.Drug.Del.Rev., 38:317-338.
5 van de Wetering, P., Cherng, J.Y., Talsma, H., Crommelin, D.J., and Hennink, W.E. (1998): 2-(Dimethylamino)ethyl
methacrylate based (co)polymers as gene transfer agents. J.Control.Release, 53:145-153.
6 Maruyama, K. (2000): In vivo targeting by liposomes. Biol.Pharm.Bull., 23:791-799.
7 Langner, M. and Kral, T.E. (1999): Liposome-based drug delivery systems. Pol.J.Pharmacol., 51:211-222.
8 Storm, G. and Crommelin, D.J.A. (1998): Liposomes: quo vadis? Pharm.Sci.Tech.Today, 1:19-31.
9 Vemuri, S. and Rhodes, C.T. (1995): Preparation and characterization of liposomes as therapeutic delivery systems: 
a review. Pharm.Acta Helv., 70:95-111.
10 Gregoriadis, G. (1995): Engineering liposomes for drug delivery: progress and problems. Trends.Biotechnol., 
13:527-537.
11 Huang, A., Huang, L., and Kennel, S.J. (1980): Monoclonal antibody covalently coupled with fatty acid. A reagent for in
vitro liposome targeting. J.Biol.Chem., 255:8015-8018.
12 Martin, F.J., Hubbell, W.L., and Papahadjopoulos, D. (1981): Immunospecific targeting of liposomes to cells: a novel and
efficient method for covalent attachment of Fab’ fragments via disulfide bonds. Biochemistry, 20:4229-4238.
13 Martin, F.J. and Papahadjopoulos, D. (1982): Irreversible coupling of immunoglobulin fragments to preformed vesicles. An
improved method for liposome targeting. J.Biol.Chem., 257:286-288.
14 Sullivan, S.M., Connor, J., and Huang, L. (1986): Immunoliposomes: preparation, properties, and applications.
Med.Res.Rev., 6:171-195.
15 Forssen, E. and Willis, M. (1998): Ligand-targeted liposomes. Adv.Drug.Del.Rev., 29:249-271.
16 Allen, T.M., Hansen, C.B., and Stuart, D.D. (1998): Targeted sterically stabilized liposomal drug delivery. In: Medical
Applications of Liposomes, edited by D.D. Lasic, et al, pp. 297-323. Elsevier, Amsterdam.
17 Park, J.W., Hong, K., Kirpotin, D.B., Meyer, O., Papahadjopoulos, D., and Benz, C.C. (1997): Anti-HER2 immunoliposomes for
targeted therapy of human tumors. Cancer Lett., 118:153-160.
18 Lopes de Menezes, D.E., Pilarski, L.M., and Allen, T.M. (1998): In vitro and in vivo targeting of immunoliposomal
doxorubicin to human B-cell lymphoma. Cancer Res. , 58:3320-3330.
17
pr
ef
ac
e
19 Koning, G.A., Gorter, A., Scherphof, G., and Kamps, J.A.A.M. (1999): Antiproliferative effect of immunoliposomes
containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells. Br.J.Cancer, 80:1718-1725.
20 Tseng, Y.L., Hong, R.L., Tao, M.H., and Chang, F.H. (1999): Sterically stabilized anti-idiotype immunoliposomes improve the
therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int.J.Cancer, 80:723-730.
21 Nässander, U. K. Liposomes, immunoliposomes, and ovarian carcinoma. Thesis. 1991. Utrecht University. 
22 Vingerhoeds, M. H. Immunoliposomes against ovarian carcinoma: from targeting to antitumor activity. Thesis. 1995.
Utrecht University. 
23 Mizuguchi, H., Nakanishi, M., Nakanishi, T., Nakagawa, T., Nakagawa, S., and Mayumi, T. (1996): Application of fusogenic
liposomes containing fragment A of diphtheria toxin to cancer therapy. Br.J.Cancer, 73:472-476.
24 Ponimaskin, E., Bareesel, K.K., Markgraf, K., Reszka, R., Lehmann, K., Gelderblom, H.R., Gawaz, M., and Schmidt, M.F.
(2000): Sendai virosomes revisited: reconstitution with exogenous lipids leads to potent vehicles for gene transfer.
Virology, 269:391-403.
25 Dzau, V.J., Mann, M.J., Morishita, R., and Kaneda, Y. (1996): Fusigenic viral liposome for gene therapy in cardiovascular
diseases. Proc.Natl.Acad.Sci.U.S.A., 93:11421-11425.
26 Kaneda, Y., Saeki, Y., and Morishita, R. (1999): Gene therapy using HVJ-liposomes: the best of both worlds?
Mol.Med.Today, 5:298-303.
27 Kaneda, Y. (2000): Virosomes: evolution of the liposome as a targeted drug delivery system. Adv.Drug.Del.Rev., 
43:197-205.
28 Mastrobattista, E., Storm, G., van Bloois, L., Reszka, R., Bloemen, P.G., Crommelin, D.J., and Henricks, P.A. (1999): Cellular
uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells.
Biochim.Biophys.Acta, 1419:353-363.
29 Kirpotin, D., Park, J.W., Hong, K., Zalipsky, S., Li, W.L., Carter, P., Benz, C.C., and Papahadjopoulos, D. (1997): Sterically
stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry, 36:66-
75.
30 Huwyler, J., Wu, D., and Pardridge, W.M. (1996): Brain drug delivery of small molecules using immunoliposomes.
Proc.Natl.Acad.Sci.U.S.A., 93:14164-14169.
31 Heath, T.D., Montgomery, J.A., Piper, J.R., and Papahadjopoulos, D. (1983): Antibody-targeted liposomes: increase in
specific toxicity of methotrexate-gamma-aspartate. Proc.Natl.Acad.Sci.U.S.A., 80:1377-1381.
32 Goldstein, J.L., Anderson, R.G., and Brown, M.S. (1979): Coated pits, coated vesicles, and receptor-mediated endocytosis.
Nature, 279:679-685.
33 Okamoto, C.T. (1998): Endocytosis and transcytosis. Adv.Drug.Del.Rev., 29:215-228.
34 Suzuki, H., Zelphati, O., Hildebrand, G., and Leserman, L. (1991): CD4 and CD7 molecules as targets for drug delivery from
antibody bearing liposomes. Exp.Cell Res., 193:112-119.
35 Matthay, K.K., Abai, A.M., Cobb, S., Hong, K., Papahadjopoulos, D., and Straubinger, R.M. (1989): Role of ligand in antibody-
directed endocytosis of liposomes by human T- leukemia cells. Cancer Res., 49:4879-4886.
36 Berinstein, N., Matthay, K.K., Papahadjopoulos, D., Levy, R., and Sikic, B.I. (1987): Antibody-directed targeting of liposomes
to human cell lines: role of binding and internalization on growth inhibition. Cancer Res., 47:5954-5959.
18
re
fe
re
nc
e 
lis
t
37 Derksen, J.T., Morselt, H.W., and Scherphof, G.L. (1987): Processing of different liposome markers after in vitro uptake of
immunoglobulin-coated liposomes by rat liver macrophages. Biochim.Biophys.Acta, 931:33-40.
38 Leserman, L.D., Weinstein, J.N., Blumenthal, R., and Terry, W.D. (1980): Receptor-mediated endocytosis of antibody-
opsonized liposomes by tumor cells. Proc.Natl.Acad.Sci.U.S.A., 77:4089-4093.
39 Lopes de Menezes, D.E., Pilarski, L.M., Belch, A.R., and Allen, T.M. (2000): Selective targeting of immunoliposomal
doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim.Biophys.Acta, 1466:205-220.
40 Lundberg, B.B., Griffiths, G., and Hansen, H.J. (2000): Specific binding of sterically stabilized anti-B-cell immunoliposomes
and cytotoxicity of entrapped doxorubicin. Int.J.Pharm., 205:101-108.
41 Daleke, D.L., Hong, K., and Papahadjopoulos, D. (1990): Endocytosis of liposomes by macrophages: binding, acidification
and leakage of liposomes monitored by a new fluorescence assay. Biochim.Biophys.Acta, 1024:352-366.
42 Straubinger, R.M., Papahadjopoulos, D., and Hong, K.L. (1990): Endocytosis and intracellular fate of liposomes using
pyranine as a probe. Biochemistry, 29:4929-4939.
43 Yoshimura, T., Shono, M., Imai, K., and Hong, K. (1995): Kinetic analysis of endocytosis and intracellular fate of liposomes
in single macrophages. J.Biochem.(Tokyo)., 117:34-41.
44 Hoekstra, D. and Kok, J.W. (1989): Entry mechanisms of enveloped viruses. Implications for fusion of intracellular
membranes. Biosci.Rep., 9:273-305.
45 Marsh, M. (1984): The entry of enveloped viruses into cells by endocytosis. Biochem.J., 218:1-10.
46 Helenius, A. and Marsh, M. (1982): Endocytosis of enveloped animal viruses. Ciba.Found.Symp., 59-76.
47 White, J.M. (1992): Membrane fusion. Science, 258:917-924.
48 White, J.M. (1990): Viral and cellular membrane fusion proteins. Annu.Rev.Physiol., 52:675-697:675-697.
49 Ramalho, S. and de, L. (1998): The influenza virus hemagglutinin: a model protein in the study of membrane fusion.
Biochim.Biophys.Acta, 1376:147-154.
50 Webster, R.G. and Rott, R. (1987): Influenza virus A pathogenicity: the pivotal role of hemagglutinin. Cell, 50:665-666.
51 Wiley, D.C. and Skehel, J.J. (1987): The structure and function of the hemagglutinin membrane glycoprotein of influenza
virus. Annu.Rev.Biochem., 56:365-394.
52 Ward, C.W. (1981): Structure of the influenza virus hemagglutinin. Curr.Top.Microbiol.Immunol., 94-95:1-74.
53 Wilson, I.A., Skehel, J.J., and Wiley, D.C. (1981): Structure of the haemagglutinin membrane glycoprotein of influenza
virus at 3 Å resolution. Nature, 289:366-373.
54 Skehel, J.J., Bayley, P.M., Brown, E.B., Martin, S.R., Waterfield, M.D., White, J.M., Wilson, I.A., and Wiley, D.C. (1982):
Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion.
Proc.Natl.Acad.Sci.U.S.A., 79:968-972.
55 Skehel, J.J. and Wiley, D.C. (1995): Influenza viruses and cell membranes. Am.J.Respir.Crit.Care Med., 152:S13-5.
56 Sato, S.B., Kawasaki, K., and Ohnishi, S. (1983): Hemolytic activity of influenza virus hemagglutinin glycoproteins
activated in mildly acidic environments. Proc.Natl.Acad.Sci.U.S.A., 80:3153-3157.
57 Doms, R.W., Helenius, A., and White, J. (1985): Membrane fusion activity of the influenza virus hemagglutinin. 
The low pH-induced conformational change. J.Biol.Chem., 260:2973-2981.
19
pr
ef
ac
e
58 Harter, C., James, P., Bachi, T., Semenza, G., and Brunner, J. (1989): Hydrophobic binding of the ectodomain of influenza
hemagglutinin to membranes occurs through the “fusion peptide”. J.Biol.Chem., 264:6459-6464.
59 Stegmann, T., Delfino, J.M., Richards, F.M., and Helenius, A. (1991): The HA2 subunit of influenza hemagglutinin inserts
into the target membrane prior to fusion. J.Biol.Chem., 266:18404-18410.
60 Düzgünes, N. and Gambale, F. (1988): Membrane action of synthetic N-terminal peptides of influenza virus hemagglutinin
and its mutants. FEBS Lett., 227:110-114.
61 Clague, M.J., Knutson, J.R., Blumenthal, R., and Herrmann, A. (1991): Interaction of influenza hemagglutinin amino-
terminal peptide with phospholipid vesicles: a fluorescence study. Biochemistry, 30:5491-5497.
62 Wagner, E., Plank, C., Zatloukal, K., Cotten, M., and Birnstiel, M.L. (1992): Influenza virus hemagglutinin HA-2 N-terminal
fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-
transfer vehicle. Proc.Natl.Acad.Sci.U.S.A., 89:7934-7938.
63 Düzgünes, N. (1993): Synthetic peptides as probes of function of viral envelope proteins. Methods Enzymol., 
221:82-95:82-95.
64 Fujii, G. (1999): To fuse or not to fuse: the effects of electrostatic interactions, hydrophobic forces, and structural
amphiphilicity on protein-mediated membrane destabilization. Adv.Drug.Del.Rev., 38:257-277.
65 Siegel, D.P. (1999): The modified stalk mechanism of lamellar/inverted phase transitions and its implications for
membrane fusion. Biophys.J., 76:291-313.
66 Matsumoto, T. (1999): Membrane destabilizing activity of influenza virus hemagglutinin-based synthetic peptide:
implications of critical glycine residue in fusion peptide. Biophys.Chem., 79:153-162.
67 Steinhauer, D.A., Wharton, S.A., Skehel, J.J., and Wiley, D.C. (1995): Studies of the membrane fusion activities of fusion
peptide mutants of influenza virus hemagglutinin. J.Virol., 69:6643-6651.
68 Wharton, S.A., Martin, S.R., Ruigrok, R.W., Skehel, J.J., and Wiley, D.C. (1988): Membrane fusion by peptide analogues of
influenza virus haemagglutinin. J.Gen.Virol., 69 ( Pt 8):1847-1857.
69 Oberhauser, B., Plank, C., and Wagner, E. (1995): Enhancing endosomal exit of nucleic acids using pH-sensitive viral fusion
peptides. In: Delivery strategies for antisense oligonucleotide therapeutics, edited by S. Akhtar, pp. 247-266. 
CRC Press, Boca Raton.
70 Wagner, E., Zatloukal, K., Cotten, M., Kirlappos, H., Mechtler, K., Curiel, D.T., and Birnstiel, M.L. (1992): Coupling of
adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of
transfected genes. Proc.Natl.Acad.Sci.U.S.A., 89:6099-6103.
71 Plank, C., Oberhauser, B., Mechtler, K., Koch, C., and Wagner, E. (1994): The influence of endosome-disruptive peptides on
gene transfer using synthetic virus-like gene transfer systems. J.Biol.Chem., 269:12918-12924.
72 Baru, M., Nahum, O., Jaaro, H., Sha’anani, J., and Nur, I. (1998): Lysosome-disrupting peptide increases the efficiency of
in-vivo gene transfer by liposome-encapsulated DNA. J.Drug Target., 6:191-199.
20
re
fe
re
nc
e 
lis
t


IMMUNOLIPOSOMES FOR 
THE TARGETED DELIVERY 
OF ANTITUMOR DRUGS
1
SUMMARY
This review presents an overview of the field of immunoliposome-mediated targeting of anticancer
agents. First, problems that are encountered when immunoliposomes are used for systemic
anticancer drug delivery are discussed, as well as potential solutions. Second, an update is given of
the in vivo results obtained with immunoliposomes in tumor models. Finally, new developments on
the utilization of immunoliposomes for the treatment of cancer are highlighted.
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IMMUNOLIPOSOMES FOR THE TARGETED 
DELIVERY OF ANTITUMOR DRUGS
INTRODUCTION
An attractive strategy to enhance the therapeutic index of anticancer drugs is to specifically deliver
these agents to tumor cells, thereby keeping them away from non-malignant cells sensitive to the
toxic effects of the drug.This would allow more effective treatments achieved with doses that are
better tolerated. Among the colloidal drug carrier systems proposed for site-specific drug delivery,
liposomes have attracted considerable attention [1-6]. Liposomes consist of one or more concentric
phospholipid bilayers, each enclosing an aqueous compartment. A large variety of therapeutically
active molecules (e.g. antitumor drugs, oligonucleotides, DNA, enzymes, peptides and hormones)
have been successfully incorporated in liposomes. Especially in the field of cancer chemotherapy,
much effort has been invested to realize site-specific drug delivery with liposomal systems. Active
targeting of liposomes to tumor cells is generally attempted by conjugating ligands to the liposomal
surface which allow a specific interaction with the tumor cells [6]. Several types of ligands have
been used for this purpose, including antibodies, antibody fragments [7-10], vitamins [11],
glycoproteins [12,13], peptides (RGD-sequences) [14,15], and oligonucleotide aptamers [16].This
review will mainly focus on the use of antibodies and antibody-fragments to actively target
liposomes, as this is the type of targeting ligand mostly used.
The first report on antibody-targeted liposomes came from Torchilin et al. about two decades ago
[17].These antibody-targeted liposomes (further referred to as immunoliposomes) were shown to
be able to specifically bind to the antigen that is expressed on the target cells. Since then, several
coupling techniques have been described for conjugating antibodies or their fragments to
liposomes, each with their own advantages and drawbacks [9,18,19]. Many in vitro experiments
have demonstrated highly specific binding of immunoliposomes to target cells. However, despite the
excellent targeting properties in vitro, successful results on targeting of immunoliposomes in tumor
models are scarce up to now.
In this review we aim to present the current status regarding the application of immunoliposomes
for anticancer drug delivery in vivo. First, problems will be listed that are encountered when
immunoliposomes are used for systemic anticancer drug delivery and potential solutions will be
discussed. Second, an update will be given on the in vivo results obtained with immunoliposomes in
animal models. Finally, special emphasis will be placed on highlighting new developments regarding
the utilization of immunoliposomes for the treatment of cancer.
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IMMUNOLIPOSOMES IN VIVO: 
MANY RIVERS TO CROSS
Accessibility of tumor cells is a critical issue when immunoliposomes are to be targeted to tumors.
Unlike some types of tumors (e.g. hematological malignancies and tumors confined within a body
cavity), many tumors are located at sites that are less accessible by intravenously (i.v.) injected
liposomes.The process of targeted drug delivery with immunoliposomes can be roughly divided
into two phases: the transport phase, in which the immunoliposomes travel from the site of
administration (often i.v.) to the target cells, and the effector phase that includes the specific binding
of immunoliposomes to the target cells and the subsequent delivery of entrapped drugs.This
section deals with the physiological and anatomical barriers to cross when immunoliposomes are
administered i.v. and will point out potential solutions that have been investigated to enable
immunoliposomes to fulfill their task.
BARRIERS ENCOUNTERED IN THE TRANSPORT PHASE
Stability of immunoliposomes in the circulation
Directly after i.v. administration, immunoliposomes are exposed to a variety of factors that may
compromise the integrity of the liposomal carrier. For example, adsorption of serum proteins to
the liposome surface can induce premature leakage of entrapped compounds and liposome
aggregation upon injection into the bloodstream [20-22]. Liposome aggregates will be rapidly
cleared from the circulation by liver and spleen phagocytes and/or embolize lung capillaries.
Furthermore, it has been demonstrated that naturally occurring antibodies (class IgM and IgG) with
reactivity against the headgroup of phospholipids are present in serum of rabbits [23] and men [24].
Such naturally occurring polyclonal antibodies were able to activate complement via the alternative
pathway, resulting in complement-mediated lysis of liposomes.
Clearance of immunoliposomes from the circulation
Perhaps the most important barrier limiting the usefulness of immunoliposomes for targeted
drug delivery has been the rapid recognition and removal from the blood by cells of the
mononuclear phagocyte system (MPS), particularly the macrophages in liver and spleen [25,26].
In addition, the presence of whole antibodies conjugated to the liposomal surface makes
immunoliposomes highly susceptible to Fc-receptor-mediated phagocytosis and, as a result, even
more prone to rapid clearance [25,27].The Fc-receptor family, which is expressed by different
cells of the MPS, binds the constant region (Fc) of antibodies resulting in internalization of
antibody-opsonized complexes (e.g. bacteria) [28]. Similarly, immunoliposomes bearing whole
antibodies are cleared rapidly due to exposed Fc parts [25,27,29].
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The advent of so-called long-circulating liposomes produced by coating the liposome surface with
the polymer polyethylene glycol (PEG), has revived interest in targeted drug delivery [30,31].
The PEG-coating has a dual effect. It sterically stabilizes the liposomal membrane by decreasing
interactions with destabilizing and opsonic factors in vivo. As a consequence, PEG-coated liposomes
show longer circulation times and reduced uptake by the MPS, relative to conventional liposomes.
Although the exact mechanism behind the MPS avoidance phenomenon is still under discussion, it
is thought that stabilization occurs by the formation of a highly hydrated shield of polymer
molecules around the liposome which sterically inhibits both electrostatic and hydrophobic
interactions of serum components with the liposomal bilayer [32,33].Therefore, PEG-liposomes
are often referred to as sterically stabilized liposomes.
There are different methods available for coupling antibodies to PEG-liposomes [58].The pros and
cons were recently discussed [9]. For attaching antibodies to the surface of PEG-liposomes, two
main strategies have been followed: those in which the ligand is coupled directly to the liposome
bilayer (Figure 1A) and those in which the ligand is attached to the terminal end of PEG (Figure
1B,C,D) [8,10,34].The latter strategy yields protein present at the surface of the PEG coating.
Indeed, it has been shown that the clearance rate of PEG-immunoliposomes is dependent on the
antibody density at the liposome surface [8,10,35]. At low antibody density (below about 50 µg
mAb/µmol PL), the PEG-immunoliposomes are cleared at rates only slightly more rapid than those
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Figure 1 — Overview of the currently used types of PEG-immunoliposomes. The main difference is the position of the anti-
bodies on the PEG-liposomes; they can be attached either directly to the liposomal bilayer (A) or to the distal end of the PEG-
chains (B, C and D). In most coupling methods antibodies are randomly derivatized for attachment to functionalized groups on
the liposome. This results in a random orientation of the antibody molecules on the liposomal bilayer (A) or on the PEG-chains
(B), thereby resulting in exposition of the Fc-portion of at least part of the attached antibodies. One method has been described
in which the antibody molecules are specifically attached via their Fc-portions to a hydrazide-group at the terminal end of the
PEG-chains (C), resulting in correctly orientated antibodies at the PEG-chains and diminished Fc-exposition [36]. The
presence of the Fc-portion can be avoided by using Fab’-fragments, which can be attached to the terminal end of PEG-chains,
for example by exploiting the free thiol-group that is created after reducing F(ab’)2-fragments into Fab’ (D).
A B
C D
PEG
Fab’
MoAb
seen for antibody-free PEG-liposomes. At higher antibody density (>100 µg mAb/ µmol PL), the
clearance becomes very rapid with half-lives of only a few minutes [8]. Likely, clearance is mediated
by the exposed Fc-region of the whole antibodies conjugated to the PEG-terminal ends.
An interesting observation came from Maruyama et al. who investigated whether the use of Fab’-
fragments instead of whole antibodies makes a difference in terms of pharmacokinetics and
biodistribution of PEG-immunoliposomes [10,36]. PEG-immunoliposomes exposing per particle
approximately 51 whole antibody molecules conjugated at the distal ends of the PEG-chains were
found to be rapidly removed from the circulation (60% after 1 h), whereas the same type of PEG-
immunoliposomes, bearing per particle an average of 517 Fab’-fragments derived from the same
monoclonal antibody, showed a 6-fold longer circulation time [36]. Moreover, accumulation of
Fab’-bearing PEG-liposomes directed against the human carcinoembryonic antigen (CEA) in human
gastric cancer tumors in nude mice was 2-fold higher compared to the accumulation of PEG-
liposomes bearing whole IgG (approximately 20 and 10% of injected dose/g tissue, respectively)
and was comparable with the accumulation of non-targeted PEG-liposomes.These results suggest
that either the chemical modification of whole antibody molecules needed for coupling to the
liposomes or the Fc-portion of antibody molecules mediate an enhanced clearance rate of antibody-
targeted PEG-liposomes.Therefore, the use of Fab’-fragments rather than whole antibodies coupled
to the distal ends of PEG-chains seems preferable for directing sterically stabilized liposomes to
solid tumors. Nevertheless, many investigators still tend to use whole antibodies as targeting
devices for PEG-liposomes.
Immunogenicity
It has become clear that the presence of antibodies on the liposome surface can lead to an immune
response. Repeated subcutaneous injections of avidin-liposomes bearing biotinylated murine
antibodies elicited isotype-specific antibody responses against the liposome-associated antibodies in
mice [37]. Antibodies against phospholipids were not raised. Another study evaluating the
immunogenicity of immunoliposomes showed that repeated i.v. injections of PEG-
immunoliposomes bearing antibodies coupled to the distal ends of PEG-chains via a hydrazide
linker elicited antibodies with specificity for the Fc-portion of liposome-conjugated antibodies [38].
This immunogenicity resulted in drastically decreased circulation times of liposomes in case of
repeated administration. Remarkably, it was demonstrated that antibodies coupled to the liposomes
are more immunogenic than antibodies given in free form [38].This suggests that either the
membrane-associated presentation of antibodies or the chemical modification of the antibodies
needed for coupling to the liposomes accounts for the enhanced immunogenicity. Immunogenicity
occurring when murine antibodies are used for liposome-targeting may become less of a problem
when smaller antibody fragments (like Fab’ or scFv) and humanized antibodies are used.
Nevertheless, immunogenicity is an important factor to take into account when developing
immunoliposomal drug carriers for cancer therapy and deserves more attention in future studies.
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Passage of the vascular endothelium
Immunoliposomes need to cross the tumor vasculature in order to reach tumor cells located
outside the blood compartment. Normal vascular endothelium consists of a continuous lining of
endothelial cells, which are tightly connected with each other by tight junctions. Beneath this
cellular layer is the basement membrane and in larger vessels, an additional layer of smooth muscle
cells is present.This tight barrier prevents the passage of large molecules and particulates. At
certain sites in the body, such as liver and spleen, the vascular anatomy is different. At these sites,
the endothelial lining contains fenestrations that are approximately 80 to 120 nm in diameter. In
solid tumors the vessels formed by the process of angiogenesis often show an increased
permeability due to large fenestrae (up to 400 nm) and an irregularly formed basement membrane
[39,40]. At tumor sites with an increased vascular permeability liposomes can extravasate, provided
that they are small enough and circulate long enough [41-43]. It has also been suggested that
liposomes may extravasate by transcytosis through endothelial cells [44]. However, convincing
experimental evidence that this is really the case is still lacking.
Intra-tumoral transport 
Unfortunately, tumors often develop in such a way that intratumoral penetration of particles
through the interstitium is hindered [45,46]. Rapidly growing tumors often have a poorly developed
lymphatic drainage system.This, together with the increased vascular permeability of the
neovascular bed results in high interstitial pressure inside tumors opposing the convective transport
of extravasated liposomes towards the tumor core. Moreover, though the angiogenesis process may
yield vessels that have structural defects, such vessels showing increased permeability are not
equally distributed within the tumor. As a consequence, extravasated liposomes are heterogeneously
distributed throughout the tumor and are mainly located in perivascular regions [42,43].
There has been controversy whether extravasated PEG-liposomes are taken up by tumor-residing
macrophages, thus limiting interaction with tumor cells. A recent study showed that the uptake of
extravasated PEG-liposomes by macrophages within the tumor is minor [47]. In contrast to these
findings, other reports show perivascular retention of extravasated PEG-liposomes and uptake by
tumor-resident macrophages [48,49].The different findings may be explained by model-related
differences in tumor architecture and the number of tumor-residing macrophages. Actively targeted
liposomes that expose the constant regions (Fc) of whole antibodies may be even more susceptible
to macrophage uptake [50].The use of antibody fragments lacking the constant part (like Fab’ or
scFv) may be helpful in reducing the uptake of immunoliposomes by tumor-associated macrophages
[48,51].
The binding site barrier hypothesis, proposed by Weinstein et al. [52] for antibodies, suggests that
immunoliposomes will not penetrate deeply into the tumor but bind to the first target cells they
encounter. In case of solid tumors, the first target cells encountered by i.v. administered
immunoliposomes will be those located directly behind the endothelial lining (perivascular zone).
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Allen et al. showed that non-targeted long-circulating liposomes containing doxorubicin had a
better antitumor activity than similar liposomes bearing whole antibodies [53]. According to the
binding site barrier hypothesis, it was suggested that the passively targeted long-circulating
liposomes may show better penetration into solid tumors compared to the immunoliposomes and
therefore show a better antitumor activity [53,54]. However, convincing evidence for the
perivascular retention of immunoliposomes limiting tumor penetration has not been provided so
far.Recently, Park et al. [48] showed by using colloidal gold-containing PEG-immunoliposomes
bearing anti-HER2/neu Fab’ fragments at the distal ends of PEG chains that these
immunoliposomes were abundantly deposited throughout the tumor mass, indicating that the
binding site barrier hypothesis does not hold here. A striking difference with the findings of Allen et
al. [53] is that Park et al. did not use whole antibodies but Fab’-fragments.Whole antibodies may
have evoked Fc-receptor mediated endocytosis by macrophages located in the perivascular space.
Moreover, Fc-receptor expression has been observed on activated endothelial cells [55,56] which
may also contribute to the perivascular retention of immunoliposomes targeted with whole
antibodies.
BARRIERS ENCOUNTERED IN THE EFFECTOR PHASE
Although much attention has been given in optimizing the transport phase of immunoliposomes in
the past years, not much work has been done to improve the next step of effective delivery of
immunoliposomal drugs within tumor sites. A dilemma the liposome field is facing is that liposomal
drug carrier systems are optimized to retain drugs while in the circulation and not to yield optimal
therapeutic availability of encapsulated drugs at tumor sites. Ideally, immunoliposomes should be
developed in such a way that they do not release their drug content during the transport phase, but
efficiently deliver their encapsulated compounds within the target site.This may require a
transformation of the liposomal stability properties once the immunoliposomes have reached the
target site to enable the efficient release of entrapped drug at tumor sites. Such a transformation
may be induced by an external trigger, like change in pH or temperature, or may involve a slow
change of the liposome composition in time, such as loss of the PEG coating resulting in
destabilization of liposomes containing non-bilayer forming lipids (e.g. DOPE) [57]. Both the target
cell binding step and the subsequent therapeutic availability step are discussed in more detail below.
Tumor cell binding
Choice of a target epitope – For the successful delivery of antineoplastic drugs by targeted
liposomes, it is required that the drugs are delivered to every malignant cell.Therefore, liposomes
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should be targeted to surface molecules that are present on each tumor cell and, most importantly,
that are not expressed at similar levels by normal cells. Since tumor cells are notorious for their
heterogeneity with respect to phenotype, expression of the target epitope on all malignant cells is
very unlikely.Target epitopes on cancer cells may be up- or down-regulated depending on the cell
cycle or the differentiation state of cancer cells. Moreover, target epitopes may be shed from the
surface of tumor cells.Targeted drug delivery will mainly affect those cells expressing the target
epitopes at high densities whereas target epitope-negative cells or those with low-density
expression are likely to become less susceptible to the treatment. As a consequence, a target
epitope-negative population of cells may be positively selected.Targeting of immunoliposomes to
more than one tumor-associated surface antigen may decrease the chance of positively selecting a
tumor cell population lacking targeting receptors.
Steric stabilization and specific binding – Targeting of immunoliposomes to solid tumors
requires extravasation at the site of the tumor. For efficient extravasation, liposomes with
sufficiently long circulation times are necessary.The most popular means to achieve long circulation
times is steric stabilization of the liposome surface with PEG. For active targeting of long-
circulating liposomes to tumor cells located at extravascular sites, the presence of homing devices
on the liposome surface in addition to PEG is required. For maximal prolongation of the circulation
time, liposomes should contain 5-10 mol% in case of the use of PEG-2000 [9,58]. Several studies
have shown that with increasing PEG content and increasing PEG size, the coupling efficiency of
antibodies to the bilayer of liposomes decreases [8,9]. Furthermore, the interaction of antibodies
coupled to the bilayer of PEG-grafted liposomes with their target antigens may be hampered due to
steric hindrance caused by the long PEG chains [59-62].Thus, although PEG-liposomes with
antibodies coupled directly to the liposome surface show circulation times comparable to non-
targeted PEG-liposomes [58,63], the targeting efficiency can be reduced by the presence of long
PEG chains on the surface of these liposomes.This problem of steric hindrance has been
successfully solved by coupling the antibodies or antibody-fragments to the distal end of
functionalized PEG-lipids [9,64]. Such PEG-immunoliposomes combine active targeting capacity
with long circulation properties.
Antibody orientation is a major factor influencing the target cell binding of PEG-immunoliposomes.
As in most coupling methods the antibodies are randomly derivatized for achieving attachment to
functionalized groups on liposomes, part of the antibodies will be attached to the liposomes via
their antigen-binding domain resulting in loss of target receptor-binding capacity of at least part of
the attached antibodies (Figure 1). Methods that result in specific orientation of either whole
antibodies or Fab’-fragments exist [9,65] and are preferred for optimal binding.
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Therapeutic availability
After tumor cell binding, the encapsulated drug should become therapeutically available. In
principle, the delivery of encapsulated compounds to tumor cells can take place via four different
mechanisms: (1) release of encapsulated compounds from cell surface-bound immunoliposomes
with subsequent uptake of free drug by the tumor cells, (2) transfer of lipophilic drugs from the
immunoliposomal bilayers to the plasma membrane of tumor cells, (3) endocytosis of cell-surface
receptor-bound immunoliposomes with subsequent intracellular release of encapsulated
compounds, and (4) fusion of the immunoliposomal membrane with the target cell-membrane or
endosomal membrane.The first mechanism aims for extracellular release of liposome-encapsulated
compounds, whereas in the latter three mechanisms, the drug will be released onto or inside the
cell. Intracellular release of antitumor drug has as main advantage that it may overcome multidrug
resistence [66-68]. In general, tumor cells circulating in the bloodstream require intracellular
delivery as extracellular delivery will result in fast diffusion and redistribution of the drug over the
blood compartment [69]. In case of solid tumors, the extracellular release of drug at the tumor site
seems preferable as this may lead to diffusion of drug within the tumor mass allowing the drug to
reach also those tumor cells that do not express the targeted antigens or that are out of reach for
the relatively large immunoliposome carriers.This so-called bystander effect may also occur after
intracellular delivery of certain drugs which have physico-chemical characteristics that promote the
leakage or active transport of a fraction of these drugs out of the target cells.
Extracellular release of encapsulated drug from surface-bound immunoliposomes –
Drug may be released from immunoliposomes which are bound to the surface of tumor cells.The
major advantage of this mechanism of delivery is that it does not require that immunoliposomes
bind to all tumor cells.The distribution of free drug throughout the tumor will enhance the
‘bystander effect’ to those tumor cells that do not have any immunoliposomes bound to their
surface. In this case, immunoliposomes act as an intratumoral drug depot from which free drug is
slowly released and taken up by target cells as well as non-target cells within a solid tumor. For
effective delivery, immunoliposomes should retain the encapsulated drug while circulating and
efficiently release the drug after tumor cell binding.The recent discovery that PEG-modified lipids
can undergo spontaneous transfer between membranes and the development of cleavable PEG-
lipids [70] provide the technical tools to develop PEG-immunoliposomes that destabilize in time
due to slow shedding of the PEG coat. Based on this PEG-shedding mechanism, liposomes have
been developed that, after loss of PEG-modified lipids, become highly fusogenic and unstable [57].
In addition, target-sensitive immunoliposomes have been constructed that were composed of
dioleoylphosphatidylethanolamine (DOPE) (80%), dioleoylphosphatidic acid (DOPA) (20%), and a
small amount of specific antibody conjugated to N- glutaryl-phosphatidylethanolamine.The
presence of N- glutaryl-phosphatidylethanolamine equally distributed in the liposomal bilayer
stabilizes the lipid bilayer containing high amounts of hexagonal phase-forming DOPE. Upon target
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cell binding of these target-sensitive immunoliposomes, it is thought that capping of the N- glutaryl-
phosphatidylethanolamine-conjugated antibodies results in an unequal distribution of N-glutaryl-
phosphatidylethanolamine within the liposome bilayer inducing rapid destabilization [71].Whether
such liposomes are stable during circulation in the bloodstream remains to be investigated.
An external trigger can potentially enhance the release of immunoliposome-encapsulated drugs in
close proximity of tumor cells, provided that the immunoliposomes have an appropriate
composition. Such an external trigger may be the local heating of a tumor (thermosensitive
immunoliposomes) [72-74],[75] change in pH (pH-sensitive immunoliposomes) [55,76] or laser
light (photosensitive immunoliposomes) [77-79]. An obvious requirement for such trigger
approaches is that the exact location of the tumor within the body must be known. Besides, the
released drug should be able to enter the target cell on its own, as most anticancer agents exert
their function inside the cell.
Selective transfer of lipophilic (pro)drugs from immunoliposomes to tumor cells –
Immunoliposomes are an attractive carrier system for the delivery of lipophilic anticancer drugs or
prodrugs to tumor cells.The liposomal bilayer may be exploited for incorporation of either
lipophilic drugs or lipophilic derivatives (prodrugs) of hydrophilic drugs that are not efficiently
retained in the aqueous phase of the liposome. Examples of the latter are arabinofuranosylcytosine
(Ara-C) [80], 5-fluorouracil (5-FU) [81], 5-fluoro-2’-deoxyuridine (FUdR) [82,83] and
methotrexate [84].To date, only a few studies have been published regarding the incorporation of
lipophilic drugs into immunoliposomes for specific targeting [85-87]. One example of lipophilic
drug incorporation in immunoliposomes will be further discussed as this shows a unique way by
which lipophilic drugs can enter tumor cells. FUdR, which as a free substance is used in the clinic
for the treatment of liver metastases of colon cancer, shows rapid leakage after encapsulation in
liposomes.Therefore a lipophilic dipalmitoyl prodrug (FUdR-dP) was developed, which remains
firmly associated with the liposomes, also under in vivo conditions [83,88]. FUdR-dP incorporated
in long-circulating immunoliposomes targeted to lung endothelial cells, resulted in increased
antitumor activity towards lung metastatic growth of mouse mammary carcinoma [85]. More
recently, FUdR-dP incorporated in tumor cell targeted immunoliposomes showed a more than 10-
fold increased antiproliferative activity in vitro towards rat CC531 colon cancer cells as compared to
drug-containing liposomes without antibody [87]. Although these immunoliposomes bind to a high
extent to the target cells, they are not internalized. However, the cells rapidly hydrolyze the FUdR-
dP yielding the active drug intracellularly. Inhibition of endocytic uptake and intralysosomal
degradation resulted in a major inhibition of the hydrolysis of the prodrug, demonstrating that the
hydrolysis takes place intracellularly [89].These results led to the postulation of a selective transfer
mechanism for immunoliposomal FUdR-dP (Figure 2). During the high-affinity interaction of the
immunoliposomes with the tumor cells the FUdR-dP is selectively transferred from the
immunoliposomal bilayer to the plasma membrane (step 1). From there the drug is transferred into
the cell by constitutive pinocytic and endocytic processes (step 2) and hydrolyzed intralysosomally
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(step 3). Subsequently, the hydrolyzed drug diffuses into the cytoplasm (step 4) from where it is
either transferred to the nucleus exerting its cytotoxic effect (step 5) or released into the
extracellular compartment (step 6), where it can have cytotoxic effects on other tumor cells
(‘bystander effect’). An important message to be learnt from these studies is that immunoliposomes
can mediate efficient intracellular delivery of a lipophilic drug without being internalized.We
believe that this advantage may be more generally applicable for lipophilic (pro)drugs incorporated
in immunoliposomes.
Internalization of surface-bound immunoliposomes – Certain proteins that bind to cell-
surface receptors are rapidly internalized by the cells before they can dissociate from their
receptors.This process, which is called receptor-mediated endocytosis, is recognized as an
important and general mechanism by which cells take up nutritional and regulatory proteins from
extracellular fluid.This internalization process can also be utilized for the cellular uptake of
immuno-liposomes. A number of reports have demonstrated that small immunoliposomes targeted
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Figure 2 — Schematic presentation of a selective transfer model proposed for a lipophilic dipalmitoyl prodrug of the
anticancer agent FUdR from immunoliposomes to the plasma membrane of tumor cells. After target cell binding, the
immunoliposome incorporated FUdR-dP is transferred to the plasma membrane of the tumor cell (1). The prodrug is
internalized by constitutive endocytic or pinocytic processes (2) and hydrolyzed intralysosomally (3). The active drug FUdR
then diffuses into the cytoplasm (4) from where it is either transferred into the site of action, the nucleus (5), or released
extracellularly (6) where it can exert a cytotoxic effect on surrounding tumor cells (‘bystander effect’). Adapted from
Scherphof et al. [51].
‘bystander effect’
endosome
lysosoom
to certain cell-surface receptors (e.g. epidermal growth factor receptor, transferrin receptor, folate
receptor) are internalized in a way that closely resembles receptor-mediated endocytosis
[13,35,59,90]. Unfortunately, this route of entry does not guarantee full therapeutic availability of
internalized drug molecules. Many therapeutic agents act at an intracellular target site to be
reached via the cytosol. Immunoliposomes internalized by the mechanism of receptor-mediated
endocytosis will eventually end up in lysosomes where they are degraded together with the
encapsulated drug molecules.The physico-chemical nature of the encapsulated drug may be
compatible with the need to escape from the endosomal or lysosomal compartment [91]. Molecules
like doxorubicin [92] may be resistant to the action of lysosomal enzymes and/or low pH and able
to cross the endosomal or lysosomal membranes. Also, lipophilic drugs may transfer from the
liposomal to the endosomal membrane during endocytosis via the mechanism described before.
Endosomal escape of hydrophilic drugs into the cytosol may be promoted by the incorporation
structures with pH-dependent fusogenic properties into the liposomal carrier.These pH-dependent
fusion mechanisms will be dealt with in the next section.
Fusion with the plasma membrane of target cells – Fusion of immunoliposomes with cells
is an attractive strategy to deliver entrapped drug molecules into the cytosol. In principle, there are
two routes by which cytosolic delivery via fusion can be achieved: (1) fusion of immunoliposomes
with the plasma membrane of the target cells initiated after the immunoliposomes have bound to
the target cells, or (2) pH-dependent fusion of immunoliposomes with the endosomal membrane,
after being internalized by the target cells via receptor-mediated endocytosis.
Fusion of surface-bound immunoliposomes with the plasma membrane of the target cells has two
major advantages. First, it does not require internalization of the immunoliposomes and
consequently there is no need to target to an internalizing epitope, which increases the number of
potential target epitopes for immunoliposomes. Second, plasma membrane fusion does not add a
restriction to the size of fusogenic immunoliposomes in contrast to immunoliposomes that are
designed for internalization.Third, fusion of immunoliposomes with the plasma membrane results
in release of encapsulated drug directly into the cytosol. However, it should be realized that
immunoliposomes with fusogenic activity at neutral pH may also fuse with non-target cells as a
consequence of nonspecific adherence. In addition, unwanted inter-liposomal fusion events may
occur.
In contrast to fusion of immunoliposomes directly with the plasma membrane, fusion with the
endosomal or lysosomal membranes requires internalization.To this end, immunoliposomes should
be targeted to receptors with known internalizing properties. In addition, the size of liposomes
should not hamper endocytosis and should therefore be small (preferably < 100 nm) [93]. pH-
sensitive liposomes have been used for the cytosolic delivery of encapsulated drug via the pathway
of receptor-mediated endocytosis [76]. Liposomes with pH-dependent fusogenic properties can be
constructed from dioleoylphosphatidylethanolamine (DOPE) in combination with acidic lipids, such
as N-palmitoylhomocysteine (PHC), cholesterylhemisuccinate (CHEMS), oleic acid (OA) or
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diacylsuccinylglycerols. Under physiological conditions, DOPE preferentially forms inverted
hexagonal phase (HII) rather than bilayers. However, admixing DOPE with one of the acidic lipids
mentioned above prevents HII phase formation and yields stable bilayers at neutral pH. Upon acidic
exposure, however, protonation of the acidic lipids occurs, thereby neutralizing their negative
charges and inducing destabilization of the liposomal bilayers and/or induction of pH-dependent
lipid mixing [94-97]. Another strategy to achieve pH-dependent membrane destabilization or fusion
is to incorporate pH-sensitive polyethylene glycol derivatives having carboxyl groups [98]. It was
demonstrated that succinylated poly(glycidol) (SucPG) coupled to egg yolk phosphatidylcholine
(PC) liposomes as a fusogenic polymer induced pH-dependent lipid mixing of liposomal lipids and
yielded cytoplasmatic delivery of encapsulated calcein [98].
Membrane-active peptides can also be used to promote the cytosolic delivery of liposome-
encapsulated drug from the endosomal/lysosomal compartment. Such peptides may act by
destabilizing membranes, forming pores or inducing membrane fusion (reviewed by Plank et al.
[99]). A number of synthetic, amphipathic peptides have been shown to exert fusogenic activity. For
example, the amphipathic 30-residue peptide named GALA mimics the behavior of fusion peptides
derived from viral fusion proteins. It was shown that GALA induces fusion of liposomes composed
of PC in a pH-dependent fashion [100]. Puyal et al. [101] attached a 14-amino acid residue GALA-
type peptide to liposomes and showed that intermixing of lipid between the liposomes occurs in a
pH-dependent fashion. Similar results were obtained with a synthetic fusion peptide that induces
fusion at neutral pH when coupled to the liposomal membrane [102,103].The latter two studies
clearly show that membrane-active properties can be grafted onto liposomes in order to enhance
the cytosolic delivery of encapsulated compounds. Up to now no reports have been published
demonstrating the utility of fusogenic peptide-bearing immunoliposomes for cytosolic delivery
enhancement.
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IMMUNOLIPOSOMES IN VIVO: CURRENT STATUS
In early days, the utility of conventional immunoliposomes in vivo was strongly limited by their
rapid clearance by the MPS.With the advent of long-circulating liposomes that are able to oppose
uptake by the MPS, targeting of liposomes to tissues other than the MPS is now much more
realistic. One of the most critical issues to consider when developing immunoliposomal systems is
whether the surface-attached antibodies can access the tumor cell surface in vivo. Moreover, the
route of administration, in relation to the target site, is an important determinant for the degree of
in vivo targeting that can be achieved. For this reason, the current status of immunoliposomes as
drug carriers in cancer therapy will be discussed separately for targeting to cells within the
vasculature after i.v. administration, to tumor cells residing in the peritoneal cavity after local
administration and to solid tumors after i.v. administration.
INTRAVENOUS ADMINISTRATION OF IMMUNOLIPOSOMES
TO TARGET CELLS WITHIN THE VASCULATURE
Circulating tumor cells
Hematological malignancies (e.g. lymphomas, multiple myeloma or leukemias) seem attractive
candidates for immunoliposome-based therapy, as circulating tumor cells are likely easily accessible
targets for i.v. administered immunoliposomes. Lopes de Menezes et al. targeted sterically stabilized
immunoliposomes containing doxorubicin (DOX-SSIL) to CD19+ Namalwa cells (human B-cell
lymphoma) circulating in the bloodstream of severe combined immune deficiency (SCID) mice. In
vitro evidence pointed to internalization of tumor cell-bound anti-CD19 SSIL by receptor-mediated
endocytosis [69]. Evaluation of the therapeutic effect in vivo showed a significant increase in survival
(77% increase in lifespan) for the tumor-bearing mice treated with anti-CD19 DOX-SSIL in
comparison with non-targeted DOX-SSL or free DOX.The effectiveness of treatment was
dependent on the dose of inoculated tumor cells and the time interval between tumor cell
inoculation and intervention. Best therapeutic results were obtained with early interventions (i.e. 1
h after i.v. injection of tumor cells) when inoculated tumor cells are most likely still circulating.
Multiple weekly treatments (day 1,8 and 15 after tumor inoculation) only slightly improved the
survival times of mice, indicating that target cells may have become relatively inaccessible or have
grown to a size that hinders effective penetration of DOX-SSIL formulations into the tumor mass.
The better therapeutic effect of DOX-SSIL compared to non-targeted DOX-SSL was explained by
efficient internalization of CD19-bound DOX-SSIL by Namalwa cells followed by intracellular
release of DOX from the internalized liposomes. As non-targeted DOX-SSL were not internalized
by the target cells in vitro, the results show the necessity of internalization to increase the efficiency
of drug delivery to tumor cells within the vasculature.
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Recently, similar results were obtained with DOX-containing sterically stabilized anti-idiotype
immunoliposomes in a murine B-cell lymphoma model [104].Treatment of tumor-bearing mice
with DOX-containing anti-idiotype SSIL resulted in a significantly greater median survival time as
compared to mice treated with either saline, free DOX or plain DOX-SSL. Also in this study it
could be shown in vitro that anti-idotype-targeted SSIL were efficiently internalized by the
malignant B-cells. Another option to explain the better therapeutic effects of the DOX-anti-idiotype
SSIL formulations used in the above-mentioned studies, is that SSIL bound to target cells induced
the so-called target cell dragging phenomenon, as proposed by Peeters et al. [105,106].This
phenomenon implies that binding of the immunoliposomes to the circulating target cells induces an
opsonic effect leading to rapid uptake of the tumor cells by hepatosplenic macrophages.
A potential clinical hazard related to immunoliposome targeting to circulating cells is the possible
occurrence of agglutination. Circulating tumor cells may be agglutinated due to multivalent
interaction of immunoliposomes with more than one tumor cell. Moreover, immunoliposomes may
be agglutinated in the blood circulation due to the presence of soluble bi- or multivalent target
antigens shed from the surface of either circulating tumor cells or tumor cells within a solid tumor.
It was demonstrated that immunoliposomes targeted i.v. to the idiotype of B-cell receptors on
malignant B-cells caused clinical signs of dyspnea, lateral recumbancy, peripheral lymb cyanosis,
convulsion and occasional death in tumor-bearing mice [107].These clinical symptoms were the
result of agglutination of circulating immunoliposomes by soluble antibodies produced by the
malignant B-cells, which causes occlusion of small capillaries as the i.v. injection of purified
antibodies from these malignant B-cells after administration of immunoliposomes gave the same
symptoms.The above-discussed study on the therapeutic efficacy of CD19 DOX-SSIL in SCID mice
bearing CD19+ human B-cell lymphomas did not report any of these symptoms.
Endothelial cells
Endothelial cells lining the vasculature represent an easily accessible target to i.v.-administered
immunoliposomes. Maruyama et al. have targeted SSIL to lung endothelial cells by conjugating
mAb 34A to the distal ends of liposome-attached PEG-molecules [10,64,108].This mAb is specific
for thrombomodulin, which is expressed at high levels on mouse lung endothelial cells. In Balb/c
mice up to 60% of i.v.-injected 34A-SSIL was found in the lung within 15 min after injection.
Liposomes without conjugated antibodies or with irrelevant antibodies conjugated to the PEG-
chains did not accumulate in the lung (<0.4% of injected dose), but were mainly found in the liver
(50% of injected dose).The excellent targeting efficiency of 34A-SSIL has been utilized to achieve
high levels of antineoplastic drugs in lungs of mice bearing metastasized tumors [85]. It was shown
that mice treated with FUdR-dP incorporated into 34A-immunoliposomes yielded a significant
increase in lifespan compared to mice treated with FUdR-dP dispersed in a lipid emulsion or
incorporated in non-targeted liposomes.This study indicates that an indirect targeting approach (i.e.
active targeting of immunoliposomal antineoplastic drugs to cells other than the tumor cells) may
be attractive to obtain high levels of drug in close proximity of tumor cells.The lipophilic
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characteristic of the FUdR-dP was proposed to play a role in the transendothelial delivery of the
drug.
LOCAL ADMINISTRATION OF IMMUNOLIPOSOMES
TO TARGET TUMORS CONFINED TO THE PERITONEAL CAVITY
Tumor cells located in the peritoneal cavity present another accessible target for immunoliposomes
if the immunoliposomes are injected intraperitoneally (i.p.).This is examplified by studies on the
i.p. administration of immunoliposomes for the treatment of ovarian carcinoma [86,109,110].
Straubinger et al. attached whole antibodies directed against CA-125 carcinoma antigen to the
surface of liposomes [110] and showed that i.p. injected OC-125 immunoliposomes were able to
bind to ovarian cancer cells (OVCAR-3) growing as an ascitic tumor in the peritoneal cavity of
nude mice.
In another study on ovarian carcinoma treatment, the lipophilic prodrug 5’-palmitoyl-5-
fluorouridine (PF) was incorporated into immunoliposomes [86].The investigators utilized whole
antibodies directed against the CAR-3 antigen, which is abundantly expressed on human ovarian
carcinoma cells and other adenocarcinomas. Intraperitoneal injection of anti-CAR-3
immunoliposomes into the OVCAR-3 xenograft model resulted in a drastic reduction of the tumor
mass.The PF-immunoliposomes were 4 times more effective than the corresponding non-targeted
PF-liposomes and 18 times more effective than the free drug, illustrating the superiority of PF-
immunoliposomes.
Nässander et al. used immunoliposomes bearing covalently coupled Fab’ fragments of the
monoclonal antibody OV-TL3, which is directed against the antigen OA3 present on more than
90% of all human ovarian carcinoma cells [111].When these immunoliposomes were administered
i.p. in the OVCAR-3 xenograft model, a high fraction (about 70%) of the injected dose was bound
to the tumor cells within half an hour. Encouraged by these excellent in vivo targeting results,
doxorubicin (DOX) was loaded into these immunoliposomes (IL) and evaluated in the same i.p.
xenograft model [109,112]. Although the DOX-IL formulations had a superior antitumor effect
compared to non-targeted DOX-liposomes in vitro, no difference in antitumor activity between the
targeted and non-targeted formulation was observed in vivo. As no evidence for cellular
internalization of cell-bound immunoliposomes was obtained, a similar degree of premature drug
leakage from both the targeted and non-targeted DOX-liposomes within the peritoneal cavity was
suggested to underlie the antitumor effects seen.The lack of therapeutic benefit of Fab’-targeted
liposomes clearly illustrates the point that even well-targeted immunoliposomes can fail due to lack
of cellular internalization and/or uncontrolled drug release patterns.
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INTRAVENOUS ADMINISTRATION 
TO TARGET SOLID TUMORS AND METASTASES
Liposome investigators have been able to exploit the abnormal blood vessel structures associated
with tumor angiogenesis for extravasation of liposomes [46]. It is now well documented that
immunoliposomes must both be small and exhibit long circulation times to achieve preferential
localization within solid tumors [43,49]. Active targeting of sterically stabilized liposomes (SSL) by
conjugating antibodies or antibody fragments to the liposomal surface may further improve the
therapeutic efficacy by increasing the specific uptake of liposomal drug formulations into tumor
cells within a solid tumor. However, one should realize that the attachment of antibodies or
antibody fragments to the surface of SSL and especially to the distal ends of PEG-lipids on SSL may
oppose the MPS-avoiding capacities of SSL [8,36].
Maruyama et al. have evaluated the efficiency of tumor targeting of SSIL in a xenograft model of
human gastric cancer [10,36]. SSIL were constructed by conjugating either whole antibodies or
Fab’-fragments of anti-CEA mAb 21B2 to the distal ends of the PEG-chains.The tumor localization
of these SSIL 24 hrs after i.v. injection was compared with that of non-targeted SSL and bare
liposomes (i.e. without any surface-bound molecules). It was shown that the most efficient tumor
localization was obtained with non-targeted SSL or Fab’-targeted SSIL (both 20% of injected
dose/g tumor).Whole antibody-targeted SSIL localized substantially less at the tumor site (10% of
injected dose/g tumor), but tumor accumulation was still higher than for bare liposomes (7% of
injected dose/g tumor).
Reports demonstrating an improved efficacy of antitumor agents encapsulated in actively targeted
SSIL relative to non-targeted SSL are scarce. Ahmad et al. [113] studied immunoliposomes with
avidin covalently coupled to the bilayer of PEG-liposomes. Biotinylated monoclonal antibodies that
recognize specific epitopes on the surface of lung squamous carcinoma cells avidly bound to these
avidin-bearing liposomes. Such ‘two-step-targeted’ immunoliposomes were loaded with
doxorubicin (DOX) and subsequently injected i.v. in mice bearing murine squamous carcinoma
cells in the lungs.Treatment with DOX-SSIL resulted in significantly improved antitumor activity
compared to treatment with free DOX or non-targeted DOX-liposomes.The success of this
approach was ascribed to efficient targeting to tumor cells in combination with the release of DOX
from tumor cell-bound immunoliposomes and subsequent uptake of free DOX by tumor cells.
Regression of more advanced tumors did not occur, probably as a result of poor tumor penetration
or down-regulation/shedding of the target epitope.
Kirpotin at al. [114] treated HER2/neu over-expressing human breast cancer cells in vitro with
DOX-containing immunoliposomes bearing Fab’-fragments of a humanized mAb directed against
the HER2/neu antigen.The Fab’-fragments were either attached to the liposomal surface via a
short spacer or to the distal ends of PEG-chains.The in vitro tests showed that the
immunoliposomes with the Fab’-fragments attached to the distal end of PEG-chains are able to
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avidly bind to the HER2/neu over-expressing cells and are rapidly internalized via the coated pit
pathway.The DOX-loaded anti-HER2/neu SSIL produced significantly increased antitumor activity
as compared to free DOX or DOX-loaded non-targeted liposomes (SSL) in xenograft models of
HER2/neu-overexpressing breast cancer. Interestingly, the degree of localization of anti-HER2/neu
SSIL in HER2/neu-overexpressing tumor xenografts was not increased over that of non-targeted
SSL. However, the use of colloidal gold-containing SSIL revealed that the SSIL were distributed
throughout the tumor interstitial spaces as well as localized within tumor cells [115]. In contrast,
non-targeted SSL were located predominantly within tumor-associated macrophages.Thus,
increased deposition in the intercellular spaces within the tumor tissue outside tumor-associated
macrophages, as well as the intracellular delivery of DOX may have contributed to the superior
antitumor activity of DOX-loaded anti-HER2/neu SSIL.Therapeutic superiority of targeted SSIL
was not observed by Goren et al. [116].The latter group also studied the in vivo antitumor effects of
DOX-loaded anti-HER2/neu SSIL and concluded that the antitumor activity of targeted and non-
targeted DOX-SSL was similar.Whether this discrepancy in outcome is related to differences in
tumor model or to the fact that Goren et al. utilized complete mouse antibody rather than
humanized Fab’ is not clear.
In another study, mice bearing human ovarian cancer xenografts were treated with either free
DOX, DOX-SSL or DOX-SSIL (targeted with mAb B43.13 to human ovarian cancer cells) [53].
Surprisingly, the non-targeted DOX-SSL formulation was more effective than DOX-SSIL in
reducing the rate of tumor growth.This finding was ascribed to the binding site barrier
phenomenon.
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RECENT ADVANCES
A general trend that can be deduced from the previous section is that, despite successful results in
vitro, the results in vivo are somewhat disappointing: only a few examples of successful anticancer
applications of immunoliposomes in vivo exist. Clearly, the immunoliposomal system needs further
improvement in order to obtain an effective drug delivery vehicle for application in vivo. Several
major problems have been identified. Recent developments to tackle these problems are discussed
below.
DEVELOPMENT OF ALTERNATIVE HOMING DEVICES
Antibody-based homing devices
Studies with antibody-targeted PEG-liposomes have shown that a high density of antibodies attached
to the distal ends of the PEG chains evoke antibody-mediated recognition and enhanced clearance
by the RES [8].The mechanism of clearance is thought to be - at least in part - Fc-receptor-
mediated as the coupling of Fab’-fragments did not induce enhanced clearance at similar high
densities.Therefore, the use of Fab’-fragments rather than whole antibodies seems advantageous
[10,36].The presence of antibody-molecules on the liposomal surface can also induce an immune
response. Studies from Phillips et al. and Harding et al. show that upon repeated injections of
immunoliposomes in mice or rat, isotype-specific antibodies were generated against the antibodies
conjugated to the liposomes [37,38]. Likely, immunogenicity problems encountered with antibody
therapy in humans, such as human anti-mouse antibody (HAMA) responses [117] will also hold for
immunoliposomal drug formulations. Immune responses may severely hinder repeated dosing
regimens for immunoliposomes in the clinic. In order to prevent HAMA responses, humanized
mAbs have been produced, in which the complementary determining regions (CDRs) of murine
mAbs have been grafted onto human antibodies [118,119]. Although such chimeric antibodies
largely consist of regions of human origin, still an antibody response may be induced against the
grafted variable regions of murine origin. A better option is the use of fully human antibodies,
which has become a possibility with the development of transgenic mice that produce antibodies of
human origin [120,121].These mice may provide the optimal source for immuno-tolerant
antibodies for targeted drug delivery in humans. However, one should keep in mind that not only
the origin of antibodies determines their antigenicity, also coupling chemistry involving the
chemical modification of antibodies and the use of anchoring molecules may introduce
immunogenicity problems.
Besides whole antibody molecules and Fab’-fragments, smaller antibody fragments have been
studied. Lipid-tagged human scFv have been constructed and successfully incorporated into
liposomes [122,123] and used to target liposomes to B-lymphocytes in vitro [123].Theoretically,
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there are several advantages for using lipid-tagged scFvs over whole antibodies for liposome
targeting: (1) The smaller size of scFv antibodies together with their human origin may make
immunoliposomes less immunogenic than whole antibodies. (2) The absence of an immunoglobulin
constant region will prevent rapid Fc-receptor mediated clearance of scFv-targeted liposomes. (3)
There is no need to chemically modify the lipid-tagged scFv-antibodies for coupling to liposomes.
They will spontaneously insert into the phospholipid bilayers because of the presence of the lipid
tag. Potential loss of binding affinity and/or induction of immunogenicity due to chemical
modification procedures are therefore avoided. (4) The availability of large phage display libraries of
human scFv-fragments, the possibility of large scale production, and the simple selection procedure
of antigen-specific scFv-fragments favor the use of scFv fragments instead of murine antibodies.
However, in vivo studies utilizing scFv-immunoliposomes are lacking at present; issues like
immunogenicity and stable insertion of the lipid tag into the bilayer have not been addressed yet.
Oligonucleotide aptamers 
Recently, a novel method for the production of antigen binding molecules has been developed.This
method makes use of oligonucleotide aptamers that in their specific three-dimensional
conformation can bind to proteins with specificities and affinities comparable to antibody
molecules. Aptamers can be selected from large libraries of nucleic acid sequences with the
systemic evolution of ligands by the exponential enrichment (SELEX) method [124-126]. From
such libraries (>1015 different aptamers) aptamers to virtually any structure can be selected and
potentially be used as homing devices to target liposomes [16].
Other ligands 
Naturally occurring ligands to cell-surface receptors such as vitamins, hormones and growth factors
may also be used as immuno-tolerant homing devices.They offer some potential advantages over
antibodies, such as lack of immunogenicity and low preparation costs. It was shown that liposomes
to which the epidermal growth factor (EGF) was covalently coupled could be targeted to hepato-
cytes expressing the EGF-receptor [13]. As many carcinoma cells show a relatively high expression
of the EGF-receptor, EGF-targeted liposomes may be useful for tumor targeting [12,13].
Folate has also been studied as targeting ligand [11,127].The folate receptor has been identified as a
surface marker in ovarian carcinomas. Receptor overexpression is found in many other types of
cancer as well. Folate-targeted liposomes that specifically bind to cells that overexpress the folate
receptor have been designed [128].When folate is directly attached to the phospholipid headgroups
or when a short spacer is used to couple folate with the bilayer, the folate-exposing liposomes are
not recognized by the folate receptor. A long PEG spacer (MW 3,350) between the folate and the
liposome surface is required for receptor recognition. Such folate-targeted liposomes are
extensively internalized by receptor-mediated endocytosis after target cell binding. Incorporation of
DOX resulted in 86-fold higher cytotoxicity to folate receptor-expressing tumor cells compared to
non-targeted liposomes and 2.7-fold higher cytotoxicity relative to free DOX [129].
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IMPROVING THE THERAPEUTIC AVAILABILITY
OF IMMUNOLIPOSOMAL DRUGS
Thermo-sensitive immunoliposomes
Evidence that the therapeutic efficacy of liposomal drugs can be drastically improved by enhancing
the drug release from liposomes extravasated into tumor tissue was elegantly demonstrated with
thermo-sensitive liposomes [72-75,130,131].The heat-induced drug release concept is based on the
large increase in permeability of liposomal bilayers around their phase-transition temperature. Local
heating of tumor tissue up to this phase transition temperature will enhance drug release out of
liposomes present in the heated area [74]. In vivo fluorescence videomicroscopy has been used to
study the extravasation of thermo-sensitive liposomes and the release of their contents in a rat skin
flap window chamber, which contained a well-vascularized mammary adenocarcinoma [72].
Extravasation and contents release were measured at different temperatures (34ºC, 42ºC, and
45ºC). At hyperthermic conditions both the degree of extravasation as well as the rate of drug
release from thermosensitive liposomes (composed of DPPC, HSPC, CHOL, PEG-PE) were
substantially increased. Improved therapeutic efficacy of thermo-sensitive liposomes in combination
with local heat application has been demonstrated in several studies [73,132,133].The above men-
tioned studies all used non-targeted thermo-sensitive liposomes. Only one study with thermo-
sensitive immunoliposomes in vitro has been reported [75].The in vivo applicability of thermo-
sensitive immunoliposomes as targeted drug vehicles in cancer therapy remains to be investigated.
pH-sensitive immunoliposomes
pH is another factor that may be utilized to trigger the release of drugs from immunoliposomes.
pH-sensitive immunoliposomes have been prepared that became highly unstable and fusogenic at
low pH [76,95,96]. pH-sensitive immunoliposomes targeted to internalizing receptors will end up
in endosomes where acidification will trigger liposome destabilization and possibly fusion with the
endosomal membrane.They have been applied in vitro for the delivery of antitumor drugs into the
cytoplasm of tumor cells [134,135]. Indeed it was demonstrated that pH-sensitivity strongly
increases the potency of immunoliposomal antitumor drugs. pH-sensitive immunoliposomes have
never been tested for in vivo drug delivery to tumors, probably because of evidence pointing to
instability in the circulation [136].The recent discovery that PEGylation of pH-sensitive liposomes
improves their stability in vivo may revive the interest in using pH-sensitive immunoliposomes as
drug carriers in cancer therapy [94].
Utilization of membrane-active peptides
Membrane-active peptides are short, amphipatic peptides containing hydrophobic amino acid
sequences.These sequences have in common that they can fold into specific structures (e.g. α-helix,
β-sheet) dependent on environmental conditions like pH or the presence of cell membranes. In
44
re
ce
nt
 a
dv
an
ce
s
nature such peptide stretches are efficiently utilized in many biological events involving membrane
interactions [99]. Many of these membrane-active peptides have been synthesized and tested for
membrane-destabilizing and/or fusogenic properties [100,103,137-139].They show membrane
destabilizing activities either at low pH [100,101,140,141] or at neutral pH [102,103,138,142].
Certain membrane-active peptides have fusogenic properties as they can induce the mixing of lipids
between distinct liposome particles. Several studies have shown the possibility of coupling
membrane-active peptides to the bilayer of liposomes [101,102,139]; in some cases an increase in
membrane activity of the peptide could be observed after coupling to the bilayer [101,102].The
feasibility of the use of pH-dependent, membrane-active peptides coupled to the surface of
immunoliposomes to enhance the cytosolic delivery of anticancer drugs to tumor cells is currently
under investigation.
Immuno-enzymosome approach
A totally different approach to obtain high concentrations of therapeutically available drug at tumor
sites is the use of immunoliposomes for antibody directed enzyme prodrug therapy (ADEPT)
[143,144]. ADEPT was originally described for antibodies [145] but has been adapted for the use of
immunoliposomes. Instead of entrapping drug molecules inside immunoliposomes, the immuno-
liposomes carry anticancer prodrug-activating enzyme molecules on their surface (immuno-
enzymosomes). In this two-step approach, the first step involves the targeting of the immuno-
enzymosomes to the tumor site. Subsequently, an anticancer prodrug matched with the enzyme is
given, which will then be converted to its cytotoxic parent compound selectively near the tumor
cell surface, thereby inducing an antitumor effect without systemic toxicity. Recently, we have
coupled the enzyme ?-glucuronidase, capable of activating anthracycline-prodrugs, to the external
surface of immunoliposomes directed towards ovarian carcinoma cells [144,146]. It was demon-
strated that after tumor cell binding and subsequent addition of prodrug, the immuno-enzymo-
somes were able to convert almost all prodrug added resulting in killing of ovarian carcinoma cells
in vitro, whereas enzymosomes (bearing no specific antitumor antibodies) or immunoliposomes
(bearing no enzymes) were clearly ineffective.These findings point to the potential usefulness of
immuno-enzymosomes in prodrug activation therapy.The immuno-enzymosome approach is a
conceptually attractive strategy as it circumvents the problem of insufficient therapeutic availability
of the encapsulated drug contents at the target cell surface.The ‘bystander effect’ described above
may promote that also those tumor cells are killed that are not reached by the immuno-enzymo-
somes.The possible advantages that immuno-enzymosomes offer over antibody-enzyme conjugates
usually used in ADEPT are that: (1) one carrier unit of immuno-enzymosomes delivers much more
enzyme than one antibody unit, and (2) multivalent interaction of immunoliposomes with target
cells may result in higher avidity to the target epitopes as compared to antibodies. Currently, in vivo
studies are focussed in our group on the i.p. administration of immuno-enzymosomes for the
therapy of ovarian cancer micrometastases localized in the peritoneal cavity. It is obvious that i.v.
administration of immuno-enzymosomes to target solid tumors will require steric stabilization of
their surfaces to prolong circulation times.
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MULTIPLE LAYER LIPOSOMES
As mentioned before, immunoliposomes designed for in vivo cancer therapy should be able to retain
drug while in the circulation, but upon interaction with the target cells, they should efficiently
release the drug. Ironically, those liposomal characteristics needed to retain the drug in circulation,
may counteract the efficient release of drug after binding to the target cell. Several paradoxal
requirements should be combined into one immunoliposomal carrier system allowing
immunoliposomes (1) to retain drug completely following intravenous administration, (2) to avoid
rapid clearance by the MPS and allow extravasation, (3) to bind to tumor cells and (4) to efficiently
release the entrapped drug after binding to the tumor cells. As these attributes are not needed all at
the same time, it may be possible to construct liposomes with different layers in which each layer
fulfills one or more of the above mentioned functions (Figure 3). After performing its function a
layer should be shed from the liposomes in order to expose the next layer. Such transformable
liposomes or ‘multiple layer’ liposomes have recently been proposed by Bally et al. [147].The
feasibility of these putative ‘multiple layer’ liposomes has been illustrated in a study in which
cleavable PEG (thiolytic cleavage) was used to stabilize liposomes containing the non-bilayer
forming fusogenic lipid DOPE [70].The PEG-lipid in this system has a dual function. First, its
presence provides steric stabilization to yield prolonged circulation properties and second, it
stabilizes the lipid bilayer, thereby preventing DOPE-mediated destabilization of the bilayer and
contents release.The study showed that DOPE-mediated membrane destabilization - and as a result
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Figure 3 — Schematic representation of ‘multiple layer’ immunoliposomes at successive stages. Stage A represents a ‘multiple
layer’ immunoliposome while in the circulation. PEG-layers with two different chain lengths preserve the bilayer stability,
thereby assuring long circulation properties. After extravasation and penetration into the tumor interstitium, the outermost
PEG-coat should be shed in order to expose the homing devices for tumor cell-binding (stage B). Upon transfer of the
innermost layer of PEG-lipids or upon PEG-cleavage, the membrane destabilizing properties of liposomes become activated
either by exposure of membrane-active peptides (as shown in stage C) or by hexagonal phase formation of DOPE thereby
enabling effective delivery of encapsulated drug.
A B C
homing device fusogenic peptide long PEG-chain short PEG-chain
release of contents - only occurs upon cleavage of PEG.The ‘multiple layer’ liposomes may contain
PEG-lipids with different PEG-chain lengths (Figure 3). For instance, the first outermost layer may
consist of PEG-5000 for creating the steric stabilization effects, the second layer of functionalized
PEG-2000 for coupling of homing devices for specific binding and subsequent internalization, and
the third layer of ‘instable’ bilayers, stabilized by the two layers of PEG-lipids. Such ‘multiple layer’
liposomes should shed their layers one by one, starting with the outermost layer.The shedding of
the different layers of PEG may be regulated by using different PEG-lipid conjugates. It has been
shown that the rate of transfer of PEG-lipids to a large excess of neutral acceptor liposomes is
dependent on the length and degree of saturation of the acyl chains present in the lipid anchor [57].
This difference in PEG-lipid transfer can be utilized to control the shedding of PEG-layers from
multiple layer liposomes. In addition, PEG can be coupled to liposomes by using cleavable bonds
with different cleavage kinetics (e.g. acidic or enzymatic hydrolysis) [70,148].
TARGETING TO THE TUMOR VASCULATURE
An indirect approach to fight tumor cells with immunoliposomes may be to target to the tumor
vasculature with the aim to obstruct the blood supply to the tumor (Figure 4). As tumor cells rely
on the continuous supply of nutrition and oxygen like normal cells, depriving the blood supply will
result in tumor cell death. As compared to tumor cell targeting, vascular targeting has several
attractive features: (1) The endothelial cells are directly accessible to circulating immunoliposomes.
Therefore, tumor cell accessibility problems related to poor extravasation and tumor tissue
penetration are avoided. (2) Even the destruction of a small number of endothelial cells may be
enough to induce coagulation, resulting in the formation of an occlusive thrombus interfering with
tumor perfusion and leading to necrosis.Therefore, tumor vasculature-directed liposomes can be
expected to have a greater capacity to induce antitumor effects than liposomes designed for drug
delivery directly to tumor cells. (3) As most solid tumors rely on similar blood vessels for growth,
the vascular targeting approach should be applicable to most or possibly all solid tumors. (4)
Endothelial cells are genetically stable and therefore expected not to mutate to become resistant to
the therapy, as tumor cells often do. A prerequisite for tumor vascular targeting is of course the
existence of highly specific tumor vascular markers. In humans, several cell-surface receptors have
recently been identified that are specifically expressed on tumor vascular endothelium and are
potentially suitable for tumor vascular targeting purposes [149,150].
The feasibility to kill tumors by attacking their blood supply was demonstrated by several
investigators, utilizing tumor vasculature-directed antibody or peptide conjugates [151-153].
Successful targeting of immunoliposomes to endothelial cells has been shown in vitro [154-157] and
in vivo [64,158].The fact that endothelial cells are well accessible for intravenously injected
immunoliposomes is illustrated by work of Maruyama et al. showing targeting efficiencies of
immunoliposomes targeted to lung endothelial cells of up to 60% of the injected dose [10,108].
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However, immunoliposome-based applications of tumor vasculature targeting have not been
reported yet.
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Figure 4 — Concept of tumor vascular targeting versus tumor cell targeting in vivo. Immunoliposomes containing cytotoxic drugs
are injected intravenously and travel through the circulation where they can reach tumor vessels. If drug-loaded immunoliposomes
are targeted to tumor cells (upper panel), they should extravasate in order to reach and kill the tumor cells behind the tumor
vascular endothelial lining. Immunoliposomes targeted to specific receptors on tumor endothelium (e.g. αVβ-integrins or VEGF-
receptors) can lead to endothelial cell damage and the induction of blood coagulation (lower panel). In this way, the blood supply
to the tumor is obstructed, resulting in massive tumor cell death. Adapted from J.E. Schnitzer et al. [150]. 
FINAL REMARKS
We hope that this review on the current situation regarding the use of immunoliposomes for the
use in cancer chemotherapy provides a realistic perspective on where the field is going and where
opportunities can be found for rational improvement of the immunoliposome system. Ideally, two
objectives should be met: (1) all administered immunoliposomes should bind to their target
epitopes in vivo and (2) all encapsulated drug molecules should become therapeutically available
upon binding of immunoliposomes to the target receptors.To date, all targeted systems, including
immunoliposomes, fall short of meeting both criteria. However, recent advances have improved the
prospects for immunoliposome-based applications.These advances include development of
technological solutions for the preparation of long-circulating immunoliposomes, design of
‘immunotolerant’ targeting ligands, development of new coupling chemistries for attaching
targeting ligands to the liposome and attempts to enhance the therapeutic availability of associated
drugs. Certainly, encouraging results have been obtained. Over the last two decades, major
pharmaceutical achievements have been realized in liposomology and this maturing process will
facilitate the development of immunoliposome formulations that are pharmaceutically acceptable.
In conclusion, immunoliposomes still have a long way to go, but the strong need for more effective
chemotherapeutics will continue to motivate studies on immunoliposomes.
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2CELLULAR UPTAKE OF
LIPOSOMES TARGETED TO
INTERCELLULAR ADHESION
MOLECULE-1 (ICAM-1) ON
BRONCHIAL EPITHELIAL CELLS
SUMMARY
Previously, it was demonstrated that immunoliposomes, bearing anti-intercellular adhesion
molecule-1 (ICAM-1) antibodies (mAb F10.2), can specifically bind to different cell types
expressing ICAM-1. In this study, we have quantified the amount of immunoliposomes binding to
IFN-γ activated human bronchial epithelial cells (BEAS-2B) in vitro and studied the subsequent
fate of cell-bound anti-ICAM-1 immunoliposomes.We demonstrate that binding of the
immunoliposomes to the epithelial cells is depending on the liposome concentration used. After
binding to the cell surface, the anti-ICAM-1 immunoliposomes are rapidly internalized by the
epithelial cells. Sixty percent of cell-bound immunoliposomes were internalized by the epithelial
cells within one hour of incubation at 37ºC.The results indicate that ICAM-1 targeted
immunoliposomes may be used as carriers for the intracellular delivery of anti-inflammatory
drugs to sites of inflammation characterized by an increased expression of ICAM-1.
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INTRODUCTION
Adhesion molecules are cell surface glycoproteins that mediate physical and functional interactions
between two cells or between cells and their extracellular matrix.They play an important role in
many biological processes as diverse as the complex organization of tissues and organs, the
migration of cells during embryogenesis and the regulation of immune responses by mediating the
communication between different immune cells and the extravasation of inflammatory cells into
inflamed tissues [1-3].The process of leukocyte extravasation is induced by the local release of
pro-inflammatory mediators (vasoactive amines and cytokines) at the site of inflammation.This
results in a locally induced or increased expression of a variety of adhesion molecules on
endothelial cells, which allows multiple adhesive events with circulating leukocytes to occur.
Intercellular adhesion molecule-1 (ICAM-1) is an important adhesion molecule involved in the
process of leukocyte adhesion and extravasation. ICAM-1 is an immunoglobulin-like
transmembrane glycoprotein that is constitutively expressed at low levels on vascular endothelial
cells, epithelial cells and on a subset of leukocytes. Its expression is increased by the pro-
inflammatory cytokines interferon-γ (IFN-γ), tumor necrosis factor α (TNF-α) or interleukin-1
(IL-1) [4-9]. Numerous studies have demonstrated a locally enhanced ICAM-1 expression in
inflammation-related diseases, such as rheumatoid arthritis [10], asthma [11,12], nephritis [13,14],
inflammatory dermatosis [15,16], and atherosclerosis [17,18].The increased expression of ICAM-
1 and other cell adhesion molecules at sites of inflammation is under investigation for therapeutic
intervention.These molecules may be used as targets for drug carrier systems that can selectively
deliver anti-inflammatory compounds to sites of inflammation. In this light, we have previously
constructed liposomes bearing antibodies to ICAM-1 [19].These antibody-containing liposomes
(immunoliposomes) were shown to strongly bind to different cell types expressing ICAM-1 on
their surface and their binding was positively correlated with the expression level of ICAM-1 on
the target cells. After this first report on immunoliposome targeting to cells expressing adhesion
molecules, two other reports have appeared confirming the concept of adhesion molecule
targeting with immunoliposomes [20,21].
Specific binding of immunoliposomes to their target cells is an important prerequisite to fulfill,
but on its own this is not enough for effective drug delivery. As many drugs act at intracellular
sites, it is required that immunoliposome-encapsulated drugs are delivered intracellularly. In
principle, three routes that may lead to intracellular delivery of encapsulated compounds can be
discerned. Firstly, immunoliposomes may, after specific cell binding, release their contents in close
proximity of the target cells, with subsequent cellular uptake of released molecules. Secondly,
immunoliposomes may fuse with the cell membrane, thereby releasing their contents into the
cytosol.Thirdly, cell-bound immunoliposomes may be internalized by the target cells via receptor-
mediated endocytosis, followed by the intracellular release of encapsulated agents.Whether
immunoliposomes will be internalized or not is dependent on a variety of factors, such as
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liposome size [22-25], type of cell, and type of target receptor [26-28].Targeting of
immunoliposomes to receptors with known internalizing capacities (e.g. transferrin receptor, low
density lipoprotein-receptor, epithelial growth factor receptor) will likely result in internalization
of bound immunoliposomes, provided that they are relatively small in size (<0.2 µm) [29-31]. On
the other hand, it has been shown that immunoliposomes targeted to non-internalizing cell-
surface molecules on tumor cells remain located at the cell surface [32].
Here, we report on the interaction of ICAM-1-directed immunoliposomes with ICAM-1
expressing human bronchial epithelial cells in vitro.We have quantified the degree of cell binding
of ICAM-1-directed liposomes and we demonstrate that specific binding of these
immunoliposomes to ICAM-1 on the bronchial epithelial cell line BEAS-2B triggers rapid
internalization of cell bound immunoliposomes.The results are discussed in the context of
targeted drug delivery to sites of inflammation, characterized by an increased expression of
ICAM-1.
MATERIALS AND METHODS
MATERIALS
Liposome-related materials
Cholesterol (CHOL), N-succinimidyl-S-acetylthioacetate (SATA), N-ethylmaleimide, and calcein
were obtained from Sigma Chemical Co. (Rockford, IL, USA). Chloroform and methanol (pro
analysi) were obtained from Merck (Darmstadt, Germany), and N,N-dimethylformamide (DMF)
and hydroxylamine hydrochloride from Janssen Chimica (Geel, Belgium). Partially hydrogenated
egg-phosphatidylcholine with an iodine value of 40 (PHEPC; Asahi Chemical Industry Co.,
Ibarakiken, Japan) was prepared as described previously [33]. Egg-phosphatidylglycerol (EPG)
was kindly donated by Nattermann GmbH (Cologne, Germany), N-[4-(p-maleimidophenyl)
butyryl]phosphatidyl-ethanolamine (MPB-PE) was synthesized as described before [32,34].
Cell-related materials
Interferon-γ (IFN-γ) was purchased at Boehringer-Mannheim GmbH (Mannheim, Germany),
keratinocyte medium (keratynocyte-SFM) and supplements for keratinocyte-SFM, containing
recombinant human epithelial growth factor (rhEGF), and bovine pituitary extract came from
Gibco. (Grand Island, NY, USA). Bovine serum albumin (fraction V), fluorescein isothiocyanate
(FITC)-labeled goat anti-mouse F10.2 IgG (Fab’-specific) and R-phycoerythrin (PE)-labeled goat
anti-mouse IgG were obtained at Sigma Chemical Company. Anti-ICAM-1 mAb (IgG1), clone
F10.2 was prepared and isolated as described before [35]. Formaldehyde was obtained at Janssen
Chimica (Geel, Belgium).
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CELL CULTURE
The human bronchial epithelial cell line BEAS-2B obtained from Dr. J.F. Lechner (National
Institutes of Health, Bethesda, MD, USA) was cultured in serum-free keratinocyte medium,
supplemented with bovine pituary extract (25 µg/ml), recombinant human epidermal growth
hormone (rhEGF; 2.5 ng/ml) and gentamicin (50 µg/ml). In order to obtain an enhanced
expression of ICAM-1, BEAS-2B cells were stimulated with IFN-γ (200 U/ml) 24 hrs prior to
use in immunoliposome binding and internalization experiments [7]. BEAS-2B cells were
cultured at 37ºC with 5% CO2 in humidified air.
PREPARATION OF IMMUNOLIPOSOMES
Immunoliposomes, bearing covalently coupled F10.2 mAbs on their surface, were prepared as
described previously [19]. In short, liposomes were made from PHEPC, EPG, CHOL, and MPB-
PE (38.5:4:16:0.06 molar ratio) by lipid film hydration and subsequent extrusion through 0.2
µm polycarbonate filters [36].When indicated, calcein was incorporated as an aqueous marker at
a concentration of 90 mM and/or rhodamine-PE at an amount of 0.1 mol% of total lipid. Freshly
thiolated mAb F10.2 (100 µg/ml final concentration) was added to the liposomes (73.3 µmol
phospholipid/8 ml) and incubated for 1 h and 45 min at room temperature under constant
rotation.The coupling reaction was terminated by adding 50 µl of freshly prepared 8 mM N-
ethylmaleimide in HEPES buffer (10 mM HEPES, 1 mM EDTA, 135 mM NaCl, pH 7.4).
Liposomes were separated from unconjugated mAbs by ultracentrifugation (4 runs of 30 min at
60,000xg) and stored at 4ºC. As a control in binding and internalization experiments, liposomes
with the above mentioned composition were used without conjugated F10.2 mAb.
LIPOSOME CHARACTERIZATION
Mean particle size was determined by dynamic light scattering as described before [19]. Mean
size of liposomes was 0.2-0.25 µm with a polydispersity index varying from 0.06 to 0.15.
Phospholipid concentration was determined by the colorimetric method of Fiske and Subbarow
[37].The amount of conjugated IgG on the liposomal surface was determined with the Biorad DC
protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA) with mouse IgG as standard.The
protein coupling ratios for the different batches of immunoliposomes were in the range of 2-4 µg
IgG/µmol phospholipid, which corresponds with approximately 7-15 IgG molecules per
liposome.
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QUANTIFICATION OF THE DEGREE OF CELL BINDING
IFN-γ-activated BEAS-2B cells were detached from culture flasks with trypsin/EDTA (Gibco) in
phosphate buffered salt solution (PBS, pH 7.4) for 5 min at 37ºC, pelleted by centrifugation (5
min at 750xg) and washed once with immunofluorescence (IF)-buffer (1% bovine serum albumin
and 0.05% sodium azide in PBS, pH 7.4). A typical washing step involved resuspension of cells
into 1 ml of indicated buffer, followed by centrifugation (5 min at 750xg). Cells (2.5x105 cells
for each sample) were resuspended in 300 µl of IF-buffer containing varying concentrations of
control liposomes or F10.2 immunoliposomes with entrapped calcein as fluorescent label. Cells
were incubated in the presence of liposomes for 1 h on ice, washed three times with IF-buffer to
remove unbound liposomes and resuspended in 300 µl IF-buffer before a sample of 50 µl was
taken (corresponding with 2.5x104 cells). Samples were diluted with 150 µl of 1% Triton X-100
in PBS and incubated for 15 min at room temperature. Solubilized samples were transferred to a
96 well-plate and the fluorescence intensity of the sample was measured with a LS-50B
luminescence spectrometer (Perkin Elmer, Beaconsfield, Buckinghamshire, England) with
excitation wavelength set at 490 nm and emission at 520 nm. A reference curve was constructed
from calcein-containing F10.2 immunoliposomes with a known phospholipid concentration.
Background value was obtained from solubilized cells without prior incubation with liposomes.
CELLULAR INTERNALIZATION ASSAYS
Determination of the amount of cell-surface bound immunoliposomes as 
a function of incubation time
Cell surface-bound F10.2 immunoliposomes were determined by indirect immunofluorescence
analysis as described by Suzuki et al. [38]. In short, IFN-γ-activated BEAS-2B cells (2x105) were
detached from culture flasks using trypsin/EDTA and 2x105 cells were incubated with F10.2
immunoliposomes (0.5 µmol phospholipid/ml) in a total volume of 200 µl keratinocyte medium
for 60 min on ice. Cells were washed twice with ice-cold keratinocyte medium, resuspended into
300 µl medium and cultured for 0-3 hrs at 37ºC. Cells were washed once with IF-buffer and
incubated with goat anti-mouse IgG-fluorescently labeled with phycoerythrin (100-fold diluted in
IF-buffer) for 30 min on ice. After washing twice with IF-buffer, cells were analyzed by flow
cytometry using a FACscan flow cytometer (Becton&Dickinson, Mountain View, CA).The
procedure above was also performed on formaldehyde-fixed cells (cells were fixed by incubating
with 2% formaldehyde in PBS for 10 min at room temperature).
Determination of intracellular calcein 
Detached IFN-γ stimulated BEAS-2B cells were incubated with calcein containing F10.2
immunoliposomes. After two washing steps with ice-cold keratinocyte medium to remove the
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unbound liposomes, cells were cultured at 37ºC for varying time periods (0-2 hrs). Hereafter,
cells were incubated for 10 min in citric acid buffer (40 mM citric acid, 120 mM NaCl, pH 3.0),
washed twice with IF-buffer and analyzed by flow cytometry using a FACscan flow cytometer for
cell-associated calcein fluorescence.The mean fluorescence intensity of 10,000 cells was
determined for each sample.
Confocal Laser Microscopy 
In these experiments, the F10.2 immunoliposomes contained encapsulated calcein (90 mM) as a
fluorescent aqueous content marker and were labeled with rhodamine-PE as a liposomal lipid
marker. Detached, IFN-γ stimulated BEAS-2B cells were mixed with F10.2 immunoliposomes in
keratinocyte medium on ice as described above. Cells were washed once with IF-buffer and once
with keratinocyte SFM medium and resuspended into 300 µl medium. Subsequently, cells were
incubated for varying time periods (0-60 min) at 37ºC.Thereafter, cells were either washed twice
with IF-buffer or 3 times with citric acid buffer (pH 3.0) and once with IF-buffer. Cells were
then fixed with 2% formaldehyde in PBS for 1 h on ice and fixed to slides. Fixed cells were
analyzed for fluorescence using a laser confocal scanning microscope (Leica TCS NT Laser
confocal scanning microscope, Heidelberg GmbH, Germany). By using filters of 525/550 nm
and >590 nm, rhodamine and calcein fluorescence could be detected separately.
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RESULTS AND DISCUSSION
QUANTIFICATION OF THE DEGREE OF CELL BINDING
In a previous study, we have demonstrated that F10.2 immunoliposomes are able to specifically
bind to different cell types expressing ICAM-1.The degree of cell binding appeared to be
positively correlated with the degree of ICAM-1 expression [19]. In this study, we have quantified
the degree of binding of F10.2 immunoliposomes to IFN-γ-activated human bronchial epithelial
cells (BEAS-2B).The activated epithelial cells were used as a model system to study targeting
efficiency of F10.2 immunoliposomes to cells with an increased expression of ICAM-1 as found
at sites of inflammation.The degree of binding of F10.2 immunoliposomes to IFN-γ-stimulated
BEAS-2B cells was fluorometrically determined by analyzing cell-associated calcein fluorescence
after cells were incubated with calcein-containing F10.2 immunoliposomes for 1 h on ice. Figure
1 shows that the absolute amount of cell-bound immunoliposomes increased with increasing
concentrations of calcein-containing F10.2 immunoliposomes. Control liposomes with the same
lipid composition but without conjugated F10.2 mAbs showed a much lower degree of cell
binding. From the calcein fluorescence values, the number of bound liposomes per cell can be
estimated, assuming an average of 1.5 phospholipid bilayers per liposome and an average size of
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Figure 1 — Effect of liposome concentration on the extent of liposome binding to BEAS-2B cells. INF-γ stimulated BEAS-2B
cells (1x106 cell/ml) were incubated with F10.2 immunoliposomes z or with control liposomes  for 1 h on ice. After
removal of unbound liposomes, cell-associated calcein-fluorescence was determined with a fluorometer (n=3).
200 nm (Figure 2). At the highest concentration of F10.2 immunoliposomes used, approximately
15,400 liposome particles are estimated to be bound per cell. However, at such high
concentrations, liposomes without conjugated F10.2 mAbs also show considerable cell binding
(4,200 liposomes bound per cell), indicating that at high liposome concentrations part of the cell
binding is mediated by other interactions than antibody-antigen interaction.Therefore, the
experiments described below were carried out with immunoliposome concentrations of 300-500
nmol phospholipid/ml, at which the binding ratio of F10.2 immunoliposome versus control
liposomes is maximal. At these concentrations, approximately 4,000-7,000 F10.2
immunoliposomal particles were binding per cell as compared to only 200-300 particles in case
of control liposomes.
DETERMINATION OF THE AMOUNT OF CELL SURFACE-BOUND 
F10.2-IMMUNOLIPOSOMES AS A FUNCTION OF INCUBATION TIME
Cell surface-bound F10.2 immunoliposomes were determined by indirect immunofluorescence
analysis as a function of incubation time at 37ºC. Cells were incubated with F10.2
immunoliposomes for 1 h on ice and after removal of unbound particles, the cells were cultured
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Figure 2 — Effect of liposome concentration on the number of liposomes bound per cell. IFN-γ-stimulated BEAS-2B cells were
incubated with F10.2 immunoliposomes (black bars) or with control liposomes (white bars) essentially as described in Figure 1.
The exact values of the number of bound liposomes are depicted above each bar. Results of a typical experiment are shown. 
at 37ºC for varying time periods before analysis by flow cytometry.The amount of
immunoliposomes that could be detected on the surface of BEAS-2B cells with FITC-conjugated
antibodies directed against the liposome conjugated antibodies decreased during prolonged
incubation times at 37ºC (Figure 3). After 1 h incubation at 37ºC, 60% of the starting amount of
cell-bound liposomes had disappeared from the cell surface. Control experiments using cells
fixed with formaldehyde prior to liposome binding did not show any reduction in the amount of
cell-bound F10.2 immunoliposomes, indicating that the decrease of cell surface-bound
immunoliposomes is not caused by dissociation of immunoliposomes from the cell surface, but is
related to an active cellular process.This finding strongly suggested that F10.2 immunoliposomes
are internalized by BEAS-2B cells.
CALCEIN RELEASE FROM F10.2 IMMUNOLIPOSOMES DURING
CELLULAR INTERNALIZATION
The next step was to look at the fate of the encapsulated fluorescent marker calcein upon
internalization of F10.2 immunoliposomes by BEAS-2B cells. Cells were incubated with F10.2
immunoliposomes for 1 h on ice and unbound particles were washed away. Hereafter, cell-
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Figure 3 —Determination of cell surface-bound F10.2 immunoliposomes on BEAS-2B cells during prolonged incubation
periods at 37°C. Intact (z) or formaldehyde-fixed () cells (1x106/ml) were incubated with F10.2 immunoliposomes (500
nmol phospholipid/ml) for 1 h on ice, washed twice with keratinocyte SFM medium (without serum), and then cultured at 37°C
in SFM medium for the indicated time periods. Subsequently, cells were then labeled with phycoerythrin-conjugated goat anti-
mouse mAbs and analyzed by flow cytometry (n=4).
associated calcein-fluorescence was determined by flow cytometry, either directly or after 1 h
incubation at 37ºC (Figure 4).The results show that after 1 h incubation at 37ºC, the amount of
cell-associated calcein-fluorescence had increased in comparison with the cell-associated calcein-
fluorescence before the 1 h incubation at 37ºC. As calcein is encapsulated in the liposomes at a
quenching concentration (90 mM), an increase of calcein fluorescence intensity can be explained
as a dequenching effect due to calcein release from the liposomes.
In order to demonstrate that dequenching of calcein fluorescence is caused by the intracellular
release of calcein from internalized F10.2 immunoliposomes and not merely by extracellular
leakage of encapsulated calcein from cell-bound F10.2 immunoliposomes, an attempt was made
to remove the cell-bound immunoliposomes by short exposure to low pH (10 min at pH 3.0). It
is described in literature that such exposure to low pH will liberate immunoliposomes from the
cell surface, without disrupting the cell membrane [39,40]. However, confocal laser microscopic
analysis showed us that acidic exposure of BEAS-2B cells does not result in the detachment of
bound F10.2 immunoliposomes from the cell surface, but rather in release of calcein from the
cell-bound liposomes (Figure 6B,D). Nevertheless, acidic treatment of cells can be used to
discriminate between immunoliposome-encapsulated calcein located at the cell-surface from
internalized immunoliposome-encapsulated calcein as this method completely removes
immunoliposome-encapsulated calcein-fluorescence located at the cell surface.The acid
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Figure 4 — Flow cytometry analysis of cell-associated calcein fluorescence. BEAS-2B cells were incubated with F10.2
immunoliposomes (500 nmol phospholipid/ml) on ice and unbound liposomes were removed. Thereafter cells were either
directly analyzed for associated calcein fluorescence (black line) or after 1 h incubation at 37°C (dotted line).
Autofluorescence of BEAS-2B cells are also illustrated (solid filled histogram).
treatment method was used to determine the degree of intracellular calcein-fluorescence as a
function of incubation time at 37ºC (Figure 5). For this experiment, cells were pre-incubated
with F10.2 immunoliposomes for 1 h on ice to load cells with immunoliposomes. Hereafter, cells
were cultured at 37ºC for varying time periods followed by acid-treatment to remove the calcein
from immunoliposomes located at the cell-surface. Figure 5 shows that the amount of
intracellular calcein fluorescence increases at increasing incubation times at 37ºC.The
observation that cell associated calcein fluorescence decreases after 2 hrs incubation at 37ºC may
be caused by intracellular compounds that are able to quench the calcein fluorescence. For
example, Fe2+ ions present in the cell will quench calcein fluorescence [41]. However, the
possibility that calcein that is released intracellularly will subsequently leak out of the cells
cannot be excluded.
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Figure 5 — Flow cytometry analysis of immunoliposome-encapsulated calcein internalization into BEAS-2B cells.
Cells (1x106 cells/ml) were incubated with F10.2 immunoliposomes at a concentration of 500 nmol phospholipid/ml
for 1 h on ice, washed twice with keratinocyte SFM medium and incubated at 37°C in SFM medium for the indicated
time periods. Thereafter, cells were exposed to acidic condition (citric acid buffer, pH 3.0) for 10 min and washed
twice with IF-buffer before flow cytometry analysis (n=2). 
CONFOCAL LASER MICROSCOPIC ANALYSIS OF F10.2
IMMUNOLIPOSOME INTERNALIZATION
AND SUBSEQUENT INTRACELLULAR RELEASE OF CALCEIN
We have further analyzed the process of liposome internalization by confocal laser microscopy
(Figure 6). Cells were incubated with F10.2 immunoliposomes containing two fluorescent
markers; rhodamine-PE as a lipid marker and encapsulated calcein as an aqueous marker. After
incubation for 1 h at 4ºC, both calcein fluorescence and rhodamine fluorescence were observed
associated with the cell membrane (Figure 6A). By superimposing two pictures taken with two
different filter settings (525-550 nm and >550 nm), it can be seen that the liposomal membrane
marker rhodamine-PE and calcein are co-localized as visualized by the yellow fluorescence.
Calcein fluorescence, but not rhodamine fluorescence, could be removed from the cell surface by
exposing the cells for 10 min to pH 3.0 (Figure 6B). Incubation of cells with surface-bound
F10.2 immunoliposomes at 37ºC resulted in the appearance of bright fluorescent vacuoles in the
cell interior, besides the cell membrane associated fluorescence (Figure 6C). Exposure to low pH
showed the disappearance of surface-bound calcein fluorescence, but not of calcein located inside
intracellular vacuoles (Figure 6D), confirming the fact that immunoliposomes, together with the
encapsulated calcein, are internalized.
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Figure 6 — Confocal laser microscopic analysis of the internalization of F10.2 immunoliposomes containing calcein and
rhodamine-PE as fluorescent tracers into IFN-γ-activated BEAS-2B cells. BEAS-2B cells were incubated with F10.2
immunoliposomes either for 1 h on ice (Figures 6A,B) or for 1 h on ice and subsequently for 1 h at 37°C (Figures 6C,D).
Thereafter, cells were either directly analyzed by confocal laser microscopy (Figures 6A,C) or exposed to citric acid buffer (pH
3.0) for 10 min (Figures 6B,D) before analysis. Used filter settings were 525-550 nm (green fluorescence) and >590 nm (red
fluorescence). Superimposed pictures of both filter settings are also illustrated. Scale bars represent 10 µm. 
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OVERALL CONCLUSIONS
Taking all results together, we can conclude that immunoliposomes targeted to ICAM-1 on IFN-γ
activated human bronchial epithelial cells are able to bind to these cells. Depending on the
concentration of immunoliposomes added, 1-14 nmol liposomal phospholipid appeared to bind
per 106 BEAS-2B cells after 1 h incubation on ice, which corresponds with 680-15,400 particles
bound per cell.
Furthermore, we studied whether ICAM-1-directed immunoliposomes are internalized by BEAS-
2B cells. Little is known about the internalization characteristics of ICAM-1 molecules. ICAM-1
is utilized as a target receptor by the major group of human rhinoviruses. Binding to ICAM-1
results in receptor-mediated endocytosis of the bound virus particles [42]. On the other hand,
internalization of monoclonal antibodies directed against ICAM-1 (mAb RR1/1) on human
umbilical vein endothelial cells (HUVEC) could not be detected [43].
In this study, it was observed that F10.2 immunoliposomes are rapidly internalized after specific
binding to ICAM-1 expressing BEAS-2B cells. After 1 h incubation at 37ºC, 60% of the surface-
bound immunoliposomes were internalized.These findings have implications for the development
of drug targeting strategies to interfere in inflammatory processes.The rapid and extensive
internalization of ICAM-1 targeted liposomes make them suitable carriers for the intracellular
delivery of anti-inflammatory drugs. Also, ICAM-1-directed immunoliposomes may be used to
selectively deliver antisense oligonucleotides to endothelial and epithelial cells to down-regulate
adhesion molecule expression at sites of inflammation. As ICAM-1 is involved in the migration of
inflammatory cells into inflamed tissues, down-regulation of ICAM-1 expression by antisense
oligonucleotides will inhibit the migration of immune cells into inflamed tissues [44], and thereby
inhibit the inflammatory response [45,46]. However, it should be realized that the liposomal
system needs to be further optimized before application in vivo.The immunoliposome
composition used in the present in vitro study may not be optimal in vivo. Also, the presence of
whole antibody molecules exposed on the liposome surface may give problems related to
immunogenicity when applied repeatedly in vivo [47,48]. In addition, circulating time after
intravenous injection might be too short to allow efficient interaction with target epitopes.
Although it was observed that calcein is released from the immunoliposomes upon
internalization, this does not guarantee that other encapsulated compounds will become available
to intracellular targets after internalization of liposomes.The confocal microscopic findings
strongly suggest that internalization occurs via receptor-mediated endocytosis. A large amount of
endocytosed liposomes will eventually end up in lysosomal, degradative compartments
[22,23,49]. For this reason, pH-dependent fusogenic properties have been incorporated into the
immunoliposomal carrier, in order to promote delivery over the endosomal membrane and
thereby improving the therapeutic availability of the encapsulated compound after cellular
internalization.This work is described in chapters 3-5 of this thesis.
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COMPARISON OF
IMMUNOLIPOSOME TARGETING
TO THREE DIFFERENT
RECEPTORS EXPRESSED BY
HUMAN OVARIAN CARCINOMA
(OVCAR-3) CELLS 
2+
SUMMARY
Immunoliposomes were targeted to three different cell-surface receptors: intercellular adhesion
molecule-1 (ICAM-1), epithelial glycoprotein-2 (EGP-2), and epidermal growth factor receptor
(EGFR) expressed on OVCAR-3 ovarian carcinoma cells. Binding and internalization of these
immunoliposomes was analyzed qualitatively by flow cytometry and confocal laser scanning
microscopy to determine which cell-surface receptor is most suitable in intracellular delivery of
immunoliposomal drugs to ovarian carcinoma cells. Under the tested conditions, the EGFR
turned out to be the best candidate to obtain receptor-mediated endocytosis of a large amount of
immunoliposomes.
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INTRODUCTION
The research described in this thesis aims at delivering therapeutic compounds encapsulated in
antibody-directed liposomes (immunoliposomes; IL) into the cytoplasm of tumor cells, in
particular of ovarian carcinoma cells (OVCAR-3) cells.This is attempted by exploiting the route
of receptor-mediated endocytosis followed by endosomal escape of immunoliposome-entrapped
drug molecules, induced by pH-dependent fusogenic peptides or proteins incorporated in the
liposomal carrier.This ‘Trojan horse’ approach of delivery requires binding and internalization of
immunoliposomes as a first step in the cytosolic delivery of entrapped drugs.
Both the occurrence of internalization and lack of internalization of immunoliposomes
specifically bound to target cell surface receptors have been reported.The occurrence of
receptor-mediated endocytosis of receptor-bound immunoliposomes is determined by the type
of receptor, provided that immunoliposomes are small enough (<150 nm).Therefore, the choice
of the target receptor for intracellular delivery of immunoliposomal drugs is of major
importance. However, not all monoclonal antibodies recognizing the same receptor mediate
internalization of the receptor/mAb complex. It was demonstrated that three different mAbs
recognizing different epitopes on the same receptor (folate-binding protein) on ovarian
carcinoma cells were processed by the cells in different ways.Two out of three mAbs were
internalized, whereas the other remained located on the cell surface.Thus, not all mAbs directed
against receptors with internalizing capacity will be able to trigger internalization as these mAb
recognize different epitopes on the same receptor. In addition, the internalizing capacity of cell-
surface receptors is also dependent on the type of cell that expresses the cell-surface receptor.
For instance, immunoliposomes targeted to the HER-2 antigen were reported to be efficiently
internalized by human breast cancer cells, less efficiently by MKN-7 human gastric or SKOV-3
ovarian carcinoma cells, and not at all by N-87 human gastric carcinoma cells. Consequently,
internalization of antibody-directed liposomes cannot be predicted a priori.
For targeting immunoliposomes to ovarian carcinoma cells, mAbs directed against several
receptors have been used. In our group Fab’ fragments of mAb OV-TL3 directed against the
tumor-associated antigen OA3, which is present on more than 90% of all human ovarian
carcinomas and mAb 323/A3 directed against the epithelial glycoprotein-2 (EGP-2) were
conjugated to the surface of doxorubicin-laden liposomes. For both OV-TL3 immunoliposomes
and 323/A3 immunoliposomes specific binding to OVCAR-3 was demonstrated in vitro and in
vivo. Binding of OV-TL3 immunoliposomes to OVCAR-3 cells residing in the peritoneal cavity of
nude mice after i.p. injection was high: after 5 hrs incubation >80% of immunoliposomes
recovered from the peritoneal cavity was found to be associated with tumor cells. In addition,
electron microscopy analysis demonstrated that OV-TL3 immunoliposomes were bound to the
surface of OVCAR-3 cells that were isolated from the peritoneal cavity of athymic mice.
Internalization of cell-bound immunoliposomes was not detected after this 5 hrs incubation.
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Internalization of 323/A3-IL by OVCAR-3 cells has not been investigated so far. It has been
shown in the immunotoxin literature that targeting to the EGP-2 receptor can lead to
internalization: 25% of cell bound immunotoxins consisting of doxorubicin conjugated to mAb
MOC31 (α-EGP-2), were internalized by small lung cancer cells after 5 hrs.
Besides the above mentioned target receptors, other receptors may be used to target
immunoliposomes to OVCAR-3 cells. In a study from our group immunoliposomes were
targeted to intercellular adhesion molecule-1 (ICAM-1) expressed on human bronchial epithelial
cells. It was demonstrated that the immunoliposomes were capable to specifically bind to these
cells; in addition, they were efficiently internalized (see chapter 2 and ). As ICAM-1 expression is
not only up-regulated at sites of inflammation but is also involved in the metastatic spread of
many types of tumor cells , this receptor may also be used for targeting immunoliposomes to
OVCAR-3 cells.The epidermal growth factor receptor (EGFR), has been found to be over-
expressed on many carcinoma cells and is often used as target for drug delivery to carcinoma
cells.
In this study we have targeted immunoliposomes to the cell-surface receptors ICAM-1, EGP-2
and EGFR expressed on OVCAR-3 cells. Binding and internalization by OVCAR-3 cells was
monitored qualitatively by flow cytometry and confocal laser scanning microscopy to determine
which antibody is most suitable to achieve specific internalization of immunoliposomes by
OVCAR-3 cells.The results show that the EGFR is the most suitable candidate to deliver
immunoliposomes into the endocytic pathway of OVCAR-3 cells.
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MATERIALS & METHODS
MATERIALS
Cholesterol (CHOL), N-succinimidyl-S-acetylthioacetate (SATA), N-ethylmaleimide, bovine
serum albumin (fraction V), fluorescein isothiocyanate (FITC)-labeled goat anti-mouse IgG (Fab’-
specific) and R-phycoerythrin (PE)-labeled goat anti-mouse IgG were obtained from Sigma-
Aldrich Co. (St. Louis, MO, USA). Chloroform and methanol were obtained from Merck
(Darmstadt, Germany), and N,N-dimethylformamide (DMF) and hydroxylamine hydrochloride
from Janssen Chimica (Geel, Belgium). Partially hydrogenated egg-phosphatidylcholine with an
iodine value of 40 (PHEPC; Asahi Chemical Industry Co., Ibarakiken, Japan) was prepared as
described previously. N-[4-(p-maleimidophenyl) butyryl]phosphatidylethanolamine (MPB-PE) and
lissamine rhodamine B-labeled glycerophosphoethanolamine (Rho-PE) were purchased at Avanti
Polar Lipids Inc. (Alabaster, AL, USA). Anti-ICAM-1 mAb (IgG1), clone F10.2 was a gift from
Dr. Henricks (department of Pharmacology and Pathophysiology, Utrecht Institute for
Pharmaceutical Sciences, Utrecht University, Utrecht,The Netherlands). Murine mAb 425 of
isotype IgG2b (EMD55900) (Merck KGaA, Bernstadt, Germany) directed against the human
epidermal growth factor receptor (EGFR) was kindly donated by Dr. G.A. van Dongen
(Department of Otolaryngology/Head and Neck Surgery, University Hospital Vrije Universiteit,
Amsterdam,The Netherlands). Monoclonal antibody 323/A3, directed against the epithelial
glycoprotein-2 (EGP-2) was kindly donated by Centocor Europe BV (Leiden,The Netherlands).
Formaldehyde was obtained from Janssen Chimica (Geel, Belgium). 1,1’-dioctadecyl-3,3,3’,3’-
tetramethylindodicarbocyanine perchlorate (DiD) was purchased from Molecular Probes
(Leiden,The Netherlands).
CELL CULTURE
The human ovarian carcinoma cell line NIH:OVCAR-3 was originally obtained from Dr.
Hamilton (National Cancer Institute, Bethesda, MD). OVCAR-3 cells were cultured in DMEM
containing 3.7 g/l sodium bicarbonate, 4.5 g/l L-glucose (Gibco, Grand Island, NY, USA) and
supplemented with 2 mM L-glutamine, 10 mM HEPES, 10% (v/v) heat inactivated fetal calf
serum (FCS), penicillin (100 IU/ml), streptomycin (100 µg/ml), and amphotericin B (0.25
µg/ml; all purchased at Gibco). Cells were maintained at 37ºC in humidified air with 5% CO2.
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PREPARATION AND CHARACTERIZATION OF IMMUNOLIPOSOMES
Immunoliposomes were prepared by conjugating mAb 425 (IgG2b), 323/A3 (IgG1), and F10.2
(IgG1) to the membrane of liposomes according to the method described previously with some
minor modifications (see chapter 2). In short, liposomes were made by hydrating a lipid film
composed of PHEPC, CHOL and MPB-PE at a molar ratio of 1.925:1:0.075, respectively in 5
mM HEPES, 150 mM NaCl, 1 mM EDTA, pH 7.4 (HBS/EDTA).When indicated either NBD-PE
or Rho-PE were included in the liposomes as a fluorescent marker at a molar amount of 0.1%
relative to the total amount of lipid. Subsequently, liposomes were sized by extrusion through 0.1
µm pore filters. Freshly thiolated mAbs (for details see chapter 2) at a final concentration of 450
µg/ml were added to the liposomes (40 mM) and incubated for 2 hrs at room temperature under
constant rotation.The coupling reaction was terminated by adding 50 µl of freshly prepared 8
mM N-ethylmaleimide in HEPES buffer (10 mM HEPES; 1mM EDTA; 135 mM NaCl pH 7.4).
Liposomes were separated from unconjugated mAbs by ultracentrifugation (4 runs of 30 min at
60,000xg) and stored at 4ºC. Mean particle size of (immuno)liposomes was determined by
dynamic light scattering as described before. Phospholipid concentration was determined by the
colorimetric method of Fiske and Subbarow and the amount of conjugated IgG on the liposomal
surface was determined with the Bio-Rad DC protein assay kit (Bio-Rad Laboratories, Hercules,
CA, USA) with mouse IgG as standard.
FLOW CYTOMETRY ANALYSIS OF IMMUNOLIPOSOME BINDING 
TO OVCAR-3 CELLS
Immunoliposomes and control liposomes (without conjugated mAb) were added to 2.5x105
OVCAR-3 cells and incubated for 1 h at the indicated temperature. Cells were washed 2 times
with 1 ml of immunofluorescence (IF) buffer (1% (w/v) BSA in PBS pH 7.4). Hereafter, cells
that had been incubated with fluorescently labeled immunoliposomes (i.e. immunoliposomes
containing Rho-PE as a lipidic fluorescent marker) were resuspended in 500 µl of IF-buffer and
analyzed by flow cytometry.To cells that were incubated with unlabeled (immuno)liposomes, 100
µl of appropriately diluted FITC-labeled goat anti-mouse IgG were added and incubated for 1 h
on ice. After two additional wash steps with IF-buffer, these cells were resuspended into 500 µl
IF-buffer and analysed for cell-associated fluorescence by flow cytometry. Quantification of the
degree of cellular internalization of cell-bound liposomes was performed as previously described
by us and another group (see also chapter 2).
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CONFOCAL LASER SCANNING MICROSCOPY (CLSM) ANALYSIS
OF CELLULAR UPTAKE OF IMMUNOLIPOSOMES
For CLSM analysis, OVCAR-3 cells, either in suspension or adhered to chamber slides (Nalge
Nunc International Corp., Naperville, IL, USA), were incubated with Rho-PE-labeled
(immuno)liposomes for 1 h after which cells were washed twice with 1 ml of PBS and
subsequently fixed with 4% (v/v) of formaldehyde in PBS for 20 min at room temperature. After
fixation, cells were washed twice with PBS. Suspension cells were mounted on object slides and
overlaid with cover slides that were sealed with nail polish. Cells were analyzed on a Leica TCS-
SP confocal laser-scanning microscope equipped with a 488 nm Argon, 568 nm Krypton and 647
nm HeNe laser.
89
ap
pe
nd
ix
 t
o 
ch
ap
te
r 
2
10 0 10 1 10 2 10 3 10 4
Fluorescence Intensity
0
12
8
N
um
be
r 
of
 c
el
ls
a 
c 
b 
d 
Figure 1 – Expression pattern of different cell-surface receptors on the surface of OVCAR-3 cells determined by indirect
immunofluorescence staining and flow cytometry. Shown are OVCAR-3 cells incubated with FITC-labeled goat anti-mouse
secondary antibody (a), with mAb 425 (αEGFR) and FITC-labeled secondary antibody (b); with mAb F10.2 (αICAM-1) and
FITC-labeled secondary antibody (c), and with mAb 323/A3 and FITC-labeled secondary antibody (d). Histograms show the
mean fluorescent intensity of 4000 cells. 
RESULTS AND DISCUSSION
In this study, immunoliposomes were targeted to three different cell surface receptors on
OVCAR-3 cells to explore which receptor is most efficient in delivering immunoliposomes into
the endosomal pathway of the cell as the first step in a strategy for cytosolic drug delivery. Based
on previous experience with immunoliposome targeting, three different surface receptors were
chosen: the intercellular adhesion-molecule-1 (ICAM-1), the epithelial glycoprotein-2 (EGP-2)
and the epidermal growth factor receptor (EGFR).The expression pattern of these cell-surface
receptors on OVCAR-3 cells was determined by flow cytometry with indirect immuno-
fluorescence using monoclonal antibodies directed against EGP-2 (mAb 323/A3), EGFR (mAb
425) and ICAM-1 (mAb F10.2).The expression levels of the different cell surface receptors are
shown in Figure 1.The expression level of EGP-2 was 10 times higher than the expression levels
of ICAM-1 and EGFR, which showed comparable expression levels. For liposome targeting, the 3
mAbs were chemically modified with SATA to allow covalent conjugation to the surface of
liposomes.The average size of liposomes and the amount of conjugated IgG are given in Table 1.
IMMUNOLIPOSOME BINDING TO OVCAR-3 CELLS
Binding of fluorescently labeled immunoliposomes to OVCAR-3 cells at 4ºC is shown in 
Figure 2. Both 323/A3-IL and 425-IL showed concentration-dependent binding to OVCAR-3
cells. Binding of 323/A3-IL was higher than binding of 425-IL at concentrations >1 µmol
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Type of Liposomes
Control Liposomes
425-Immunoliposomes (α-EGFR)
323/A3-Immunoliposomes (α-EGP-2)
F10.2-Immunoliposomes (α-ICAM1)
Average particle size (nm)/
Polydispersity Index 
133/0.08
128/0.09
155/0.13
131/0.09
Amount of conjugated mAb
(µg/µmol PL)
—
10
18
14
Table 1 – Characterization of control liposomes and immunoliposomes. Mean particle size and amount of conjugated protein
are given for each liposome preparation.
PL/ml. Binding of control liposomes (i.e. liposomes without conjugated antibody) was negligible
at the concentration range tested. Surprisingly, immunoliposomes targeted to ICAM-1 did not
show any binding to OVCAR-3 cells despite the fact that ICAM-1 cell-surface expression on
these cells was detected. It is not clear which factors underlie this lack of cell binding. One
potential reason may be that modification of mAb F10.2 with SATA necessary to conjugate the
antibody to maleimide-derivatized phospholipids in the liposome bilayer has resulted in loss of
binding activity of this mAb. In chapter 2, however, it was demonstrated that modification of
F10.2 with SATA was possible with preservation of binding activity.Yet, F10.2 used in chapter 2
was modified at a lower SATA to antibody ratio (8:1) compared to SATA modification of mAb
F10.2 used in this study (30:1). Due to the inability of F10.2 IL to bind to OVCAR-3 cells, these
immunoliposomes were excluded from further experiments.
Analysis of immunoliposome binding by confocal laser scanning microscopy (CLSM) confirmed
that both 323/A3-IL and 425-IL are able to bind to a monolayer of OVCAR-3 cells adhered to
polystyrene chamber slides as indicated by the presence of rhodamine-fluorescence on the surface
of the cells (Figure 3). Fluorescent staining of OVCAR-3 cells incubated with 425-IL is relatively
weak compared to cells incubated with 323/A3-IL, indicating a lower degree of cell binding of
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Figure 2 – Binding of immunoliposomes to OVCAR-3 cells at 4ºC. OVCAR-3 cells were incubated with liposomes labeled with
the lipophilic fluorescent probe Rho-PE for 1 h at 4ºC. After removal of unbound liposomes cells were analyzed for cell-
associated rhodamine fluorescence by flow cytometry. Each point represents the mean fluorescence intensity of 4000 cells
analyzed (n=3). 323/A3 IL: mAb 323/A3-directed immunoliposomes; F10.2 IL: mAb F10.2-directed immunoliposomes; 425-
IL: mAb 425-directed immunoliposomes; CL: control liposomes without conjugated antibodies, but with the same lipid
composition as the immunoliposomes. Error bars indicate SEM (n=3).
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Figure 3 – Confocal laser scanning microscopy (CLSM) analysis of immunoliposome binding to OVCAR-3 cells at 4ºC. A
monolayer of OVCAR-3 cells adhered to chamber slides was incubated with Rho-PE-labeled 323/A3-IL (Panel A) or 425-IL
(Panel B) for 60 min at 4ºC (500 nmol PL/ml). After removal of unbound liposomes, cells were fixed in 4% formaldehyde
solution in PBS and analyzed by CLSM and light microscopy (LM). For clarity, cell-associated rhodamine fluorescence is
indicated in greyscale (white indicates no fluorescence, black indicates highest fluorescence). Pictures obtained with CLSM and
LM have been superimposed to show the localization of fluorescence inside cells. Scale bar represents 25 µm. 
425-IL at 4ºC.The observed cell-associated fluorescence is primarily located at the plasma
membrane of OVCAR-3 cells with no detectable spots of fluorescence located intracellularly.
Binding of immunoliposomes to both OVCAR-3 cells and A-2780 cells (ovarian carcinoma cells
lacking expression of EGP-2) was also evaluated at 37ºC both with flow cytometry and CLSM.
For flow cytometry analysis, 323/A3 immunoliposomes and 425-immunoliposomes were labeled
with the fluorescent probe DiD. Figure 4 shows that the degree of binding of 323/A3-IL to
OVCAR-3 cells is again higher compared to that of 425-IL. In addition, 323/A3-IL binding was
restricted to OVCAR-3 cells, whereas 425-IL also bound to A2780 cells, although less than
binding to OVCAR-3 cells. CLSM analysis with Rho-PE-labeled immunoliposomes demonstrates
that cell-associated fluorescence is more intense at 37ºC compared to binding at 4ºC (Figure 5),
indicating that the degree of binding is higher at 37ºC. Interestingly, the distribution of cell-
bound 323/A3-IL is primarily confined to cells located at the edges of the monolayer, whereas
425-IL binding is more equally distributed over the cells present in the monolayer. Basolateral
expression of EGP-2 epithelial cells has been demonstrated in a study comparing the expression
patterns of EGP-2 in 84 different human colorectal adenomas and adeno-carcinomas as well as
healthy tissue. Although the complex organization of epithelial cells in vivo cannot be compared
with the in vitro situation it might well be that EGP-2 expression on adherent OVCAR-3 cells
growing as a monolayer is restricted to the basolateral side of the cells, which may explain the
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Figure 4 – Flow cytometry analysis of immunoliposome binding to OVCAR-3 and A2780 cells as a function of liposome
concentration. Cells were incubated with increasing concentrations of DiD-labeled immunoliposomes or control liposomes for
60 min at 37ºC. Cells were analyzed by flow cytometry after removal of unbound liposomes. Each point represents the average
of the mean fluorescence intensity of 4000 cells. Error bars indicate SEM (n=3). 
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Figure 5 – CLSM analysis of immunoliposome binding to OVCAR-3 cells at 37ºC. A monolayer of OVCAR-3 cells adhered to
chamber slides were incubated with rhodamine-labeled 323/A3-IL (Panel A) or 425-IL (Panel B) for 60 min at 37ºC (500
nmol PL/ml). After removal of unbound liposomes, cells were fixed in 4% formaldehyde solution in PBS and analyzed by
CLSM and light microscopy (LM). For clarity, cell-associated rhodamine fluorescence is indicated in greyscale (white indicates
no fluorescence, black indicates highest fluorescence). Pictures obtained with CLSM and LM have been superimposed to show
the localization of fluorescence inside cells. Scale bar represents 25 µm.
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Figure 6 – CLSM analysis of immunoliposome binding to OVCAR-3 cells in suspension. Panel A: OVCAR-3 cells incubated
with 500 µmol/ml PL of 425-IL for 1 h at 37ºC. Panel B: same as panel A but in the presence of 1 mg/ml free mAb 425;
Panel C: same as panel A but in the presence of 1 mg/ml of free mAb 323/A3. Scale bars represent 25 µm.
lower degree of cell binding. Besides cell membrane-associated fluorescence also spots of
fluorescence located inside cells can be discerned when the cells were incubated with 425-IL.
The frequency and intensity of intracellular fluorescent spots is much less when cells were
incubated with 323/A3-IL, indicating that 425-IL are more efficiently internalized by OVCAR-3
cells than 323/A3-IL.
Binding of 425-IL to OVCAR-3 cells could be blocked by adding high concentrations (1 mg/ml)
of free mAb 425 to the cells prior to the addition of the immunoliposomes. Pre-incubation with
the same concentration of mAb 323/A3 did not have an effect on the degree of 425-IL binding to
OVCAR-3 cells (Figure 6).These results strongly indicate that 425-IL binding to OVCAR-3 cells
is exclusively mediated by the conjugated monoclonal antibodies present on the surface of 425-IL.
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Figure 7 – Determination of the amount of immunoliposomes bound to the surface of OVCAR-3 cells. OVCAR-3 cells, both
vital and fixed with 4% formaldehyde, were incubated with immunoliposomes (500 µmol PL/ml) for 1 h at 4°C. After removal
of unbound liposomes, cells were further incubated in culture medium at 37ºC for indicated time periods. Hereafter,
immunoliposomes still present on the cell surface were stained with a FITC-labeled goat anti-mouse antibody and analyzed by
flow cytometry. The amount of immunoliposomes present on the cell surface is expressed relative to the initial amount of cell-
bound immunoliposomes (i.e. at t=0 min, directly after incubation at 4°C). Error bars indicate SEM (n=3).
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Figure 8 – CLSM close-up analysis of immunoliposome internalization into OVCAR-3 cells. OVCAR-3 cells were incubated
with 500 µmol PL/ml of immunoliposomes for 2 hrs at 37ºC. Unbound immunoliposomes were removed prior to fixation of
cells with 4% formaldehyde. Panel A: OVCAR-3 cells grown in suspension and incubated with 323/A3 IL. Panel B: OVCAR-3
cells grown in suspension and incubated with 425-IL. Panel C: OVCAR-3 cells grown as a monolayer and incubated with 425-
IL. Scale bars represent 10 µm.
INTERNALIZATION OF IMMUNOLIPOSOMES BY OVCAR-3 CELLS
Internalization of cell-bound immunoliposomes was also confirmed by indirect
immunofluorescence analysis as described previously. Immunoliposomes were incubated with
OVCAR-3 cells at 4ºC for 1 h. After removal of unbound immunoliposomes, cells were
incubated at 37ºC for the indicated time period.Then the immunoliposomes still attached to the
cell-surface of OVCAR-3 cells were labeled with FITC-conjugated antibodies directed against the
liposome-conjugated mAbs.The results of this experiment are shown in Figure 7. It can be seen
that the amount of immunoliposomes located on the surface of OVCAR-3 cells decreased within
time. After 2 hrs, the amount of 323/A3-IL initially bound to OVCAR-3 cells was decreased
with approx. 25% and the amount of 425-IL with approx. 50%. Control experiments using cells
fixed with formaldehyde prior to immunoliposome binding show a marginal reduction in
immunoliposome binding (approx. 10%). As fixed cells do not internalize particles, differences in
reduction of immunoliposomes bound to the surface of OVCAR-3 cells between fixed and non-
fixed cells can be ascribed to an active process of the cell, which strongly suggests that both
323/A3-IL and 425-IL are internalized by OVCAR-3 cells.
To ascertain the occurrence of internalization, close-ups of OVCAR-3 cells incubated with either
323/A3-IL or 425-IL were made by confocal laser scanning microscopy to check for
intracellularly localized immunoliposomes (Figure 8). 323/A3-IL incubated with OVCAR-3 cells
at 37ºC are primarily located at or near the cell membrane of OVCAR-3 cells as illustrated by a
rim of fluorescence around OVCAR-3 cells. Only minor amounts of internalized spots of
fluorescence can be observed (Figure 8A). In contrast, 425-IL incubation yield many fluorescent
spots inside OVCAR-3 cells besides fluorescence at the cell surface (Figure 8B). Internalization of
425-IL by OVCAR-3 cells is more pronounced when adherent OVCAR-3 cells are used as
compared to OVCAR-3 cells in suspension (Figure 8C).
Taking these results together it can be concluded that both EGP-2 and EGFR can be used as
receptors to target immunoliposomes into the endosomal pathway of OVCAR-3 cells. Although
the expression level of EGP-2 is much higher than the expression level of EGFR, the capacity of
this receptor to internalize immunoliposomes is much lower (~15% of cell-bound IL after 2 hrs)
as compared to the EGFR (~40% after 2 hrs).This finding together with the poor accessibility of
EGP-2 on OVCAR-3 cells observed in vitro suggest that the EGF-receptor is the most suitable
candidate of the 3 tested for achieving receptor-mediated endocytosis of immunoliposomes and
their entrapped drugs by OVCAR-3 cells.
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SUMMARY
Reconstituted influenza virus envelopes (virosomes) containing the viral hemagglutinin (HA)
have attracted attention as delivery carriers for cytosolic drug delivery as they possess membrane
fusion activity. Here, we show that influenza virosomes can be targeted towards ovarian
carcinoma cells (OVCAR-3) with preservation of fusion activity by incorporating PEG-
derivatized lipids into the virosome membrane.This PEG-layer shields the interaction of HA with
ubiquitous sialic acid residues and also serves as spatial anchor for antibody attachment. Coupling
of Fab’ fragments of mAb 323/A3 (anti-epithelial glycoprotein-2) to the distal ends of the PEG-
lipids resulted in specific antibody-mediated binding of virosomes to OVCAR-3 cells.These
antibody-redirected virosomes fused with membranes of OVCAR-3 cells in a pH-dependent
fashion.
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INTRODUCTION
The cytosol of cells is an important, but relatively inaccessible compartment for many
therapeutic macromolecules. As these molecules often show restricted ability to pass through cell
membranes due to their unfavorable physicochemical characteristics, in particular large size
and/or excessive charge, there is a strong need for a carrier that can deliver these membrane-
impermeable macromolecules into the cytosol of target cells. Although liposomes have been
widely used for the delivery of therapeutic compounds to target cells, thus far liposome-
mediated delivery of membrane-impermeable macromolecular agents into the cytosol has been
inefficient.This is mainly due to the poor endosomal/lysosomal escape of these agents after
cellular uptake in liposome-encapsulated form. In fact, often the fate of liposome-encapsulated
macromolecules is intralysosomal degradation [1-3]. One approach to enhance cytosolic delivery
through escape from the endosomes is the use of reconstituted envelopes (virosomes) of the
human influenza virus A [4-7].
The human influenza virus is an enveloped virus, which enters its host cell by receptor-mediated
endocytosis [8,9].The acidic environment within the endosomes triggers fusion of the viral
envelope with the endosomal membrane resulting in release of viral nucleic acids into the cytosol
of the host cell. Both receptor binding and low pH-induced membrane fusion are mediated by
the viral integral membrane protein hemagglutinin (HA), which forms trimers in the viral
envelope [10,11]. Each HA monomer consists of two subunits: HA1, which contains the sialic
acid binding pocket and HA2, which mediates membrane fusion. At low pH a conformational
change occurs within HA resulting in the exposure of the hydrophobic N-termini of the HA2
subunits at the distal ends of the HA trimers.These hydrophobic sequences interact with target
membranes thereby inducing membrane fusion. Reconstituted influenza virus envelopes
(virosomes) containing HA have been developed that retain fusogenic activity and can be utilized
as carriers for the delivery of normally membrane-impermeable substances into the cytosol of
cells [5,12-14]. However, as influenza virosomes have a tropism for sialic acid-bearing cells and
sialic acid residues are ubiquitous on the cell surface of many different cell types, targeting of
influenza virosomes to specific cell types for the purpose of drug delivery is a challenge. In order
to obtain cell specificity, influenza virosomes have to be redirected. Redirection involves two
steps. First, the binding to the natural receptor of influenza virosomes (i.e. sialic acid residues)
has to be prevented and second, specific homing devices (e.g. antibodies) have to be introduced.
Despite both modifications fusogenic activity must be preserved. Although binding and fusion
functionalities are integrated in one protein, studies have shown that HA-mediated fusion can
occur without HA-mediated binding to sialic acid cell surface receptors as long as the HA protein
is present in its native form [15,16].
This study shows for the first time that influenza virosomes can be redirected to specific cell
types without loss of fusogenic activity. For redirection we used the steric shielding capacity of
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poly(ethylene glycol) (PEG) that, when exposed on the virosome membranes, may effectively
prevent HA from binding to sialic acid residues on target cell membranes. Dependent on the
PEG-chain length and the PEG density on the surface, HA-mediated binding to sialic acid
residues was fully inhibited. By conjugating antibody Fab’ fragments of mAb 323/A3 (directed
against epithelial glycoprotein-2) to the distal ends of surface-exposed PEG molecules antigen-
specific binding of influenza virosomes to ovarian carcinoma cells with full retention of fusogenic
activity was obtained.
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MATERIALS AND METHODS
CHEMICALS AND REAGENTS
Octa(ethylene glycol)-mono(n-dodecyl) ether (C12E8) was from Calbiochem (Darmstadt,
Germany).The hydrophobic resin Bio-Beads SM-2 were from Bio-Rad (Hercules, CA, USA).
Before use, Bio-Beads kept in methanol were extensively washed with HEPES-buffered salt
solution (HBS; 5 mM HEPES, 150 mM NaCl, pH 7.4). PyrPC (1-hexadecanoyl-2-(1-
pyrenedecanoyl)-sn-glycero-3-phosphocholine) was from Molecular Probes (Eugene, OR, USA).
Neuraminidase from Clostridium perfringens was obtained from Sigma-Aldrich Co. (St. Louis,
MO, USA). PEG-5000-DSPE (1,2-distearoyl-glycero-3-phosphoethanolamine-N-[poly(ethylene
glycol)5000], PEG-2000-DSPE (1,2-distearoyl-glycero-3-phosphoethanolamine-N-[poly(ethylene
glycol)2000] and L-α-phosphatidylethanolamine–N-(lissamine rhodamine B sulfonyl) (Rho-PE)
were from Avanti Polar Lipids (Alabaster, AL, USA). Maleimide-PEG-2000-DSPE was obtained
from Shearwater polymers (Huntsville, AL, USA). Iso-Octylphenoxypolyethoxyethanol 
(Triton X-100) was from BDH (Poole, England). All other chemicals were from the highest grade
available.
CELLS AND VIRUSES
The X47 recombinant strain of influenza virus, carrying the HA of influenza A/Victoria/3/75,
was grown and purified as described elsewhere [17]. Human erythrocytes were isolated from
whole blood of a healthy volunteer as described elsewhere [18].The human ovarian cancer cell
lines NIH:OVCAR-3 [19] and A2780 [20] were maintained in DMEM (Gibco) containing 3.7 g/l
sodium bicarbonate, 4.5 g/l L-glucose and supplemented with 10% heat inactivated fetal calf
serum, L-glutamine (4.5 g/l), penicillin (100 IU/ml) and streptomycin (100 µg/ml) and
amphothericin B (0.25 µg/ml).
VIROSOME PREPARATION
Reconstitution of influenza virus envelopes was carried out according to [4], with some minor
modifications. Briefly, an amount of virus corresponding to 1.5 mmol of phospholipid was
pelleted by ultracentrifugation for 1 h at 100,000xg using a fixed angle rotor. Pelleted virus was
resuspended in 0.5 ml of 30 mM C12E8 in HBS and incubated for 30 min at room temperature.
To incorporate pyrPC and PEG-DSPE conjugates into the virosome membrane, solubilized viral
components were added to either pyrPC or a mixture of pyrPC and PEG-DSPE after removal of
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the nucleoprotein complex by centrifugation at 100,000xg for 30 min.The amount of pyrPC
relative to the total amount of phospholipid was 10%, the amount of PEG-DSPE varied from 0-
20%.To be able to conjugate Fab’-molecules to the virosomes, the sulfhydryl-reactive maleimide-
PEG2000-DSPE was incorporated at a 2% lipid density.The mixture was added to 45 mg (dry
weight) of Bio-Beads prewashed in HBS and incubated for 2 hrs on a shaking-device (1,400 rpm)
at room temperature while protected from light. Subsequently, 2 batches of 25 mg of fresh Bio-
Beads were applied to the mixture within a time interval of 30 min while shaking was continued.
For targeting purposes, Fab’-fragments of mAb 323/A3 were covalently conjugated to the distal
ends of maleimide-derivatized PEG-DSPE incorporated in the virosome membrane as previously
described for liposomes [21,22].The formed virosomes were layered atop a discontinuous
sucrose gradient (10-40-50-60 % w/v) and centrifuged at 100,000xg for 90 min at 4ºC.
Hereafter, the virosomes sedimented atop the 40% sucrose band were collected and dialyzed
overnight against HBS at 4ºC. In all cases, formed virosome particles had an average size of
approx. 100-200 nm with a polydispersity index varying between 0.1-0.4 as determinded by
dynamic light scattering.
PREPARATION OF LIPOSOMES FROM RECONSTITUTED MEMBRANES
OF OVARIAN CARCINOMA CELLS
Liposomes composed of the reconstituted membranes of OVCAR-3 cells were prepared
essentially as described before [23]. A total amount of 1x107 OVCAR-3 cells were collected from
culture flasks and washed twice with 10 ml of PBS by subsequent centrifugation (200xg, 5 min)
and resuspension steps. Pelleted cells were resuspended in 5 ml of hypotonic buffer (10 mM Tris-
HCl; 1mM MgCl2; 1 mM KCl; 0.5 mM phenylmethylsulfonylfluoride (PMSF), pH 7.3) and
subjected to 4 freeze/thaw cycles with liquid nitrogen and lukewarm water, respectively.
Hereafter, cells were vigorously shaken for 5 min and centrifuged at 1,000xg for 5 min to
remove cell debris. Supernatant was collected and remaining pellets were washed twice with
isotonic buffer (10 mM Tris-HCl; 140 mM NaCl; 0.5 mM PMSF, pH 7.3) and supernatants were
pooled. Pooled supernatants were centrifuged at 100,000xg and pellet was solubilized into 3 ml
150 mM OG in HBS by incubating at 37ºC for 30 min. After removal of insoluble cell debris by
centrifugation (700xg; 5 min), the clear solution was applied to a Slide-A-Lyzer dialysis cassette
(Pierce, Rockford, IL, USA) with a molecular weight cut off of 10,000 Da and dialyzed against 1
l of HBS overnight at 4ºC.The formed liposomes were collected and analyzed for size
distribution, phospholipid and protein contents. OVCAR-3 liposomes had an average size of 140
nm with a polydispersity index of 0.2.
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MEMBRANE FUSION ASSAY
Membrane fusion experiments were carried out essentially as described before [15]. In short,
virosomes at a final concentration of 2.5 µM phospholipid and donor membranes (either
erythrocyte ghosts or OVCAR-3 liposomes at a final concentration of 50 µM or 200 µM
phospholipid, respectively) were added to a thermostatted and stirred cuvette that contained
HBS. After 2 min, the pH of the medium in the cuvette was lowered to 5.1 by adding 1/20
volume of fusion buffer (0.1 M 2-[N-morpholino]ethanesulfonic acid] (Mes); 0.1 M Acetic Acid
pH 4.1). Fusion was continuously monitored at 37ºC by measuring the decrease in pyrPC
excimer fluorescence with an LS50B fluorescence spectrophotometer (Perkin Elmer) set at an
excitation wavelength of 345 nm and an emission wavelength of 480 nm.The decrease of
fluorescence was expressed relative to the difference in the initial fluorescence and the excimer
fluorescence at infinite dilution, which was obtained by adding 70 µl of 10% (v/v) Triton X-100
in HBS.
HEMAGGLUTINATION (HA) ASSAY
The hemagglutination assay was carried out essentially as described [24]. In short, 100 µl of
virosomes at a starting concentration of 68 µM phospholipid were applied to the first well of
each row in a V-shaped 96-wells plate and a 2-fold serial dilution was made to obtain a
concentration of virosomes corresponding to 8.3 nM of phospholipid in the last well of each row.
Human erythrocytes were isolated from whole blood as described by Yoneda et al. [18]. A 0.5%
suspension of freshly isolated erythrocytes in HBS was prepared and 100 µl of this suspension
was applied to each well. Erythrocytes were allowed to sediment after which the occurrence of
agglutination was screened by visual inspection.
CELL BINDING OF VIROSOMES, PEG-VIROSOMES 
AND PEG-IMMUNOVIROSOMES
Cell binding of virosomes, PEG-virosomes and antibody-targeted PEG-virosomes (all
fluorescently labeled with NBD-PE) was assessed by flow cytometry.Virosomes (10 µM of
phospholipid) were added to 2x105 OVCAR-3 or A2780 cells and incubated for 120 min at 4ºC
in the dark. Hereafter, cells were washed twice with wash-buffer (1% BSA in HBS) and cells
were resuspended in 500 µl wash-buffer before analysis with a FACscan flow cytometer (Becton
and Dickinson, Mountain View, CA, USA).
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RESULTS 
EFFECT OF SURFACE-EXPOSED PEG ON SIALIC ACID BINDING 
The influence of the presence of PEG molecules present on the surface of virosomes on the
capacity to agglutinate human red blood cells was determined with a hemagglutination assay [24].
This test is based on HA-mediated binding to sialic-acid-containing receptors present on red blood
cells. Influenza virosomes bearing HA bind to these receptors and cause clumping or agglutination
of red blood cells in suspension. It is demonstrated that the presence of PEG molecules on the
surface of virosomes completely inhibits HA-mediated sialic-acid binding (Table 1). Binding of
influenza virosomes to red blood cells negatively correlated with the molecular weight and density
of surface-exposed PEG. For PEG-2000-DSPE, 20 mol% was needed to fully block agglutination
of red blood cells; the same result could be achieved with 8 mol% PEG-5000-DSPE.
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Table 1 — Effect of PEG exposed on the surface of virosomes on the capacity of virosomes to agglutinate human red blood cells
(hemagglutination) as a measure for the degree of sialic acid residue binding. A serial dilution of the different virosome
preparations was made and added to a 0.5% suspension of human red blood cells. After incubation for 3-4 hrs at room
temperature to allow sedimentation of non-agglutinated red blood cells, the occurrence of agglutination was scored visually. +
indicate wells positive for agglutination; – indicate wells negative for agglutination and +/- indicate wells where agglutination is
observed together with sedimentation of red blood cells.
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Virosome
preparation
0%
PEG
2%
PEG-5000
5%
PEG-5000
8%
PEG-5000
10%
PEG-5000
13,5%
PEG-5000
20%
PEG-5000
No
virosomes
2 4 8 16 32 64 128 256 512 1024 2048 4096Dilution
EFFECT OF SURFACE-EXPOSED PEG ON MEMBRANE FUSION 
Knowing that PEG molecules present at the surface of virosomes can inhibit HA-mediated sialic
acid binding, we investigated the effect of surface-exposed PEG on the rate and extent of fusion
with erythrocyte membranes induced by low pH exposure. Figure 1 shows that PEG inclusion
reduced the degree of lipid mixing between erythrocyte ghosts and PEG-virosomes. At PEG
densities that fully block hemagglutination (8 mol% PEG-5000-DSPE and 20 mol% PEG-2000-
DSPE) the rate of lipid mixing was drastically reduced compared to virosomes without
membrane-coupled PEG.
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Figure 1 — Effect of surface-exposed PEG on fusion of influenza virosomes with erythrocyte ghosts. Erythrocyte ghosts (50 µM
phospholipid) were added to pyrPC-labeled virosomes (2.5 µM phospholipid). At the time-point indicated with the arrow the
medium was acidified to pH 5.1. Pyrene excimer fluorescence was continuously monitored at 37°C, whilst stirring the cuvette
contents. The decrease of fluorescence was expressed relative to the difference in the initial fluorescence and the excimer
fluorescence at infinite dilution (i.e. after vesicle solubilization with detergent). Curve a: unmodified virosomes; curve b: virosomes
prepared with 8 mol% of PEG-5000-DSPE; curve c: virosomes prepared with 20 mol% PEG-2000-DSPE.
COUPLING OF ANTIBODY FRAGMENTS TO PEGYLATED VIROSOMES
Fab’ fragments of mAb 323/A3 directed against the epithelial glycoprotein-2 (EGP-2) were
conjugated to the distal ends of lipid-anchored PEG-chains present in the virosome membrane in
order to achieve antibody-mediated binding to OVCAR-3 cells. Figure 2 shows that influenza
virosomes without PEG bound to both A-2780 (EGP-2 negative) and OVCAR-3 (EGP-2 positive)
cells most likely by HA-mediated binding to sialic acid residues present on the tumor cells.
Incorporation of 20 mol% PEG-2000-DSPE (hemagglutination-inhibitory concentration) almost
completely inhibited the binding to both types of tumor cells. 323/A3-PEG-virosomes only
bound to EGP-2-expressing OVCAR-3 cells and not to A-2780 cells lacking this cell surface
receptor.Thus, by conjugating 323/A3 Fab’-fragments to the distal ends of PEG-chains present
on the virosome surface, influenza virosomes could be specifically redirected to OVCAR-3 cells.
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Figure 2 — Virosome binding to OVCAR-3 cells (expressing high levels of the target receptor EGP-2) and A2780 cells 
(no EGP-2 expression). Virosomes, PEG-2000-virosomes (prepared with 20 mol% PEG-2000-DSPE) and 323/A3 Fab’-PEG-
2000-virosomes (prepared with 20% PEG-2000-DSPE), all labeled with 0.1% NBD-PE were incubated with either OVCAR-3
cells or A2780 cells (1x106 cells/ml) for 1 h at 4°C at a concentration of 10 µM phospholipid. Unbound virosomes were removed
by 2 centrifugal wash steps before cells were analyzed by flow cytometry. Histograms in black show the fluorescence intensity of
3,000 cells incubated in buffer. Transparent overlays show the fluorescence intensity of 3,000 cells after incubation with the
indicated virosome preparation.
FUSOGENIC ACTIVITY OF REDIRECTED INFLUENZA VIROSOMES 
To determine whether binding of 323/A3-PEG-virosomes to OVCAR-3 cells via
antibody/antigen interaction results in comparable levels of fusion as virosomes that bind to
target membranes via the natural HA/sialic-acid interaction, the degree of lipid mixing induced
by virosomes, PEG-virosomes or 323/A3-PEG-virosomes was measured. As we were unable to
measure lipid mixing between virosomes and intact cells with the pyrPC assay, due to a very high
scattering signal when intact cells were used, liposomes prepared from crude membrane extracts
of OVCAR-3 cells according to the method of Bergers et al. [23] were used.These reconstituted
cell membranes (OVCAR-3 liposomes) bear all the membrane proteins and lipids of the native
cell membranes among which the EGP-2 cell surface antigen and sialylated proteins and lipids.
Because of their relatively small size (100-200 nm) their scattering signal is much lower than that
of whole cells.The results show that PEG virosomes containing 20 mol% of PEG-2000-DSPE
were not able to induce lipid mixing with OVCAR-3 liposomes upon lowering the pH of the
incubation medium to 5.1. As expected, plain virosomes induced lipid mixing with OVCAR-3
liposomes.The extent of lipid mixing was lower compared to lipid mixing with erythrocyte
ghosts as acceptor membranes.This may be related to differences in the density of sialylated
receptors expressed on the surface of the membrane vesicles. It is well known that erythrocyte
membranes are a rich source of sialic acid bearing glycolipids and glycoproteins.When 323/A3-
PEG-virosomes were added to OVCAR-3 liposomes and the pH of the medium was lowered to
5.1, a very low degree of lipid mixing was observed (results not shown). After pre-binding of the
323/A3-PEG-virosomes to the surface of OVCAR-3 liposomes for 1 h at room temperature, the
extent of lipid mixing was as high as with unmodified virosomes (Figure 3A).Treatment of
OVCAR-3 liposomes with neuraminidase to remove the sialic acid residues resulted in a
drastically decreased level of lipid mixing induced by virosomes but only slightly altered the
degree of lipid mixing observed for 323/A3-PEG-virosomes, indicating that in the latter case
target cell binding is mainly mediated by antibody/antigen interaction and not by binding of HA
to sialic acid residues (Figure 3B).
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Figure 3 — Fusion of influenza virosomes with OVCAR-3 liposomes (Panel A) or OVCAR-3 liposomes treated with neuraminidase
to remove sialic acid residues (Panel B). OVCAR-3 liposomes (200 µM phospholipid) were added to pyrPC-labeled virosomes 
(2.5 µM phospholipid). At the time point indicated with an arrow, the medium was acidified to pH 5.1 and fusion was monitored
as previously described (see legend Figure.1). Results were obtained with virosomes (a); virosomes prepared with 20% PEG-2000-
DSPE (b) and antibody-targeted virosomes also prepared with 20% PEG-2000-DSPE (c). 
DISCUSSION
The results presented here show that influenza virosomes can be redirected to ovarian carcinoma
cells with full retention of fusogenic activity. In the past, unsuccessful attempts have been made
to target virosomes prepared from the reconstituted envelopes of Sendai virus and influenza virus
to specific cell surface receptors [25-28].The lack of success of targeting can be ascribed to the
dominance of the natural binding tropism of the virosomes. Studies with influenza virus have
demonstrated that removal or modification of the HA1 domain responsible for binding to the
ubiquitous sialic acid residues, results in an impaired fusogenic activity mediated by the HA2
domain [29,30]. In addition, introduction of new, specific targeting elements by chemical
conjugation of proteins to HA (personal observation) or by creating chimeric HA-scFv proteins
at a genetic level also result in loss of fusogenic activity of the HA protein [25].
In this study we have chosen a different approach to redirect influenza virosomes without the
need to modify HA. Inspired by the well-described use of PEG to shield surface-exposed proteins
on colloidal systems as recently demonstrated for influenza virosomes by Chams et al. [31], we
have anchored PEG to the surface of influenza virosomes by incorporating PEG-lipids into the
viral envelope for two reasons: (1) to sterically shield HA thereby preventing it to interact with
its natural ligand sialic acid and (2) to use the surface-grafted PEG layer as a spacer to conjugate
specific homing devices to the distal end of the PEG-chains in order to obtain specific binding to
target cells.The present results confirm that high concentrations of surface-grafted PEG (20
mol% PEG-2000-DSPE or 8 mol% PEG-5000-DSPE) on the virosomes fully block the binding of
virosomes to sialic acid bearing receptors on human erythrocytes.Whether this inhibition of
binding is caused by steric shielding of the sialic acid binding pocket of HA by incorporated PEG-
lipids is not completely certain. X-ray crystallography has demonstrated that HA molecules
protrude 13.5 nm from the viral membrane surface [32].The effective thickness of the PEG coat
has been reported to be approximately 6.5-7 nm at a surface coverage of 9 mol% PEG-1900 and
15 nm for PEG- 5000 at 7 mol% surface coverage [33]. Considering the dimensions of the PEG-
layer and the HA protein one would expect that only PEG-5000 would be able to sterically shield
the sialic acid binding pocket of HA. However, we observed that PEG-2000-DSPE incorporated
in the virosome membrane at a density of 20 mol% also blocks the binding of influenza
virosomes to erythrocytes. As high densities of surface-grafted PEG cause the PEG-chains to
stretch out (i.e. brush formation) [34], it may well be possible that — at a density of 20 mol%
PEG-2000 — the PEG-chains are reaching the fully stretched conformation which has a
theoretical dimension of 15.8 nm (45 units of ethylene glycol of 3.5 Å each). However, it cannot
be excluded that other mechanisms than steric shielding also play a role in the mechanism of
sialic acid binding hindrance by the PEG-layer [35].
It should be noted that the amount of PEG-lipids that can be incorporated in bilayers is limited
due to the tendency of PEG-lipids to form mixed micelles above a certain concentration [36].
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Indeed, we observed that at the highest PEG-lipid concentration used (20 mol% PEG-2000), the
recovery of viral phospholipids present in the virosome particles after removal of micelles and
protein aggregates by density gradient centrifugation was low (recovery between 30-40%)
compared to virosome preparations without PEG-lipids (recovery between 70-80%).This
indicates that — at the highest concentration of PEG lipids used — solubilization of components
from the viral envelope (lipids, spike proteins) into mixed micelles has occurred. Nevertheless,
functional virosome particles containing PEG-lipids could be isolated.
Previous studies have shown that influenza virus HA-mediated fusion is independent of binding to
sialic acid [15].The binding step can be replaced by any other molecular interaction such as
biotin/streptavidin interactions, which indicates that fusion is independent of any specific
behavioral property of the underlying (cell surface) protein or lipid to which the sialic acid is
linked. Presumably, the only function of the HA binding to sialic acid residues is to initiate
receptor-mediated endocytosis of the virosome particles and then to hold the virosome in close
proximity of the endosomal membrane while the membrane fusion takes place.This study
demonstrates that binding of influenza virosomes via antibody-antigen interaction results in
specific binding and subsequent membrane fusion.The antibody Fab’-fragments are displayed on
the outer edge of the PEG layer whereas the sialic acid binding pocket of HA is shielded by the
same PEG-layer.Therefore, the initial binding event of the virosomes to the target cell surface
will be accomplished by the exposed antibody fragments. In view of the dimensions of the HA
molecule (see above) it cannot be excluded that the initial binding of antibody to cell surface
antigen, which brings the virosome particles in close proximity of the glycocalyx of the cell
membrane favors the chance of HA to interact with sialic acid residues as a second binding mode.
The choice of targeting ligand for redirecting influenza virosomes is critically important. It
should not only specifically bind to target cell surface receptors but binding should also lead to
receptor-mediated endocytosis, as the virosome will only become fusogenic at the low pH
environment within endosomes. Indeed, it has been reported that the antibody used here as
targeting ligand is internalized after binding to EGP-2 [37,38].
Besides the advantage of grafted PEG-lipids to shield the binding function of HA, it may also
prevent or inhibit unwanted immune recognition of the antigenic viral HA proteins after systemic
administration of PEG-virosomes. Studies with PEGylated adenoviruses have demonstrated that
surface PEG molecules can inhibit the antibody response against viral proteins [39,40]. In vivo
pharmacokinetic studies on repeated injections of PEGylated influenza virosomes should be
performed to address this issue.
In conclusion, this study demonstrates that influenza virosomes can be redirected towards ovarian
carcinoma cells by incorporating PEG-lipids into the virosome membrane with conjugated
antibodies at the distal ends of PEG-chains. Studies to address whether these antibody-redirected
influenza virosomes can be utilized for enhancement of the cytosolic delivery of otherwise cell-
impermeable substances are currently underway in our laboratory.
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SUMMARY
In this study, a novel method of influenza virosome preparation is presented.This method is based
on the post-insertion of influenza virus envelope components (consisting predominantly of
hemagglutinin (HA) spike proteins) that are solubilized with short-chain phosphatidylcholines
into preformed liposomes. It was hypothesized that with the ‘post-insertion’ method of virosome
preparation, the problem of low encapsulation efficiency of water-soluble compounds related to
the traditional method of virosome preparation (i.e. reconstitution of influenza virus envelopes
solubilized with C12E8) could be circumvented. It is demonstrated that influenza virus spike
proteins can be post-inserted into preformed liposomes with full retention of fusion activity of
HA. Unfortunately, under the conditions needed for effective post-insertion of viral spike
proteins into liposomes, the post-insertion procedure induced extensive leakage of liposome-
entrapped molecules, both small (calcein) and large (DNA). Nevertheless, the use of dicaproyl
phosphatidylcholine (DCPC) as detergent in the post-insertion method is advantageous as
bilayer-associated DCPC molecules can be readily removed from the virosomes by dialysis, in
contrast to the low CMC detergent used in the traditional method of virosome preparation. It is
anticipated that post-insertion virosomes are applicable for cytosolic delivery of molecules which
can be entrapped in virosomes via remote loading procedures.
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INTRODUCTION
Reconstituted membranes of enveloped viruses (virosomes) have attracted attention as drug
carriers because they possess fusogenic activity towards target membranes enabling the cytosolic
deposition of entrapped drug molecules.Virosomes have been prepared from a variety of
enveloped viruses, among which vesicular stomatitis virus (VSV) [1,2], Sendai virus [3-5],
Semliki Forest virus (SFV) [6] and influenza virus [7-13]. Influenza virosomes have been prepared
in different ways, but only a few methods resulted in reconstitution of viral envelopes with
preservation of fusogenic activity [7,9,10]. One successful reconstitution procedure that is
commonly used is based on solubilization of the viral envelope with C12E8 detergent with a low
critical micelle concentration (CMC), removal of the viral nucleocapsid by ultracentrifugation,
and subsequent controlled removal of the detergent from the supernatant by adsorption to
hydrophobic, polystyrene beads [10]. SDS-PAGE analysis of influenza virosomes prepared via the
traditional method utilizing the C12E8 detergent has demonstrated that the proteins reconstituted
in virosomes primarily consist of the spike proteins hemagglutinin (HA) and neuraminidase (NA)
in a ratio of 5:1. Cryo-EM analysis showed that virosomes are unilamellar vesicles of
approximately 150-200 nm in size and densely covered with spikes, which appear to be present
on both sides of the membrane.The presence of fusion-active HA molecules in the bilayer of
influenza virosomes allows fusion of the virosome membrane with the endosomal membrane
after internalization by the target cells. In this way virosome-entrapped compounds can be
delivered into the cytosol of cells. Indeed, several groups have reported that influenza virosomes
can be used as carriers for the cytosolic delivery of bacterial toxins [14,15], peptides [16,17], and
DNA [18].Yet, virosome-mediated cytosolic delivery of molecules is limited by a poor
encapsulation efficiency of water-soluble compounds into the virosome carrier system [14].
Moreover, as fusogenic influenza virosomes are prepared with detergents having a low CMC, the
presence of residual detergent molecules in the virosome membrane is to be expected. Residual
detergent in influenza virosomes prepared with the standard method has been determined to be
7.5-9 mol% relative to total virosomal lipid [10]. Favored by the presence of residual detergent
monomers, the virosomal bilayers are rather leaky for entrapped molecules. An attempt to
prepare influenza virosomes using the detergent octyl glucoside, which can be readily removed
by dialysis yielding low residual amounts in the virosomal bilayers, resulted in the formation of
vesicles lacking pH-dependent membrane fusion activity [10].
Different methods of liposome preparation are available that provide efficient entrapment of
water-soluble (macro)molecules as well as flexibility in choice of bilayer constituents [19].
Ideally, one would like to combine the flexibility in choice of lipid composition and preparation
method with the pH-dependent membrane fusion capacity of virosomes. One way to achieve this
may be the incorporation of influenza virus spike proteins into preformed liposomes with the
desired bilayer composition.Viral spike proteins of VSV and Sindbis virus have been successfully
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incorporated into preformed liposomes [20,21]. In addition, several other membrane proteins
have been incorporated into liposomes by spontaneous insertion of the purified protein [22,23]
or by detergent-aided insertion [24-27]. Several detergents, among which short-chain lecithins,
have been used for facilitating insertion of membrane proteins [28,29].The latter have the
advantage that they can be readily removed from the phospholipid bilayers by dialysis and do not
seem to impair the biological activity of membrane proteins during solubilization [28,29].
In this study, an attempt is made to circumvent the problems of low encapsulation efficiency and
poor bilayer stability related to the traditional influenza virosome preparation methods by
preparing influenza virosomes in two separate steps. In the first step, small-sized liposomes were
prepared by lipid-film hydration and subsequent extrusion [30], which allows for more efficient
entrapment of water-soluble compounds.The second step involved post-insertion of influenza
virus spike proteins that were solubilized with short-chain phospholipids (dicaproyl
phosphatidylcholines; DCPC) into the preformed liposomes with subsequent removal of the
short-chain PCs by dialysis.This study shows for the first time that membrane fusion-active
influenza virosomes can be prepared by post-insertion of viral spike proteins utilizing a high
CMC detergent.
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MATERIALS AND METHODS
MATERIALS
The X47 recombinant strain of influenza virus, carrying the HA of influenza A/Victoria/3/75,
was grown and purified as described elsewhere [31]. Octa(ethylene glycol)-mono( n-dodecyl)
ether (C12E8; CMC: 0.11 mM) was purchased at Calbiochem (Darmstadt, Germany). PyrPC (1-
hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphocholine) and the green fluorescent cell-
impermeant SYTOX green nucleic acid stain were from Molecular Probes (Eugene, OR, USA).
Bovine brain gangliosides purified from bovine brain, cholesterol, 1,2-dihexanoyl-sn-glycero-3-
phosphocholine (DCPC; CMC: 14.4 mM) and calcein were from Sigma-Aldrich Co. (St. Louis,
MO, USA). Egg phosphatidylcholine (EPC), egg phosphatidylethanolamine (EPE), 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine (DPPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) were all from Avanti Polar Lipids Inc.
(Alabaster, AL, USA). DNase I from bovine pancreas was obtained from Boehringer Mannheim
(Mannheim, Germany). Sepharose CL-4B came from Amersham Pharmacia Biotech (Uppsala,
Sweden). All other chemicals were of analytical grade.
PREPARATION OF LIPOSOMES
Lipids used for all liposome preparations were dissolved in CHCl3:MeOH (2:1 v/v ratio) and
stored at –20ºC. Lipids from stock solutions were mixed at the appropriate molar ratio in a
round bottom flask and dried under vacuum by rotary evaporation.The obtained lipid films were
further dried for at least 1 h under a stream of N2 to remove all traces of organic solvent. Lipid
films were hydrated with 1 ml of HEPES-buffered salt solution (HBS; 5 mM HEPES, 150 mM
NaCl, pH 7.4), containing the substances to be encapsulated (DNA or calcein), by shaking in the
presence of glass beads.The formed multilamellar liposomes were extruded through 0.2 µm
filters using a hand-extruder from Avanti Polar Lipids (Alabaster, AL, USA). If needed, extruded
liposomes were separated from non-encapsulated materials by column chromatography using a
Sepharose CL-4B column. Lipid concentration of liposomes was determined by measuring the
amount of lipid phosphate according to Fiske et al. [32]. Liposomes used for post-inserting
influenza virus spike proteins were composed of EPC, EPE and cholesterol at a molar ratio of
4:2:3, respectively. For lipid mixing experiments 10 mol% (relative to phospholipid) of pyrPC
was incorporated in these liposomes. Liposomes used as ‘target’ membranes in lipid mixing
studies had the same lipid composition as liposomes used for post-insertion, supplemented with
10 mol% or 30 mol% gangliosides (relative to the total amount of phospholipid).
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VIRUS SOLUBILIZATION
An amount of virus corresponding to 200 nmol of phospholipid was pelleted by
ultracentrifugation (1 h; 100,000xg; 4ºC) using a fixed angle rotor. Pelleted virus was
resuspended in 400 µl of high salt HNE buffer (5 mM HEPES; 1 M NaCl; 0.1 mM EDTA; pH 7.4)
using a 26G needle. Resuspended virus was transferred to a tube containing a dry film of 16 µmol
DCPC and incubated for 30 min at ambient temperature. Insoluble nucleocapsids were removed
by ultracentrifugation at 100,000xg for 20 min at 4ºC and supernatant containing the solubilized
viral envelope components was collected. After lipid phosphate determination (corrected for the
presence of DCPC), solubilized viral envelopes were directly used for post-insertion.
PREPARATION OF POST-INSERTION (PI)-VIROSOMES
Preformed liposomes (200 µM of phospholipid) were incubated in HBS containing 8 mM of
DCPC (below CMC of detergent) for 30 min at room temperature. Detergent-containing
liposomes were admixed with viral envelopes solubilized in 40 mM DCPC at such volume ratios
that the final detergent concentration did not exceed 11 mM. Mixtures were incubated for 30
min at room temperature and gently shaken every 5 min. Samples were dialyzed overnight using
a Slide-A-Lyzer dialysis cassette with a molecular weight cut-off (MWCO) of 10,000 (Pierce,
Rockford, IL, USA) at 4ºC against two changes of HBS in 1000-fold volume excess.
LIPID MIXING ASSAY OF MEMBRANE FUSION
The extent of membrane fusion was determined as described in chapter 3 [33]. Briefly, PI-
virosomes labeled with the fluorescent probe pyrPC (10 mol% relative to the total amount of
lipid) at a concentration of 10 or 20 µM of PL were admixed with an excess of donor membranes
(i.e. erythrocyte ghosts prepared as described in [34] (100 µM of PL) or ganglioside liposomes in
a total volume of 1.4 ml of HBS).The virosome mixture was placed into a cuvette and stirred at
a temperature of 37ºC. After 2 min, the pH of the medium in the cuvette was lowered to 5.1 by
adding 1/20 volume of fusion buffer (0.1 M 2-[N-morpholino]ethanesulfonic acid] (MES), 0.1 M
acetic acid, pH 4.1). Fusion was continuously monitored at 37ºC by measuring the decrease in
pyrPC excimer fluorescence with a LS50B fluorescence spectrophotometer (Perkin Elmer,
Beaconsfield, UK) set at an excitation wavelength of 345 nm and an emission wavelength of 480
nm.The decrease in fluorescence was expressed relative to the difference in the initial
fluorescence and the excimer fluorescence at infinite dilution, which was determined by adding
70 µl of 10% (v/v) Triton X-100 in HBS to the PI-virosome dispersion.
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LEAKAGE ASSAYS 
Leakage of calcein
Liposomes (500 nmol PL/ml) containing 100 mM of the fluorescent probe calcein (at this
concentration calcein is >95% self-quenched) were incubated for indicated time periods at 37ºC
with increasing DCPC concentrations (0-20 mM) to determine detergent-induced leakage. In
addition, leakage of calcein from liposomes was also investigated in the presence of DCPC-
solubilized influenza virus spike proteins (0.5 mM PL) at increasing final detergent
concentrations (0-20 mM) to determine the effect of post-insertion on the extent of calcein
leakage. Calcein leakage was expressed relative to the difference in fluorescence of calcein-
containing liposomes incubated at 37ºC in the presence of 0.5% (v/v) of Triton X-100 in HBS
(defined as 100% leakage) and incubated in the absence of DCPC at 37ºC (defined as 0%
leakage). Fluorescence was measured with an LS50B fluorescence spectrophotometer set at an
excitation wavelength of 488 nm and an emission wavelength of 520 nm.
Leakage of DNA
Plasmid DNA (5,800 basepairs in size) was entrapped in liposomes composed of EPC, EPE and
cholesterol (molar ratio 4:2:3, respectively) as described by Schoen et al. [35]. After two
centrifuge steps (100,000xg for 1 h at 4ºC) to remove non-encapsulated DNA, these DNA
liposomes were used for post-insertion of viral spike proteins. DNA-containing liposomes and,
after post-insertion and dialysis, DNA-containing PI-virosomes were analyzed for the presence of
DNA not entrapped within the lipid vesicles (i.e. either free in solution or associated with the
liposome surface) with the membrane-impermeant SYTOX Green nucleic acid stain. Liposomes
or PI-virosomes (50 µM of PL) were added to a cuvette containing 1 mM MgCl2 and SYTOX
Green nucleic acid stain (1 µM in HBS, pH 7.4) and fluorescence was measured with an LS50B
fluorometer set at an excitation wavelength of 504 ± 2.5 nm and an emission wavelength of 523
± 4 nm.The amount of DNA that was not entrapped within liposomes before and after post-
insertion was expressed relative to the difference in SYTOX Green fluorescence obtained after
disruption of the DNA-liposomes or PI-virosomes with 0.5% (v/v) of Triton X-100 and the
SYTOX Green fluorescence obtained with DNA-liposomes or PI-virosomes from which the
externally located DNA had been degraded by DNase I (10 U/ml).
Electron microscopy
Influenza virus particle, influenza virosomes and liposomes were adsorbed to glow-discharged
carbon-stabilized formvar-coated grids, negatively stained using 2.0% potassium
phosphotungstate (pH 5,2) and analyzed using a Philips TEM 400 electron microscope at an
operating voltage of 80 kV. Images were digitally stored and analyzed using analySIS (Soft-
imaging software, Germany).
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RESULTS 
EFFECT OF DCPC ON LEAKAGE OF CALCEIN FROM LIPOSOMES
Several membrane proteins have been successfully inserted into preformed liposomes aided by bilayer-
associated amphipathic molecules such as cholesterol, short-chain phosphatidylcholines, detergents,
and lyso-derivatives of fatty acids into the liposomal bilayer [36]. Similarly, in this study we focused on
the post-insertion of influenza virus spike proteins (approximately 80% HA and 20% NA) solubilized
with dicaproyl phosphatidylcholine (DCPC) into preformed liposomes, whose bilayers contained sub-
solubilizing amounts of DCPC molecules to facilitate spike protein insertion. As leakage of liposome-
entrapped compounds during the post-insertion procedure is undesirable, we first determined the
maximum concentration of DCPC that can be utilized without causing extensive leakage of liposome-
entrapped compounds. Figure 1 shows that the degree of leakage of the fluorescent probe calcein
from liposomes composed of EPC, EPE and cholesterol (molar ratio 4:2:3, respectively) is dependent
on the concentration of DCPC added to the dispersion and the incubation time at 37ºC. Extensive
leakage of calcein is observed at DCPC concentrations >12 mM. Dynamic light scattering
measurements were performed to monitor integrity of liposome particles (results not shown). At 20
mM of DCPC a decrease in average particle size was observed, indicating that at this detergent
concentration liposome solubilization had occurred. For all experiments described hereafter, a final
concentration of 8 mM DCPC was used to facilitate viral spike protein insertion, as at this
concentration leakage of calcein is marginal, even after 6 hrs incubation at 37ºC (Figure. 1).
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Figure 1 — Calcein release from liposomes at increasing concentrations of DCPC. Liposomes (EPC:EPE:CHOL 4:2:3; 100
nmol PL) were incubated for 15, 60 or 360 min at 37ºC at increasing concentrations of DCPC. Calcein release was
determined relative to the difference in release between Triton X-100-solubilized liposomes (100% release) and liposomes
incubated for 360 min in the absence of DCPC (0% release).
ELECTRON MICROSCOPY ANALYSIS
The morphology of influenza virosomes prepared by post-inserting influenza virus spike proteins
into preformed liposomes (PI-virosomes) was analyzed by electron microscopy and compared
with the morphology of native influenza virus particles, liposomes without post-inserted spike
proteins and influenza virosomes prepared with the C12E8 method [10].The EM-pictures (Figure
2) show that the size of both PI-virosomes (panel D) and C12E8 virosomes (panel C) is
approximately 150-200 nm, which is comparable to the size of intact influenza virus particles
(panel A).The viral spike proteins in the bilayer of virosomes prepared with the C12E8 method
are both facing inwards and outwards. In contrast, the spike proteins post-inserted into
preformed liposomes are primarily pointing outwards, similar to the orientation of spike proteins
in native influenza virus particles.
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Figure 2 — Electron micrographs of influenza virus particles (A), liposomes (B), C12E8 virosomes (C), and PI-virosomes (D)
negatively stained with 1% sodium phosphotungstate, pH 7.0. The bar in each micrograph represents 200 nm. Arrows indicate
viral spike proteins inserted in the virosome bilayer. Note that spike proteins located in the bilayer of virosomes prepared with
the C12E8 method are facing inwards as well as outwards. 
PI-VIROSOME-INDUCED LIPID MIXING
Effect of viral spike protein density
A lipid mixing assay was performed to determine whether PI-virosomes are fusogenic. PI-virosomes
were prepared by post-inserting increasing amounts of solubilized influenza virus spike proteins into
a fixed amount of pyrPC-labeled liposomes. Bilayers of liposomes were composed of EPC, EPE and
cholesterol at a molar ratio of 4:2:3, respectively. Lipid mixing between PI-virosomes and an excess
of erythrocyte ghosts was monitored continuously for 5 min after lowering the pH of the buffer to
5.1. It can be seen that the degree of lipid mixing between PI-virosomes and erythrocyte ghosts is
proportional to the amount of spike proteins added for post-insertion (Figure 3). PI-virosomes
prepared at a lipid to protein (w/w) ratio of 1:2 show the same extent of lipid mixing as observed
for influenza virosomes prepared with the traditional C12E8 method [10]. Control liposomes with the
same composition as used for the PI-virosomes but without spike proteins do not show lipid mixing,
indicating that lipid mixing is exclusively mediated by the post-inserted viral components. In
addition, lipid mixing is pH-dependent as it only occurs after lowering the pH of the buffer.
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Figure 3 — Lipid mixing between PI-virosomes and erythrocyte ghosts. PyrPC-labeled PI-virosomes (20 µM of PL) were
mixed with erythrocyte ghosts (100 µM of PL) in a cuvette kept at a temperature of 37ºC while continuously stirring the
mixture. The occurrence of lipid mixing expressed as the decrease in pyrene excimer fluorescence was continuously monitored
(after acidification of the buffer to pH 5.1) with an LS50B fluorescence spectrophotometer set at an excitation wavelength of
345 nm and an emission wavelength of 480.nm The decrease of fluorescence was expressed relative to the difference in the
initial fluorescence and the excimer fluorescence at infinite dilution (i.e. after vesicle solubilization with detergent). Curves
indicate lipid mixing obtained with PI-virosomes prepared at phospholipid to spike protein (w/w) ratios of 1:0 (a), 1:0.25 (b),
1:0.5 (c), 1:1 (d), and 1:2 (e), respectively. 
Effect of bilayer rigidity 
As the efficiency of insertion of influenza virus spike proteins into preformed liposomes may be
dependent on the bilayer rigidity, PI-virosomes were prepared by post-inserting spike proteins
(lipid-to-protein ratio: 1:2) into liposomes with different bilayer rigidity (EPC:EPE:CHOL,
DPPC:DPPE:CHOL, and DSPC:DSPE:CHOL, molar ratio of 4:2:3 for all compositions).These
PI-virosomes were tested for their ability to induce lipid mixing with erythrocyte membranes
(Figure 4).The relative extent of lipid mixing of PI-virosomes composed of DSPC:DSPE:CHOL
was 55% compared to 40% for PI-virosomes composed of DPPC:DPPE:CHOL and 40% for PI-
virosomes composed of EPC:EPE:CHOL.Thus, the extent of lipid mixing between PI-virosomes
and erythrocyte ghosts was highest in case of the most rigid bilayer composition.
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Figure 4 — Influence of lipid bilayer rigidity of PI-virosomes on the extent of lipid mixing with erythrocyte ghosts. Either
liposomes or PI-virosomes (20 µM of PL) were mixed with erythrocyte ghosts (100 µM of PL) in a cuvette kept at a temperature
of 37ºC. The mixture was continuously stirred. Lipid mixing was monitored after lowering the pH of the medium to 5.1. Lipid
mixing between erythrocyte ghosts and preformed DSPC:DSPE:CHOL liposomes (a), EPC:EPE:CHOL PI-virosomes (b),
DPPC:DPPE:CHOL PI-virosomes (c) and DSPC:DSPE:CHOL PI-virosomes (d) are shown.
Effect of target membranes: erythrocyte ghosts versus ganglioside liposomes
Erythrocyte ghosts are frequently used as target membranes to study lipid mixing with influenza
virus particles or virosomes, as they are a rich source of sialylated lipids (gangliosides) and
glycoproteins that form the natural receptors for influenza virus HA.To determine the effect of
target membrane composition on the extent of lipid mixing induced by PI-virosomes, liposomes
(EPC:EPE:CHOL molar ratio 4:2:3) containing 10 or 30 mol% gangliosides (purified from
bovine brain) as a source of sialic acid residues were used as target membranes. Lipid mixing of
PI-virosomes with ganglioside-liposomes was compared with that of erythrocyte ghosts. Figure 5
shows that lipid mixing of PI-virosomes with ganglioside liposomes is less efficient than with
erythrocyte membranes. Increasing the amount of gangliosides present in the liposomal bilayers
did not result in an increase in lipid mixing, indicating that the amount of natural receptors for
HA present on the liposomes is not the limiting factor. Probably, differences in bilayer
composition of erythrocyte ghost membranes and ganglioside-liposomes underlie the differences
in lipid mixing with PI-virosomes. It is noteworthy that lipid mixing still occurs despite the
presence of high amounts of cholesterol (33 mol%) in the bilayer of target membranes.
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Figure 5 — Lipid mixing of PI-virosomes with different target membranes. PI-virosomes were mixed with an excess of target
membrane vesicles (100 µM of erythrocyte ghosts or 500 µM of (ganglioside) liposomes) in a cuvette kept at 37ºC. Lipid
mixing was continuously monitored upon acidification of the buffer to pH 5.1. During measurements cuvette contents were
continuously stirred. Target membrane vesicles used for lipid mixing were EPC:EPE:CHOL (4:2:3 molar ratio) liposomes (a),
EPC:EPE:CHOL liposomes containing 10 mol% gangliosides (relative to PL) (b), EPC:EPE:CHOL liposomes containing 30
mol% gangliosides (c) and erythrocyte ghosts (d).
LEAKAGE DURING POST-INSERTION
Leakage of calcein 
The previous experiments show that, in the presence of 8 mM of DCPC, influenza virus spike
proteins can be effectively inserted into the bilayers of preformed liposomes with retention of
fusogenic activity as demonstrated by the occurrence of lipid mixing. Destabilization of liposomal
bilayers, in the presence of low amounts of DCPC (8 mM) to facilitate spike protein insertion,
resulted in only low levels of calcein leakage from the liposomes (Figure 1). As the insertion of
membrane proteins into the liposome bilayer may also influence the retention of liposome-
entrapped solutes, the extent of calcein leakage from liposomes during the viral spike protein
insertion process was determined. Influenza virus spike proteins solubilized with 40 mM of
DCPC were added to calcein-containing liposomes (2:1 lipid to protein ratio) at increasing
volume ratios to obtain final detergent concentrations varying from 2.5 mM DCPC to 20 mM
DCPC. Figure 6 shows that calcein leakage during post-insertion increased at increasing final
concentrations of DCPC. Leakage of calcein from liposomes at comparable DCPC concentration
(10 mM final concentration) as used for effective spike protein insertion (8 mM final concentration)
was high: 80% of calcein was released during the 1 h post-insertion process. No leakage of calcein
was observed at 2.5 mM DCPC and 25% of calcein was released at 5 mM DCPC. However, PI-
virosomes prepared at final DCPC concentrations (2.5 mM and 5 mM DCPC) that allowed
retention of most of the liposome-entrapped calcein during the post-insertion process, did not
13
3
ch
ap
te
r 
4
0
25
50
75
100 2.5 mM DCPC
5 mM DCPC
10 mM DCPC
20 mM DCPC
%
 C
al
ce
in
 r
el
ea
se
 f
ro
m
 li
po
so
m
es
Figure 6 — Calcein leakage from liposomes during post-insertion of influenza virus spike proteins in the presence of varying
DCPC concentrations for a period of 60 min.
show much fusogenic activity (Figure 7). Clearly, effective post-insertion of influenza virus spike
proteins into preformed liposomes is accompanied by extensive leakage of encapsulated calcein.
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Figure 7 — Lipid mixing between PI-virosomes prepared at final DCPC concentrations of 2.5 and 5 mM and erythrocyte
ghosts. PI-virosomes were prepared by solubilizing influenza virus spike proteins with 40 mM DCPC and mixing solubilized
spike proteins with preformed liposomes at different volume ratios to obtain varying final DCPC concentration in the PI-
virosome mixture. Lipid mixing between an excess of erythrocyte ghosts (100 µM of PL) and PI-virosomes (20 µM of PL)
prepared at final DCPC concentrations of 2.5 mM (curve b) and 5 mM (curve c) obtained after detergent dialysis are shown as
well as lipid mixing between erythrocyte ghosts and preformed liposomes without post-inserted spike proteins (curve a).
DNA leakage from liposomes during post-insertion
To determine whether the calcein leakage phenomenon during post-insertion of influenza virus
spike proteins also applies to membrane-impermeant macromolecules, influenza virus spike
proteins were post-inserted into liposomes in which DNA had been encapsulated according to
the method of Schoen et al. [35].The percentage of externally located DNA (i.e. DNA associated
with the surface of liposomes and DNA free in solution) before and after post-insertion of spike
proteins into DNA-containing liposomes was determined with the membrane-impermeant
SYTOX Green nucleic acid stain (Figure 8).The results show that before post-insertion, approx.
40% of liposome-associated DNA was entrapped within liposomes, whereas after post-insertion
of viral spike proteins all DNA could be stained with SYTOX Green, indicating that all DNA had
been released from the liposomes during the post-insertion process.
13
5
ch
ap
te
r 
4
0
10
20
30
40
before post-insertion
after post-insertion
P
er
ce
nt
ag
e 
of
lip
os
om
e-
en
tr
ap
pe
d 
D
N
A
Figure 8 — Leakage of DNA from liposomes during post-insertion of influenza virus spike proteins. The amount of DNA
entrapped within liposomes (EPC:EPE:CHOL, molar ratio 4:2:3) was determined before and after post-insertion of influenza
virus spike proteins at a lipid-to-spike protein ratio of 1:2. The amount of entrapped DNA is expressed relative to the total
amount of liposome- or PI-virosome-associated DNA. 
DISCUSSION
In an attempt to obtain fusogenic influenza virosomes with a higher encapsulation efficiency of
water-soluble (macro)molecules, we have post-inserted influenza virus spike proteins solubilized
with DCPC into preformed liposomes.This method has several advantages over the traditional
method of influenza virosome preparation that involves viral envelope solubilization with C12E8
and subsequent controlled removal of detergent by adsorption to hydrophobic, polystyrene beads
[10]. First, the use of preformed liposomes as basis to construct fusogenic virosomes allows
substantially higher encapsulation efficiencies for water-soluble compounds by using standard
liposome preparation techniques. Second, the post-insertion method of virosome preparation
provides flexibility in the choice of lipid composition of the virosomal bilayer.Third, post-
insertion of viral spike proteins into preformed liposomes favors the correct orientation of these
integral membrane proteins in the bilayer of virosomes with no spike proteins facing inwards as is
the case for the traditional method of virosome preparation. Fourth, the use of DCPC as a mild
detergent to solubilize influenza virus spike proteins allows more efficient removal of detergent
molecules from the virosomal membranes by dialysis, which favors membrane stability and
provide the possibility to entrap drug molecules inside these PI-virosomes with remote loading
procedures [28,29,37].
Post-inserting membrane proteins into preformed liposomes either directly or aided by
detergents have been described for integral membrane proteins, among which viral spike proteins
[22-27].The underlying principle of the method appears to be that membrane proteins insert
spontaneously into small unilamellar phospholipid vesicles in which there are defects in the
packing of the acyl chains, induced either spontaneously or by amphipathic molecules such as
detergents, short-chain lecithins or lyso-derivatives.
In this study, it was demonstrated that detergent-aided post-insertion of influenza virus spike
proteins into preformed liposomes results in the formation of fusion-active virosomes with a
morphology similar to the native virus particles. Post-insertion resulted in correct orientation of
the viral spike protein in the bilayer with most (if not all) spikes facing outwards (Figure 2).This
is in contrast to the orientation of spike proteins in virosomes prepared with the traditional C12E8
method. In the latter case, approximately half of the spike proteins are facing inwards as seen on
EM micrographs (Figure 2).The correct orientation of influenza virus spike proteins is obviously
important when influenza virosomes are used as model systems to study the HA-mediated
membrane fusion mechanism [38,39].
PI-virosome-induced lipid mixing was dependent on the amount of post-inserted spike proteins
and was exclusively pH-dependent with no lipid mixing observed at neutral pH. Lipid mixing
was only observed with target membrane vesicles displaying sialic acid residues on their surface.
These findings strongly suggest that fusion is mediated by the post-inserted viral HA. Several
studies have reported on the effect of HA density on the kinetics of fusion of influenza virus [40-
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42]. Although it is not clear whether one trimer of HA is enough to induce fusion [40] or the
concerted action of several HA trimers is needed to induce membrane fusion [41,42], they all
show positive correlation between HA density and rate and extent of fusion. Furthermore, it was
demonstrated that membrane fusion is dependent on the composition of target membranes as has
been reported for native virus [43,44].
Effective post-insertion of spike proteins required destabilization of the liposome bilayers with
short-chain phospholipids at a concentration of 8 mM prior to protein insertion. Unfortunately,
the post-insertion procedure was accompanied by extensive leakage of both small (calcein) as
well as large (DNA) molecules entrapped inside the liposomes. Due to this leakage we were
unable to determine the occurrence of aqueous contents mixing between PI-virosomes and
ganglioside liposomes (results not shown). It was demonstrated that the retention of liposome-
encapsulated substances was not compromised by the presence of DCPC detergent (Figure 1),
but leakage was caused by the detergent-aided insertion of viral spike proteins (Figure 6 and 8).
It is believed that the wedge-shaped DCPC molecule destabilizes membranes by inserting into
the outer leaflet of phospholipid bilayers thereby causing considerable tension between the two
membrane leaflets [29].This tension facilitates the insertion of membrane proteins. As both
influenza virus HA and NA are integral membrane proteins that span the bilayer, it is well
possible that insertion of these proteins causes extensive leakage by temporarily forming bilayer
perturbations that allow the passage of entrapped molecules. It was not expected, however, that
also large macromolecules such as DNA would be released during the post-insertion process.
Lowering the final concentration of DCPC present during post-insertion from 8 mM to 5 or 2.5
mM resulted in a decrease in calcein leakage. However, it also reduced the extent of lipid mixing
observed with PI-virosomes, most likely caused by less efficient insertion of the viral spike
proteins into liposomes (Figure 7).
As demonstrated in this study, the post-insertion procedure to prepare PI-virosomes is not
compatible with retention of entrapped (macro)molecules during the post-insertion procedure.
Nevertheless, after PI-virosomes have been formed and the detergent has been removed by
dialysis, these PI-virosomes may be subjected to remote loading of drugs [45-47]. As the remote
loading procedure is only effective when a transbilayer gradient (either pH or potential) can be
maintained, virosomes with stable, non-leaky bilayers are required. Due to the flexibility in
choice of bilayer composition and the ease of detergent removal with the post-insertion
procedure of virosome preparation, both favorable for bilayer stability, it is expected that PI-
virosomes will be more suitable for remote loading of drugs than virosomes prepared with the
C12E8 method.The latter method yields virosomes with high amounts (7.5-9 mol%) of residual
detergent present in the virosome bilayer [10].The possibility to incorporate water-soluble
agents in PI-virosomes via remote loading procedures requires further investigation.
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SUMMARY
With advances in biotechnology, a growing number of biotherapeutic molecules are becoming
available. As these biotherapeutic macromolecules (proteins and nucleic acids) often act on
intracellular targets that are out of reach for these large, membrane-impermeable molecules, a
carrier is needed that can specifically deliver these kind of drugs into the cytosol of target cells.
Antibody-targeted liposomes (immunoliposomes) are frequently used for cell-specific drug
delivery. However, delivery of large biotherapeutic molecules with immunoliposomes is often
hampered by an inefficient release of entrapped macromolecules after target cell binding and
subsequent immunoliposome internalization.To enhance cytosolic drug delivery from
immunoliposomes present inside endosomes a pH-dependent fusogenic peptide (diINF-7)
resembling the N-terminal domain of influenza virus hemagglutinin HA2 subunit was used.
Functional characterization of this dimeric peptide showed its ability to induce fusion between
model liposome membranes and leakage of liposome entrapped compounds. More importantly,
liposome-encapsulated fusogenic peptides were able to induce leakage of compounds from
liposomes other than those in which the fusion peptides were entrapped. In a second series of
experiments diINF-7 peptides were encapsulated in immunoliposomes to enhance the endosomal
escape of diphtheria toxin A chain (DTA), which can inhibit protein synthesis when delivered into
the cytosol of target cells. Immunoliposomes with encapsulated DTA targeted to the internalizing
epidermal growth factor receptor (EGFR) on the surface of ovarian carcinoma cells (OVCAR-3)
did not show any cytotoxicity towards OVCAR-3 cells. Only when diINF-7 peptides were co-
encapsulated together with DTA in liposomes cytotoxicity was observed.Thus, synthetic fusion
peptides when entrapped inside liposomes can greatly enhance cytosolic delivery of liposomal
macromolecules by pH-dependent destabilization of endosomal membranes after cellular uptake
of liposomes.
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INTRODUCTION
To exert an optimal therapeutic effect an administered drug must safely reach not only its target
cell but also the appropriate location within that cell. Many biotherapeutic agents (e.g. peptides,
proteins and nucleic acids) act at sites in the cytosol or nucleus that are difficult to reach due to
poor membrane permeation characteristics resulting from unfavorable physicochemical
characteristics, such as large size and/or excessive charge.Therefore, these biotherapeutic agents
rely on drug carriers that allow cytosolic delivery of these agents into diseased cells.
One attractive strategy to obtain cytosolic delivery is the development of fusion-competent
antibody-directed liposomes (immunoliposomes) that, after receptor binding, can fuse with the
plasma-membrane of target cells or, after endocytosis of liposomes, with the endosomal
membranes.This membrane fusion process should result in cytosolic access of liposome-
entrapped drug molecules. Such fusion-competent liposomes can be obtained by disassembling
enveloped viruses, isolating their fusion-promoting components and re-assembling these into
vesicles to obtain so-called virosomes (see chapter 3 and 4 of this thesis) [1-4]. Another, more
refined approach involves the use of synthetic peptides designed to resemble the putative fusion
peptide of viruses to promote fusion of the liposome membrane with the host plasma membrane
or – after receptor-mediated endocytosis of immunoliposomes – fusion with the endosomal
membrane [5-8]. It is hypothesized that destabilization of endosomal membranes is less damaging
than plasma membrane destabilization.The latter may result in cytotoxicity through eradication
of the electrochemical potential generated by the asymmetric distribution of ions across the
plasma membrane.Therefore, drug delivery into the cytosol of target cells via endosomal escape
is the preferred route. It is expected that fusion and/or membrane destabilizing mechanisms that
allow endosomal escape of liposome-entrapped therapeutic macromolecules will increase the
therapeutic availability at the target site and consequently therapeutic efficacy of liposomal drug
formulations.
Many viral fusion peptides have been identified.Their mechanistic and structural role in the
fusion process occurring between the envelopes of viruses and membranes of host-cells has been
extensively studied, both with intact viral fusion proteins and with synthetic analogs of the fusion
protein domains. One of the best-characterized viral fusion peptides is the N-terminal domain of
influenza virus hemagglutinin subunit HA2 [9,10]. It is believed that this short stretch of
hydrophobic amino acids interacts with target membranes after a low pH-induced conformational
change in the HA protein. At low pH, the fusion peptide domain adopts an α-helical structure
that is thought to favor the oblique insertion of the fusion peptide in the endosomal membrane of
host cells that have endocytosed the influenza virus particles.
Studies with synthetic peptides resembling the native sequence of the influenza virus N-terminal
domain of the HA2 subunit have clearly demonstrated that such peptides are able to destabilize
both model membranes (such as liposomes) and natural membranes in a pH-dependent manner.
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Fusion peptide-induced lipid mixing and aqueous contents mixing between liposomes have been
demonstrated, indicating that the peptide analogs have fusogenic capacities [11,12]. Influenza
virus-derived fusion peptides have been used to enhance the endosomal escape of
oligonucleotides [13,14] and polycation-condensed DNA complexes [5,15,16] after cellular
uptake. Surprisingly, despite the wealth of reports on the use of liposomes to functionally
characterize fusogenic peptides, only one study reported on the utility of these peptides in
enhancing cytosolic delivery of liposome-entrapped drugs [17].
In this article the possibility to utilize co-encapsulation of pH-dependent fusion peptides into
liposomal drug formulations as a means to obtain endosomal escape of liposome-entrapped drug
molecules and release of these molecules into the cytosol of tumor cells was studied. For this
purpose a dimeric peptide (diINF-7) resembling the N-terminal domain of influenza virus
hemagglutinin was synthesized. Firstly, the membrane-destabilizing and fusogenic capacity of
diINF-7 either in free form or encapsulated in liposomes was demonstrated by using liposomes as
model membranes. Next, the capacity of these peptides to induce endosomal escape of
immunoliposome-entrapped bioactive molecules was demonstrated by measuring cytosolic
delivery of diphtheria toxin A chain (DTA) as model compound. Co-encapsulation of diINF-7
into DTA-containing immunoliposomes resulted in drastically increased cytotoxicity towards
ovarian carcinoma cells, indicating that this peptide can be used to obtain cytosolic delivery of
liposome-entrapped drugs with poor membrane permeation capacities.
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MATERIALS AND METHODS
MATERIALS
Cholesterol (CHOL), 2’,7’-[bis(carboxymethyl)amino]methyl-fluorescein (calcein), N-
succinimidyl-S-acetylthioacetate (SATA), and sodium 3’-[1-(phenylaminocarbonyl)-3,4-
tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate (XTT) were obtained from
Sigma-Aldrich Co. (St. Louis, MO, USA). Egg phosphatidylcholine and 1,2-distearoyl-glycero-3-
phosphoethanolamine-N-[poly(ethylene glycol)2000] (PEG2000-DSPE) were from Avanti Polar
Lipids (Birmingham, AL, USA). Maleimide-PEG2000-DSPE (MAL-PEG2000-DSPE) was
obtained from Shearwater Polymers (Huntsville, AL, USA). 1-hexadecanoyl-2-(1-
pyrenedecanoyl)-sn-glycero-3-phosphocholine (PyrPC) and 1,1’-dioctadecyl-3,3,3’,3’-
tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD) were purchased from
Molecular Probes Europe BV (Leiden,The Netherlands). Iso-octylphenoxypolyethoxyethanol
(Triton-X100) was obtained from BDH Laboratory Supplies (Poole, England). Dithiothreitol
(DTT) was from Pierce (Rockford, IL, USA). Formaldehyde solution was obtained from Janssen
Chimica (Geel, Belgium). Murine mAb 425 of isotype IgG2b (EMD55900) (Merck KGaA,
Bernstadt, Germany) directed against the human epidermal growth factor receptor (EGFR) was
kindly donated by Dr. G.A. van Dongen (Department of Otolaryngology/Head and Neck
Surgery, University Hospital Vrije Universiteit, Amsterdam,The Netherlands). Irrelevant isotype-
matched murine mAb directed against the influenza virus HA (clone 12CA5) was kindly donated
by Ms E. Boot (Immunology Division, Department of Infectious Diseases & Immunology, Faculty
of Veterinary Medicine, Utrecht University, Utrecht,The Netherlands).
CELL CULTURE
The human ovarian carcinoma cell line NIH:OVCAR-3 originated from the laboratory of Dr.
Hamilton (National Cancer Institute, Bethesda, MD) [18]. OVCAR-3 cells were cultured in
Dulbecco’s modified Eagle’s medium containing 3.7 g/l sodium bicarbonate, 4.5 g/l L-glucose
and supplemented with L-glutamine (2 mM), HEPES (10 mM), 10% (v/v) fetal calf serum
(FCS), penicillin (100 IU/ml), streptomycin (100 µg/ml), and amphotericin B (0.25 µg/ml) at
37ºC with 5% CO2 in humidified air. All cell-culture related material was obtained from Gibco
(Grand Island, NY, USA).
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PEPTIDE SYNTHESIS
The 24 amino acid peptide INF-7 was synthesized by standard Fmoc solid phase synthesis
essentially as described in [19]. Crude peptide was precipitated by dropwise addition of ether and
collected by centrifugation.The peptide was washed three times with ether and subsequently
dried under a stream of argon followed by high vacuum. Subsequently, the peptide was dissolved
in 1 ml of 20 mM ammonium bicarbonate, pH 8.5 and freeze-dried. Lyophilized peptide was
stored at –20ºC. Purity and identity of the peptide were confirmed by HPLC (Waters 486,
Millipore), amino acid analysis, and fast atom bombardment mass spectrometry (FAB-MS).The
presence of a cysteine residue at the carboxy-terminus resulted in dimerization of the INF-7
peptide by disulfide bond formation.
DTA PURIFICATION
The A chain of diphtheria toxin (DTA) was produced essentially as described by Oeltmann et al.
[20] and Carroll et al. [21]. In short, supernatant of cultures of Corynebacterium diphtheriae
containing high amounts of diphtheria toxin (DT), which was kindly donated by Dr. Kersten (The
National Institute of Public Health and The Environment, Bilthoven,The Netherlands) was
dialyzed against two 1 liter changes of HEPES-buffered salt solution (HBS; 5 mM HEPES, 150
mM NaCl, pH 7.4) overnight at 4ºC using Slide-A-Lyzer dialysis cassettes (Pierce, Rockford, IL,
USA) with a molecular weight cut off (MWCO) of 10,000. Four milligram of dialyzed DT was
nicked with trypsin (1 µg/ml in HBS) for 30 min at room temperature after which the trypsin
was inactivated with soybean trypsin inhibitor (5 µg/ml final concentration). DT was reduced
and denatured in HBS containing 8 M urea and 0.1 M dithiothreitol (DTT) and applied to a
1.5x50 cm column of Sephacryl S-200 equilibrated in elution buffer (50 mM Tris-HCl, 2 M urea,
10 mM DTT and 1 mM EDTA; pH 7.5). Fractions of 5 ml were collected and analyzed for the
presence of DTA by SDS-PAGE under reducing conditions. Fractions containing DTA were
pooled and dialyzed overnight at 4ºC against two 1-liter changes of HBS containing 0.1 M 2,2’-
dihydroxyethyl disulfide to reversibly block the free sulfhydryl groups.The concentration of DTA
was determined spectrometrically, versus appropriate blanks, using the extinction coefficient at
280 nm of 1.5 lxg-1xcm-1.The biological activity of DTA to inhibit protein synthesis was
determined with a rabbit reticulocyte lysate in vitro translation system (Promega, Madison,WI,
USA) [22].
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LIPOSOME PREPARATION AND CHARACTERIZATION
Lipids used for all liposome preparations were dissolved in CHCl3:MeOH (2:1 v/v ratio) and
stored at –20ºC under a nitrogen atmosphere. Egg PC and CHOL (30 µmol of lipid) dissolved in
the organic solvent were mixed at a molar ratio of 2:1 in a round bottom flask.When indicated,
0.1 mol% (relative to PL) of the lipidic fluorescence probe DiD, 10 mol% pyrPC (relative to
PL), or varying amounts of PEG2000-DSPE were added to the lipid mixture prior to solvent
evaporation using a rotary evaporator device.The formed lipid films were further dried under a
stream of nitrogen for at least 1 h to remove traces of organic solvent. Lipid films were hydrated
with 1 ml solutions of HBS, calcein (90 mM), diINF-7 (500 µg/ml in HBS), DTA (250 µg/ml in
HBS) or combinations of the latter two substances. Hydration of lipids was facilitated by shaking
the flasks in the presence of glass beads.The formed liposomes were subsequently extruded
through polycarbonate filters with pore sizes varying from 0.05 µm – 0.6 µm using a hand-
extruder from Avanti Polar Lipids (Alabaster, AL, USA). Non-entrapped material was removed
from liposomes by centrifugation steps (2x45 min at 100,000xg; 4ºC). Pelleted liposomes were
resuspended in 1 ml of HBS.The phospholipid concentration of liposome formulations was
determined by the colorimetric method of Fiske and Subbarow [23].The amount of encapsulated
protein (DTA and diINF-7) was determined with the BCA protein assay reagent kit (Pierce) after
disruption of the liposomes with 0.5% (v/v) TX-100.
IMMUNOLIPOSOME PREPARATION
For targeting purposes conjugates of mAb425-PEG2000-DSPE were transferred to liposomes
essentially as described by Ishida et al. [24]. In short, 2.5 mg of mAb 425 was modified with a 8-
fold molar excess of SATA to randomly introduce thiol groups. SATA-modified mAb 425 was
allowed to react with micelles containing PEG2000-DSPE and MAL-PEG2000-DSPE at a 4:1
molar ratio after deacetylation. One micromol of liposomes was incubated with 425-PEG-DSPE
micelles corresponding to an amount of 30 µg of conjugated protein for 90 min at 40ºC to allow
transfer of 425-PEG2000-DSPE to the liposomes. Purification of liposomes was performed on a
Sepharose CL-4B column (Amersham Pharmacia Biotech, Uppsala, Sweden).With this technique,
approximately 70% of targeting ligands could be reproducibly transferred into preformed
liposomes.
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FLOW CYTOMETRY AND CONFOCAL LASER SCANNING 
MICROSCOPY ANALYSIS 
OVCAR-3 cells grown to a confluent monolayer were detached from culture flasks by incubating
the cells for 5 min at 37ºC with trypsin/EDTA solutions from Gibco. Detached OVCAR-3 cells
(2x105 cells) were incubated with DiD-labeled liposomes in a final volume of 300 µl culture
medium for 1 h at 37ºC. Hereafter, cells were washed with immunofluorescence (IF) buffer (1%
BSA in PBS, pH 7.4) by 2 centrifugation steps (5 min at 750xg) and resuspended into 500 µl IF-
buffer before being analyzed by flow cytometry with a FACSCalibur flow cytometer
(Becton&Dickinson, Mountain View, CA, USA). For confocal laser-scanning microscopy analysis,
cells that were incubated with liposomes, were washed 3 times with 1 ml of PBS before fixation
with 2% (v/v) of formaldehyde in PBS for 20 min at room temperature. After fixation, cells that
were adhered to chamberslides were washed twice with PBS and overlaid with cover slides that
were sealed with nail polish. Cells were analyzed on a Leica TCS-SP confocal laser-scanning
microscope equipped with a 488 nm Argon, 568 nm Krypton and 647 nm HeNe laser.
CD MEASUREMENTS
Circular dichroism (CD) measurements were performed with a dual-beam DSM 1000 CD
spectrophotometer (On-Line Instrument Systems, Bogart, GA).The subtractive double-grating
monochromator was equipped with a fixed disk, holographic gratings (2400 lines/mm, blaze
wavelength 230 nm), and 1.24-mm slits. Cuvettes with a path length of 1 mm were used and the
peptide concentration was 100 µg/ml. CD spectra were recorded from 250-200 nm at 25ºC.
Each measurement was the average of six repeated scans (step resolution 1 nm, 1s each step)
from which the corresponding background spectrum was subtracted. Quantitative prediction of
the helical content was accomplished by fitting CD data with Hennessey-Johnson (H.-J.)
algorithm [25], by the program CDNN in “simple spectra”-configuration [26], using a protein
database with known secondary structure as the basis set.
LIPOSOME TURBIDITY ASSAY
Liposomes composed of EPC and CHOL (molar ratio of 2:1) and with increasing amounts of
PEG2000-DSPE (0, 2.5, 5 and 10 mol%) were added to a cuvette at a concentration of 300 µM
or 1000 µM in a final volume of 1.5 ml of HBS. Immediately after the addition of diINF-7 (lipid
to peptide molar ratio of 50), peptide-induced aggregation of liposomes at the indicated pH
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values was determined by measuring the increase in optical density of the liposome dispersion at
500 nm with a spectrophotometer over a period of 8 min at room temperature.
LIPOSOME LEAKAGE ASSAY
A serial dilution (1:5) of free or liposome-encapsulated diINF-7 peptide was prepared in a 96-
well microtiter plate by transferring 20 µl of the initial peptide solution (50 µg/ml for free
peptide and 0.3 µg/ml for liposome-entrapped peptide) from one well to the next well
containing 80 µl of HBS. Calcein-containing liposomes were added to each well at a final
concentration of 40 µM. After 60 min incubation at room temperature samples were analyzed for
fluorescence with an LS50B fluorimeter (Perkin Elmer) set at an excitation wavelength of 488
nm and an emission wavelength of 520 nm. Calcein leakage was expressed relative to the
difference in the fluorescence of calcein liposomes incubated in the absence of diINF-7 peptide
(0% leakage) and the fluorescence of calcein liposomes that had been disrupted with 0.5% (v/v)
Triton X-100 (100% leakage).The effect of Triton X-100 on calcein fluorescence intensity was
negligible at the tested concentration [27,28].
LIPID MIXING ASSAY
diINF-7-induced lipid mixing was monitored with the pyrene excimer assay developed by Galla
et al. [29]. Liposomes (5 µM) labeled with 10 mol% PyrPC (Molecular Probes) were mixed in a
total volume of 1.4 ml of HBS with a 20-fold molar excess of non-labeled donor liposomes in a
stirred cuvette kept at 37ºC. diINF-7 peptide was added at the amounts indicated and after a 2
min equilibration period, the pH of the medium in the cuvette was lowered to 5.2 by adding
1/20 volume of fusion buffer (0.1 M 2-[N-morpholino]ethanesulfonic acid] (MES), 0.1 M acetic
acid, pH 4.1). Fusion was continuously monitored at 37ºC by measuring the decrease in pyrPC
excimer fluorescence with a LS50B fluorimeter set at an excitation wavelength of 345 nm and an
emission wavelength of 480 nm.The decrease of fluorescence was expressed relative to the
difference in the initial fluorescence and the excimer fluorescence at infinite dilution, which was
obtained by disrupting the liposomes with 0.5% (v/v) Triton X-100 (final concentration).
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AQUEOUS CONTENTS MIXING ASSAY
The occurrence of diINF-7-induced intermixing of liposome-entrapped solutes was determined
with a fluorescent assay based on quenching of calcein with bivalent metal ions [30]. Unilamellar
liposomes of 150 nm in size containing calcein (0.8 mM) and CuSO4 (1 mM) in HBS were
admixed at a concentration of 50 µM with a five-fold molar excess of liposomes containing 20
mM EDTA in a stirred cuvette kept at a temperature of 37ºC. diINF-7 was added at a
concentration of 5 µg/ml.The pH of the buffer was lowered to 5.2 by adding 1/20 volume of
fusion buffer. Aqueous contents mixing and/or leakage were continuously monitored at 37ºC by
measuring the increase in calcein fluorescence with a fluorimeter set at an excitation wavelength
of 488 nm and an emission wavelength of 520 nm.To be able to determine the contribution of
both leakage and aqueous content mixing to the total increase in calcein fluorescence, 1/20
volume of 1 mM CuSO4 was added to the external medium during the fusion process.
CYTOTOXICITY ASSAY
OVCAR-3 cells were plated in 96-well cell culture plates at 5x103 cells/well and cultured for 24
hrs. Culture medium was removed by decanting the plates and cells were overlaid with 100 µl of
fresh culture medium.To the first well of each column 100 µl of liposome formulation were
added at a final lipid concentration of 1 mM (corresponding to 0.5 µg/ml of DTA).Two-fold
serial dilutions of liposome formulations were prepared by transferring 100 µl of the first well in
a column to the next and so forth. After 1 h incubation at 37ºC liposomes were removed from
the cells by decanting the plates, cells were washed with 100 µl/well of fresh culture medium
and overlaid with 100 µl of fresh culture medium before incubation was continued. Forty eight
hrs after addition of liposome formulations cell viability was assessed with the colorimetric XTT
assay as previously described [31].
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RESULTS
PRIMARY AND SECONDARY STRUCTURE OF diINF-7
The primary amino acid sequence of diINF-7 is presented in Table 1. Compared to the native
sequence of the N-terminal domain of the influenza virus HA2 subunit, diINF-7 differs in only
two amino acids: glycine on position 4 and alanine on position 7 have been substituted by
glutamic acid residues.These substitutions favor the pH dependency of the fusogenic activity of
the peptide. As fusogenic activity is thought to be directly correlated with α-helix formation of
the peptide [6,32-34], the secondary structure of diINF-7 was determined by circular dichroism
spectropolarimetry at both pH 7.4 and pH 5.2 in the presence or absence of detergent-
solubilized phospholipids. Since Subbarao et al. [35] showed that interpretation of CD-spectra
below 222 nm in the presence of phospholipid vesicles is ambiguous due to liposome scattering,
we used mixed micelles of phospholipids and detergent to determine the effect of a hydrophobic
environment on the helical content of the peptide.The CD-spectrum (Figure 1) of the free
peptide at pH 5.2 shows minima at 208 and 222 nm, typical of a highly α-helical structure; in
contrast, at neutral pH the diINF-7 peptide is primarily randomly coiled (Figure 1A and Table 2).
Interestingly, the presence of detergent-solubilized phospholipids can also induce α-helix
formation of diINF-7 (Figure 1B and Table 2).
INF HA2 GLF GAI AGFI ENGW EGMI DGWYG -------
diINF-7 GLF EAI EGFI ENGW EGMI DGWYGC
GLF EAI EGFI ENGW EGMI DGWYGC
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Table 1 — Amino acid sequences of fusion peptides. INF HA2: amino-terminal sequence of influenza virus X-31 (H3N2)
hemagglutinin subunit HA2; diINF-7: peptide analogue resembling Inf HA2 dimerized at the C-terminus by disulfide bond
formation between C-terminal cysteine residues. Differences in amino acid sequence of diINF-7 compared to the native INF
HA2 sequence are highlighted in bold. 
]
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Figure 1 — Secondary structure of diINF-7 peptides as a function of pH and presence of mixed micelles of phospholipids and
detergent. CD spectra of diINF-7 at pH 5.2 and 7.4 in the absence (A) and presence (B) of phospholipid micelles against
appropriate blanks at 25ºC. In all cases, the concentration of diINF-7 peptide was 18.6 µM. Mixed micelles consisted of 1
mM of indicated phospholipids and 40 mM of OG. As judged from the molar absorbance at 222 nm, alpha helicity of diINF-7
peptides increased with decreasing pH and in the presence of detergent or mixed micelles. EPC: egg phosphatidyl choline; OG:
octyl glucoside.
Mixed Micelles
—
—
EPC/OG
(1 mM)/(40 mM)
EPC/OG 
(1 mM)/(40 mM) 
pH
7.4
5.2
7.4
5.2
∆ε222 (M-1cm-1)
– 0.675
– 2.751
– 2.538
– 4.686
Helical content (%)
15
31
29
53
Table 2 — Molar Absorbance at 222 nm (∆ε222) and helical content of diINF-7 in absence or presence of mixed micelles and
at different pH values.
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Table 3 — Characterization of liposome preparations used throughout this study. 
Liposome
Composition
(molar ratio)
EPC:CHOL (2:1)
EPC:CHOL (2:1)
EPC:CHOL (2:1)
EPC:CHOL (2:1)
EPC:CHOL (2:1)
EPC:CHOL (2:1)
EPC:CHOL (2:1)
EPC:CHOL (2:1)
EPC:CHOL (2:1)
EPC:CHOL:PEG2000-
DSPE (1.9:1:0.5)
EPC:CHOL:PEG2000-
DSPE (1.9:1:0.5)
EPC:CHOL:PEG2000-
DSPE (1.9:1:0.5)
Lipid Concentration
(mM of PL)
8.2
8.8
7.6
7.1
6.2
10.3
7.7
8.0
6.8
6.2
7.1
7.4
Entrapped Contents
—
—
—
—
diINF-7 (12 µg/µmol PL)
DTA (0,5 µg/µmol PL)
DTA diINF-7
(12 µgtotal protein/µmol PL)
Calcein (90 mM)
Calcein (90 mM)
diINF-7 (12 µg/µmol PL)
—
—
—
—
Average Size in nm
(polydispersity index)
90 (0.110)
150 (0.101)
270 (0.326)
748 (0.555)
194 (0.397)
152 (0.123) 
193 (0.405) 
130 (0.096) 
188 (0.368) 
127 (0.091) 
128 (0.084) 
127 (0.021) 
LIPOSOME CHARACTERIZATION
In this study neutral liposomes (EPC:CHOL molar ratio 2:1) with and without incorporated
PEG2000-DSPE were used as model membranes to test the membrane-destabilizing capacity of
diINF-7 and targeted drug carriers to deliver diphtheria toxin A chain (DTA) into the cytosol of
tumor cells. Liposomes were prepared by hydrating lipid films of 30 µmol total lipid (TL) with 1
ml of the appropriate buffer after which the formed liposomes were sized by extrusion [36].The
lipid composition, phospholipid concentration, entrapped contents and liposome size of the
batches of liposomes used throughout this study are given in Table 3.
diINF-7 PEPTIDE-INDUCED AGGREGATION OF LIPOSOMES
diINF-7 peptide-induced aggregation of unilamellar liposomes as a function of pH, and presence
of PEG molecules on the surface of liposomes was monitored by measuring the changes in
turbidity of liposome dispersions at 500 nm (Figure 2).The results show that liposome
aggregation increased with decreasing pH. No aggregation of liposomes was observed at pH 8.4.
The presence of PEG molecules (Mw 2000) exposed on the surface of liposomes (2.5, 5 and 10
mol% relative to total lipid) fully inhibited diINF-7-induced liposome aggregation at low pH.
LIPID MIXING ASSAY
The capacity of diINF-7 to induce membrane fusion between liposomes was determined with the
pyrene excimer lipid-mixing assay [29]. ‘Donor’ liposomes, containing 10 mol% of pyrene-
labeled phosphatidylcholine (pyrPC) were admixed with non-labeled ‘acceptor’ liposomes. Upon
intermixing of membrane lipids between donor and acceptor liposomes, the pyrPC label will be
diluted over a larger membrane area, resulting in a decrease in excimer formation and thus a
decrease in pyrPC fluorescence. Figure 3 shows that the extent of lipid mixing increased with
increasing concentrations of diINF-7. Lipid mixing was pH-dependent. No lipid mixing was
observed at pH 7.4. At acidic environment, the rate and extent of lipid mixing increased with
increasing diINF-7 concentration (panel A) and decreasing pH (panel B). Furthermore, the
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Figure 2 — diINF-7 peptide-induced aggregation of liposomes as a function of pH, and liposome composition. Panel A:
Aggregation of liposomes (300 µM) when exposed to diINF-7 peptides dissolved in the aqueous dispersion (molar ratio lipid-
to-peptide: 50) at pH 5.2, 7.4 and 8.4. Panel B: Effect of PEG2000 exposed to the surface of liposome on diINF-7 induced
aggregation of liposomes. Concentrations of liposomes and peptide were the same as in Panel A. 
degree of lipid mixing depended on the size of ‘acceptor’ and ‘donor’ liposomes (panel C). Small
liposomes with an average size of 70 nm showed the highest degree of lipid mixing (75%),
whereas the extent of lipid mixing between liposomes with an average size of approximately 700
nm was only 22%. Furthermore, the extent of lipid mixing was negatively correlated with the
amount of PEG2000 exposed on the surface of liposomes (panel D).
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Figure 3 — Effect of diINF-7 peptide concentration, buffer pH, liposome size and surface-exposed PEG molecules on the
extent of diINF-7-induced lipid mixing. ‘Donor’ liposomes (EPC:CHOL:pyrPC, molar ratio 1.8:1:0.2) were admixed with a 20-
fold molar excess of ‘acceptor’ liposomes (EPC:CHOL, molar ratio 2:1) at a final lipid concentration of 105 µM. diINF-7
peptides were added to the liposome dispersion at the indicated concentration. At the time point indicated with a black arrow,
the external medium was acidified to pH 5.2 (unless mentioned otherwise) and lipid mixing was continuously monitored as
measured by a decrease of pyrPC excimer fluorescence. The decrease of pyrPC excimer fluorescence was expressed relative to
the initial fluorescence and the excimer fluorescence at infinite dilution (i.e. after vesicle solubilization with detergent). Panel
A: Extent of lipid mixing as a function of diINF-7 peptide concentration: 0 (a), 1, (b), 10 (c), 20 (d) µg/ml diINF-7. Panel B:
Influence of pH on degree of lipid mixing induced by diINF-7 (10 µg/ml): pH 7.4 (a), 6.5 (b), 5.2 (c), 5.0 (d), and 4.6 (e).
Panel C: Influence of liposome size on the degree of lipid mixing induced by diINF-7 (10 µg/ml). Curves show lipid mixing
between liposomes of 90 nm (a), 270 nm (b) and 750 nm (c) in size. Panel D: Effect of surface-exposed PEG molecules on the
degree of diINF-7-induced lipid mixing between 100 nm liposomes. Peptide concentration was 10 µg/ml. Relative amount of
PEG2000 molecules grafted on the surface of liposomes was 10 mol% (a), 5 mol% (b), 2.5 mol% (c), and 0 mol% (d). Each
curve respresents the average of three individual measurements. 
diINF-7-MEDIATED MEMBRANE DESTABILIZATION RESULTS 
IN LEAKY MEMBRANE FUSION
A fluorescent assay based on the method of Kendall et al. [30] to monitor vesicle fusion and lysis
was performed to determine whether diINF-7-induced lipid mixing is accompanied by
intermixing of aqueous contents between liposomes and/or leakage of liposome-entrapped
materials. Calcein/Cu2+ complexes, which are non-fluorescent, were entrapped in one set of
liposomes and admixed with a 5-fold excess of a second set of liposomes containing entrapped
EDTA.When EDTA comes in contact with Cu2+/calcein complexes, either due to aqueous
contents mixing between liposomes or due to leakage of both compounds to the external
medium, EDTA will chelate the Cu2+ ions, thereby liberating the highly fluorescent calcein.
The results of diINF-7-induced aqueous contents mixing between EDTA-containing liposomes
and Cu2+/calcein-containing liposomes are presented in Figure 4. An increase in calcein
fluorescence was observed directly after lowering the pH of the external medium to 5.2.
To be able to discriminate which part of the observed increase in calcein fluorescence was caused
by leakage of entrapped calcein and EDTA and which part was caused by intermixing of aqueous
contents, an excess of Cu2+ ions was added to the external medium.This resulted in an
instantaneous decrease in calcein fluorescence, followed by a slow decline in calcein fluorescence.
This biphasic decrease of calcein upon addition of Cu2+ ions to the external medium may be
explained by instantaneous quenching of calcein located outside liposomes, whereas quenching of
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Figure 4 — diINF-7-induced aqueous contents mixing and leakage of liposomes. Liposomes (50 µM of TL) containing 1 mM
CuSO4 and 0.8 mM calcein were admixed with a five-fold excess of liposomes containing 20 mM EDTA. Fluorescence of
calcein was continuously monitored with an LS50B fluorescent spectrophotometer set at excitation wavelength of 488 nm and
an emission wavelength of 520 nm. At indicated time points, pH of the external medium was lowered from 7.4 to 5.2 and 1/20
vol of 1 mM CuSO4 was added to the external medium. Black curve: calcein fluorescence pattern obtained in the presence of 
5 µg/mL diINF-7. Gray curve: calcein fluorescence pattern obtained in the absence of diINF-7 peptide. Results of a typical
experiment are shown.
free calcein located inside lipidic vesicles occurred at a slower rate, as this requires passage of
Cu2+ ions over the diINF-7 peptide-destabilized liposome membranes. No increase in calcein
fluorescence could be observed in the absence of diINF-7 peptides.
EFFECT OF LIPOSOME ENCAPSULATION ON THE MEMBRANE
DESTABILIZING CAPACITY OF diINF-7
Previous studies with synthetic analogs of influenza virus fusion peptides have demonstrated that
peptide-induced membrane destabilization is accompanied by leakage of liposome-entrapped
materials when peptides were added in free form to the liposomes [16,19,37,38]. Here, we
tested the capacity of diINF-7 to induce leakage of calcein from liposomes under two different
conditions: (1) by adding diINF-7 peptide free in solution to a dispersion of calcein-containing
liposomes or (2) by adding liposome-entrapped diINF-7 to calcein-containing liposomes. Figure
5A presents the results of calcein leakage from liposomes composed of EPC and CHOL (molar
ratio 2:1) after 1 h incubation at room temperature in the presence of increasing diINF-7 peptide
concentrations. Calcein leakage occurred both at pH 5.2 and pH 7.4. However, at pH 7.4 30-fold
higher concentrations of diINF-7 were needed to obtain the same level of calcein leakage. diINF-
7 also induced leakage of calcein from liposomes at pH 5.2 when encapsulated in liposomes other
than the calcein-liposomes, though less efficient than free diINF-7 (Figure 5B).
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Figure 5 — Effect of liposome-encapsulated diINF-7 peptide compared to free diINF-7 peptide on the extent of calcein
leakage from liposomes at pH 5.2 and pH 7.4. Leakage of calcein from liposomes composed of EPC and CHOL (molar ratio
2:1) and approx 130 nm in size induced by A: diINF-7 peptides free in solution and B: diINF-7 peptides encapsulated in
liposomes other than the liposomes containing the calcein. Leakage of calcein from liposomes was measured both at pH 7.4
and pH 5.2 after 1-h incubation at room temperature. Leakage of calcein is expressed relative to the difference between
leakage of calcein from liposomes after disruption with detergent (100% value) and leakage of calcein from liposomes in the
absence of peptides (0% value). Each data point represents the average of three individual measurements.
EFFECT OF LIPOSOME-ENCAPSULATED diINF-7 ON CYTOSOLIC DTA
DELIVERY
An important finding in this study is that diINF-7 induced leakage of calcein from liposomes
exclusively at low pH when these peptides were encapsulated in liposomes other than the calcein-
containing liposomes.This finding implies that diINF-7 peptides may be able to destabilize not only
the carrier liposomes in which these peptides are entrapped, but also the endosomal membranes
when these fusion-peptide bearing liposomes are endocytosed by target cells.
To evaluate the endosomolytic activity of diINF-7, we co-encapsulated DTA in diINF-7-containing
liposomes. DTA/diINF-7 liposomes were targeted to the internalizing human epidermal growth
factor receptor (hEGFR) by conjugating mAb 425 to the liposome surface.These immunoliposomes
were incubated with ovarian carcinoma cells (OVCAR-3) expressing 
the EGFR on their cell surface. Binding of DTA/diINF-7 liposomes labeled with the fluorescent
probe DiD is illustrated in Figure 6A.The figure shows that the immunoliposomes are able to bind
to OVCAR-3 cells. Cell binding could be partially blocked by adding free mAb 425 at a
concentration of 500 µg/ml. Liposomes lacking surface-grafted antibodies showed only low levels
of cell binding and liposomes bearing an isotype-matched irrelevant antibody (mAb 12CA5 directed
against influenza virus HA) grafted on their surface showed moderate binding. Confocal laser
scanning microscopy experiments show that liposomes targeted to the EGFR on OVCAR-3 cells
are efficiently internalized (Figure 6B). Cytotoxicity of native DT, free DTA and liposomal DTA
formulations towards OVCAR-3 cells is shown in Figure 7. DTA in free form was not toxic to
OVCAR-3 cells in the concentration range tested, whereas the nicked DT showed concentration-
dependent cytotoxicity towards OVCAR-3 cells (Figure 7A). Importantly, the cytotoxicity of
diINF-7/DTA-containing immunoliposomes (DTA-425-FIL) was even higher compared to native
DT, indicating that the amount of toxin molecules delivered by immunoliposomes via EGFR-
mediated endocytosis and subsequent endosomal escape is higher than the amount of toxin
delivered via the native HB-EGF receptor (Figure 7B and C). DTA-immunoliposome formulations
devoid of diINF-7 (DTA-425-IL) did not show cytotoxicity. Cytotoxicity was not due to diINF-7-
induced endosomal membrane disruption, as immunoliposomes bearing diINF-7 but no DTA (425-
FIL) did not show toxicity towards OVCAR-3 cells (Figure 7C). Non-targeted diINF-7/DTA-
liposomes or targeted with an irrelevant monoclonal antibody did not show cytotoxicity (Figure
7B). Inhibition of acidification of endosomes by adding 20 mM NH4Cl to the culture medium 30
min prior to adding the diINF-7/DTA immunoliposomes resulted in loss of cytotoxicity of this
DTA formulation (Figure 7B).The addition of 20 mM NH4Cl to the culture medium had no effect
on cell viability (results not shown). In conclusion, the results show that cytosolic delivery of DTA
into OVCAR-3 cells requires both receptor-mediated endocytosis of DTA/diINF-7
immunoliposomes and subsequent low pH-induced activation of the endosomolytic activity of
diINF-7.
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Figure 6 — Flow cytometry (A) and confocal laser scanning microscopy (CLSM;B) analysis of cellular uptake of diINF-7/DTA-
containing immunoliposomes by OVCAR-3 cells. Cells (2x105) were incubated with DiD-labeled liposomes (EPC:CHOL:DiD
2:1:0.002) or immunoliposomes (500 µM) for 1 h at 37ºC. Liposomes contained 0.5 µg/µmol PL of DTA and 12 µg/µmol PL
of diINF-7. After unbound liposomes were washed away, cells were analyzed for associated DiD fluorescence by flow cytometry.
Panel A: Cell-associated DiD fluorescence of OVCAR-3 cells incubated without liposomes (a), with 425-IL (b) with 425-IL in
the presence of free mAb 425 (500 µg/ml) (c), liposomes without surface-conjugated antibodies (d) and immunoliposomes
bearing isotype matched irrelevant mAb 12CA5 (e). Panel B: Light contrast (A and C) and CLSM (B and D) pictures taken
from OVCAR-3 cells incubated for 60 min with 425-IL with encapsulated DTA and diINF-7 (A and B) or incubated with non-
targeted liposomes containing encapsulated DTA and diINF-7 (C and D).
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Figure 7 — Cytotoxicity of free or liposome-encapsulated DTA towards OVCAR-3 cells. OVCAR-3 cells, plated at a density of
5x104 cells/mL were exposed to several DT or DTA formulations for 1 h at 37ºC. Hereafter, toxin formulations were removed
and cells were incubated for 47 hrs before cell viability was assessed with the XTT assay. Cell viability is expressed relative to
the difference in viability of untreated cells (100% value) and empty wells (0% viability). Panel A: DTA: diphtheria toxin A
chain; DT: crude diphtheria toxin activated with trypsin; DTA-425-IL: immunoliposomes targeted with an anti-EGFR antibody
(mAb 425) and containing DTA (0.5 µg/µmol PL); DTA-425-FIL: 425-IL containing DTA (0.5 µg/µmol PL) and diINF-7 (12
µg/µmol PL). Panel B: DTA-FL: non-targeted liposomes containing DTA (0.5 µg/µmol PL) and diINF-7 (12 µg/µmol PL); DTA-
IgG-FIL: immunoliposomes targeted with an isotype-matched irrelevant antibody and containing DTA (0.5 µg/µmol PL) and
diINF-7 (12 µg/µmol PL); DTA-425-FIL + 20 mM NH4Cl: DTA-425-FIL incubated with OVCAR-3 cells in the presence of 20
mM NH4Cl to inhibit endosome acidification. Panel C: 425-FIL: 425-IL containing diINF-7 (12 µg/µmol PL).
DISCUSSION
In the work presented here, a dimerized synthetic fusion peptide (diINF-7) resembling the N-
terminal domain of influenza virus hemagglutinin subunit HA2 was used for the purpose to
enhance cytosolic delivery of immunoliposome-encapsulated macromolecules after cellular uptake
of immunoliposomes by receptor-mediated endocytosis. A previous study demonstrated that
dimerization of synthetic influenza virus fusion peptides resulted in 20-fold enhanced liposome
leakage activity and high, pH specific lysis of erythrocytes [10]. For this reason, we have chosen to
use the dimerized form of the fusion peptide analogue INF-7. Structural characterization of diINF-
7 showed that the dimeric peptide adopts an α-helix when exposed to low pH and when exposed
to mixed micelles of detergent and phospholipids.The pH-dependent membrane destabilizing
capacity of diINF-7 was demonstrated by the induction of leakage of calcein from liposomes. An
important finding for the application of diINF-7 as endosomolytic agent in liposomal drug delivery
is that — though less effective than free diINF-7 peptide — liposome-encapsulated diINF-7
peptides are able to induce release of calcein from another set of liposomes (Figure 5).This
indicates that the liposome-encapsulated peptides are not only able to destabilize the liposomes in
which they are encapsulated, but subsequently also other lipid membranes.
Besides leakage, the diINF-7 peptide also induces liposome aggregation (Figure 2) and subsequent
intermixing of lipids between liposome vesicles, indicative for membrane fusion (Figure 3).The
degree of lipid mixing induced by diINF-7 seemed to be dependent on the size of liposomes. An
explanation for this may be that small liposomes have a high curvature and membrane strain,
which favors merging with other vesicles to release the strain. Conversely, multilamellarity of
large liposomes may account for the decrease in observed lipid mixing. An interesting
observation is that incorporation of only small amounts of PEG-lipids in the liposome
membranes (2.5 mol%) completely inhibited liposome aggregation and caused a large reduction
in lipid mixing (Figure 2B and 3D). Presumably, the hydrophilic PEG polymers prevented the
close juxtaposition of membranes required for peptide-induced aggregation of liposomes and
subsequent membrane exchange between aggregated liposomes. Surprisingly, the presence of
PEG on the surface of liposomes has a less pronounced inhibitory effect on peptide-induced
calcein leakage, suggesting that leakage is not merely due to liposome aggregation. diINF-7
peptide-induced fusion is a rather leaky process resulting in excessive leakage of liposome-
entrapped compounds to the external medium in addition to mixing of aqueous contents
between fused liposomes (Figure 4). Similar findings have been reported for fusion induced by
intact influenza virus particles with liposomes [39].
Indeed, when monomeric INF-7 was covalently conjugated to maleimide-derivatized PE that was
incorporated into the liposomal bilayer, the fusion peptide showed fusogenic activity already at
neutral pH thereby causing undesired aggregation and lipid mixing of liposomes (results not
shown).
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In a second set of experiments diINF-7 was tested on its capacity to enhance endosomal escape 
of immunoliposome-entrapped compounds. diINF-7 together with DTA were entrapped inside
immunoliposomes targeted to the EGFR expressed on the surface of OVCAR-3 cells.We have
utilized encapsulation of diINF-7 as a means to guarantee delivery of sufficient quantities of
peptides into the endosomal compartment, which is required for effective destabilization of
liposomal as well as endosomal membranes with subsequent cytosolic drug release.The
possibility to attach the fusogenic peptide to the liposome membrane has been explored by us
(unpublished results) and several other groups [37,40-42]. However, the general conclusion is
that lipid-modification of fusogenic peptides leads to an altered conformation of the peptides
thereby influencing their fusogenic behavior [37,42].The results presented in this study
demonstrate that co-encapsulation of diINF-7 into DTA-containing immunoliposomes results in
cytosolic delivery of DTA into OVCAR-3 cells. As inhibition of endosome acidification results in
loss of cytotoxicity of diINF-7/DTA-containing immunoliposomes, it is most likely that delivery
of DTA into the cytosol of OVCAR-3 cells is mediated by diINF-7-induced endosomal membrane
destabilization after cellular uptake of the diINF-7/DTA immunoliposomes.
In conclusion, encapsulation of the fusogenic peptide diINF-7 into immunoliposomes is an
attractive strategy to obtain endosomal escape of liposome-entrapped therapeutic compounds
after receptor-mediated endocytosis of these immunoliposomes by target cells. Future research
will focus on the in vivo applicability of this Trojan horse concept of liposomal drug delivery.
16
4
ac
kn
ow
le
dg
m
en
ts
 / 
re
fe
re
nc
e 
lis
t
ACKNOWLEDGMENTS
The authors wish to thank Ms Lovina Hofmeyer (Department of Medicinal Chemistry, Utrecht
Institute for Pharmaceutical Sciences, Utrecht University,The Netherlands) for INF-7 peptide
synthesis.
REFERENCE LIST
1 Scheule, R.K. (1986): Novel preparation of functional Sindbis virosomes. Biochemistry, 25:4223-4232.
2 Stegmann, T., Morselt, H.W., Booy, F.P., van Breemen, J.F., Scherphof, G., and Wilschut, J. (1987): 
Functional reconstitution of influenza virus envelopes. EMBO J., 6:2651-2659.
3 Schoen, P., Chonn, A., Cullis, P.R., Wilschut, J., and Scherrer, P. (1999): Gene transfer mediated by fusion protein
hemagglutinin reconstituted in cationic lipid vesicles. Gene Ther., 6:823-832.
4 Kaneda, Y. (2000): Virosomes: evolution of the liposome as a targeted drug delivery system. 
Adv.Drug.Del.Rev., 43:197-205.
5 Plank, C., Zauner, W., and Wagner, E. (1998): Application of membrane-active peptides for drug and gene delivery across
cellular membranes. Adv.Drug.Del.Rev., 34:21-35.
6 Pecheur, E.I., Sainte-Marie, J., Bienven, and Hoekstra, D. (1999): Peptides and membrane fusion: towards an understanding
of the molecular mechanism of protein-induced fusion. J.Membr.Biol., 167:1-17.
7 Fujii, G. (1999): To fuse or not to fuse: the effects of electrostatic interactions, hydrophobic forces, and structural
amphiphilicity on protein-mediated membrane destabilization. Adv.Drug.Del.Rev., 38:257-277.
8 Wagner, E. (1999): Application of membrane-active peptides for nonviral gene delivery. Adv.Drug.Del.Rev., 
38:279-289.
9 Mechtler, K. and Wagner, E. (1997): Gene transfer mediated by influenza virus peptides: The role of peptide sequences.
New J.Chem., 21:105-111.
10 Oberhauser, B., Plank, C., and Wagner, E. (1995): Enhancing endosomal exit of nucleic acids using pH-sensitive viral fusion
peptides. In: Delivery strategies for antisense oligonucleotide therapeutics, edited by S. Akhtar, 
pp. 247-266. CRC Press, Boca Raton.
11 Matsumoto, T. (1999): Membrane destabilizing activity of influenza virus hemagglutinin-based synthetic peptide:
implications of critical glycine residue in fusion peptide. Biophys.Chem., 79:153-162.
12 Düzgünes, N. and Shavnin, S.A. (1992): Membrane destabilization by N-terminal peptides of viral envelope proteins.
J.Membr.Biol., 128:71-80.
13 Pichon, C., Freulon, I., Midoux, P., Mayer, R., Monsigny, M., and Roche, A.C. (1997): Cytosolic and nuclear delivery of
oligonucleotides mediated by an amphiphilic anionic peptide. Antisense Nucleic Acid Drug Dev., 7:335-343.
14 Freulon, I., Roche, A.C., Monsigny, M., and Mayer, R. (2001): Delivery of oligonucleotides into mammalian cells by anionic
peptides: comparison between monomeric and dimeric peptides. Biochem.J., 354:671-679.
16
5
ch
ap
te
r 
5
15 Kichler, A., Mechtler, K., Behr, J.P., and Wagner, E. (1997): Influence of membrane-active peptides on lipospermine/DNA
complex mediated gene transfer. Bioconjug.Chem., 8:213-221.
16 Wagner, E., Plank, C., Zatloukal, K., Cotten, M., and Birnstiel, M.L. (1992): Influenza virus hemagglutinin HA-2 N-terminal
fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-
transfer vehicle. Proc.Natl.Acad.Sci.U.S.A., 89:7934-7938.
17 Baru, M., Nahum, O., Jaaro, H., Sha’anani, J., and Nur, I. (1998): Lysosome-disrupting peptide increases the efficiency of
in-vivo gene transfer by liposome-encapsulated DNA. J.Drug Target., 6:191-199.
18 Hamilton, T.C., Young, R.C., McKoy, W.M., Grotzinger, K.R., Green, J.A., Chu, E.W., Whang-Peng, J., Rogan, A.M., Green,
W.R., and Ozols, R.F. (1983): Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and
estrogen receptors. Cancer Res., 43:5379-5389.
19 Plank, C., Oberhauser, B., Mechtler, K., Koch, C., and Wagner, E. (1994): The influence of endosome-disruptive peptides on
gene transfer using synthetic virus-like gene transfer systems. J.Biol.Chem., 269:12918-12924.
20 Oeltmann, T.N. and Wiley, R.G. (1988): Preparation of diphtheria toxin fragment A coupled to hormone. 
Methods Enzymol., 165:204-10:204-210.
21 Carroll, S.F., Barbieri, J.T., and Collier, R.J. (1988): Diphtheria toxin: purification and properties. 
Methods Enzymol., 165:68-76:68-76.
22 Carroll, S.F. and Collier, R.J. (1988): Diphtheria toxin: quantification and assay. Methods Enzymol., 
165:218-25:218-225.
23 Fiske, C.H. and Subbarow, Y. (1925): The colorimetric determination of phosphorus. J.Biol.Chem., 66:375-400.
24 Ishida, T., Iden, D.L., and Allen, T.M. (1999): A combinatorial approach to producing sterically stabilized (Stealth)
immunoliposomal drugs. FEBS Lett., 460:129-133.
25 Hennessey, J.P.J. and Johnson, W.C.J. (1981): Information content in the circular dichroism of proteins. 
Biochemistry, 20:1085-1094.
26 Böhm, G. CDNN CD Spectra Deconvolution Software. (2.1). 1997. Computer Program
27 Memoli, A., Palermiti, L.G., Travagli, V., and Alhaique, F. (1999): Effects of surfactants on the spectral behaviour of calcein
(II): a method of evaluation. J.Pharm.Biomed.Anal., 19:627-632.
28 Memoli, A., Palermiti, L.G., Travagli, V., and Alhaique, F. (1994): Effects of surfactants on the spectral behaviour of
calcein. J.Pharm.Biomed.Anal., 12:307-312.
29 Galla, H.J. and Hartmann, W. (1980): Excimer-forming lipids in membrane research. Chem.Phys.Lipids, 27:199-219.
30 Kendall, D.A. and MacDonald, R.C. (1982): A fluorescence assay to monitor vesicle fusion and lysis. 
J.Biol.Chem., 257:13892-13895.
31 Arigita, C., Zuidam, N.J., Crommelin, D.J., and Hennink, W.E. (1999): Association and dissociation characteristics of
polymer/DNA complexes used for gene delivery. Pharm.Res., 16:1534-1541.
32 Düzgünes, N. and Gambale, F. (1988): Membrane action of synthetic N-terminal peptides of influenza virus hemagglutinin
and its mutants. FEBS Lett., 227:110-114.
33 Wharton, S.A., Martin, S.R., Ruigrok, R.W., Skehel, J.J., and Wiley, D.C. (1988): Membrane fusion by peptide analogues of
influenza virus haemagglutinin. J.Gen.Virol. ,69( Pt 8):1847-1857.
16
6
re
fe
re
nc
e 
lis
t
34 Brasseur, R. (2000): Tilted peptides: a motif for membrane destabilization (hypothesis). Mol.Membr.Biol., 17:31-40.
35 Subbarao, N.K., Parente, R.A., Szoka, F.C.J., Nadasdi, L., and Pongracz, K. (1987): pH-dependent bilayer destabilization by
an amphipathic peptide. Biochemistry, 26:2964-2972.
36 Olson, F., Hunt, C.A., Szoka, F.C., Vail, W.J., and Papahadjopoulos, D. (1979): Preparation of liposomes of defined size
distribution by extrusion through polycarbonate membranes. Biochim.Biophys.Acta, 557:9-23.
37 Bailey, A.L., Monck, M.A., and Cullis, P.R. (1997): pH-induced destabilization of lipid bilayers by a lipopeptide derived
from influenza hemagglutinin. Biochim.Biophys.Acta, 1324:232-244.
38 Steinhauer, D.A., Wharton, S.A., Skehel, J.J., and Wiley, D.C. (1995): Studies of the membrane fusion activities of fusion
peptide mutants of influenza virus hemagglutinin. J.Virol., 69:6643-6651.
39 Shangguan, T., Alford, D., and Bentz, J. (1996): Influenza-virus-liposome lipid mixing is leaky and largely insensitive to the
material properties of the target membrane. Biochemistry, 35:4956-4965.
40 Puyal, C., Maurin, L., Miquel, G., Bienvenue, A., and Philippot, J. (1994): Design of a short membrane-destabilizing peptide
covalently bound to liposomes. Biochim.Biophys.Acta, 1195:259-266.
41 Pecheur, E.I., Hoekstra, D., Sainte-Marie, J., Maurin, L., Bienvenue, A., and Philippot, J.R. (1997): 
Membrane anchorage brings about fusogenic properties in a short synthetic peptide. Biochemistry, 36:3773-3781.
42 Laczko, I., Hollosi, M., Vass, E., and Toth, G.K. (1998): Liposome-induced conformational changes of an epitopic peptide
and its palmitoylated derivative of influenza virus hemagglutinin. Biochem.Biophys.Res.Commun., 249:213-217.
16
7
ch
ap
te
r 
5

LIPID-COATED POLYPLEXES
FOR TARGETED GENE
DELIVERY TO OVARIAN
CARCINOMA CELLS 
6
SUMMARY
A non-viral gene delivery vector has been developed in our laboratory based on the cationic
polymer poly(2-(dimethylethylamino)ethylmethacrylate) (pDMAEMA). p(DMAEMA)-based
polyplexes have been successfully used for the transfection of OVCAR-3 cells in vitro. However,
these polyplexes were unable to transfect OVCAR-3 cells growing in the peritoneal cavity of
nude mice after i.p. administration, which could be ascribed to inactivation by components
(including hyaluronic acid) present in the tumor ascitic fluid.
The present work aimed at (1) protecting p(DMAEMA)-based polyplexes against destabilization
or inactivation by polyanions such as hyaluronic acid present in tumor ascitic fluid and (2) to
enhance cellular uptake of the protected p(DMAEMA)-based polyplexes by targeting with
antibody Fab’ fragments.To fulfill these requirements we have developed a detergent removal
method to coat polyplexes with anionic lipids.With this method spherical particles of ~125 nm
were obtained that were protected from destabilization by polyanions. More importantly, the
transfection efficiency of LPP was unaffected in the presence of hyaluronic acid (HyAc) indicating
that lipid coating of polyplexes protects against destabilization by HyAc. By conjugating antibody
Fab’-fragments directed against the epithelial glycoprotein-2 to the lipidic surface of these LPP,
target cell-specific transfection of OVCAR-3 cells could be obtained in vitro.
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INTRODUCTION
Ovarian cancer is one of the most common and fatal human gynecological malignancies. As
ovarian cancer remains confined to the peritoneal cavity throughout most of its clinical course,
this type of cancer is an attractive candidate for intraperitoneal cancer gene therapy [1,2]. Naked
DNA does not easily pass cell membranes.Therefore, a carrier is needed that can deliver genes
into cells.Viral vectors have been successfully utilized for the delivery of genetic material as they
contain all features necessary for efficient gene transfer (i.e. cell adhesion, membrane
translocation, efficient transcription and translation) [3,4]. However, despite efficient gene
transfer, viral vectors have some limitations, in particular their relatively small packaging capacity
of therapeutic DNA, safety concerns and immunogenicity [5,6]. In addition, the broad tropism of
viruses used for gene delivery prevents cell-specific gene delivery.These limitations of viral
vectors have led to the development and evaluation of alternative gene carriers based on
synthetic, non-viral components [5,7]. Most non-viral vectors to date are based on the
complexation of plasmid DNA with polycations by electrostatic interaction.The advantage of this
method is that relatively small and positively charged particles can be obtained that can be taken
up by cells. Moreover, complexation of DNA with polycations such as cationic peptides,
polymers (polyplexes) or lipids (lipoplexes) protects to a large extent the DNA from degradation
by nucleases.
In our laboratory a non-viral gene delivery vector has been developed based on the cationic
polymer poly(2-(dimethylethylamino)ethylmethacrylate) (pDMAEMA) that forms stable and
small (~100 nm) particles upon complexation with plasmid DNA [8-10].These cationic
polyplexes have been used successfully to introduce reporter genes into ovarian carcinoma
(OVCAR-3) cells cultured in vitro. The p(DMAEMA)-based polyplexes were subsequently used in
vivo for the transfection of OVCAR-3 cells growing in the peritoneal cavity of nude mice [11].
The results of the in vivo transfection experiments were disappointing: p(DMAEMA)-based
polyplexes showed negligible transfection of intraperitoneally localized OVCAR-3 cells after i.p.
administration. It has been reported that interaction of polymeric and liposomal gene delivery
systems with extracellular glycosaminoglycans has an inhibitory effect on gene transfer [12].
Indeed, with our polyplexes evidence was obtained that one or more components present in the
peritoneal ascitic fluid (among which hyaluronic acid) induced a detrimental effect on the in vivo
transfection capability of p(DMAEMA)-based polyplexes. Clearly, in order to obtain effective
gene transfer of ovarian carcinoma cells under in vivo conditions, polyplexes need to be protected
from the inactivating effects of tumor ascitic components.
In this study we aimed at protecting p(DMAEMA)-based polyplexes against inactivation induced
by components such as hyaluronic acid that are present in tumor ascitic fluid. In addition to
protection, we also aimed at enhancing the transfection efficiency of protected polyplexes by
conjugating targeting ligands to the transfection system to facilitate the uptake of protected
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polyplexes by ovarian carcinoma cells. For the protection of p(DMAEMA)-based polyplexes
against inactivation we have developed a detergent removal method to coat the cationic
polyplexes with anionic lipids.This method is based on the preferential formation of a lipid coat
around the positively charged polyplexes upon transition of phospholipids from mixed micellar to
lamellar state induced by slow removal of the detergent. Lipid coating of polyplexes should fulfill
several functions. First, the coating should shield the positive surface charge of polyplexes that
may cause aggregation of polyplexes upon exposure to the biological environment. Second, it
should protect the polyplexes from interaction with inactivating substances such as hyaluronic
acid.Third, as it is expected that shielding of positive surface charges prevents the aspecific
binding to cells [13], tumor-specific antibodies or antibody fragments can be conjugated to the
lipid coating to obtain specific cellular uptake. Here, we show that the intended protection and
targeting effects can be realized for p(DMAEMA)-based polyplexes using the proposed lipid
coating and antibody coupling procedures.
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MATERIALS AND METHODS
CHEMICALS
Egg phosphatidylglycerol (EPG) and egg phosphatidylcholine (EPC) were purchased from Avanti
Polar Lipids Inc. (Alabaster, AL, USA). Cholesterol (CHOL), n-Octyl β-D-glucopyranoside
(OG), o-nitrophenyl-β-D-galactopyranoside (ONPG), poly(aspartic acid) (p(Asp)), hyaluronic
acid, DNase (grade I) and sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-
6-nitro)benzene sulfonic acid hydrate (XTT) were obtained from Sigma (St. Louis, MA, USA). N-
[4-(p-maleimidophenyl)butyryl]phosphatidylethanol-amine (MPB-PE) was synthesized as
described before [14]. BioBeads SM-2 non-polar polystyrene adsorbents came from Bio-Rad
Laboratories (Hercules, CA, USA).The PicoGreen DNA detection kit was obtained from
Molecular Probes (Eugene, Oregon, USA). All other reagents were of analytical grade.
PLASMID DNA
The plasmid pCMVLacZ containing a bacterial LacZ gene preceded by a nuclear localization signal
under control of a CMV promoter was kindly donated by Dr. A. Bout (IntroGene, Rijswijk,The
Netherlands) [15].The plasmid was amplified in E. Coli (strain DH5α) and purified by column
chromatography using a purification method that fully removes endotoxins (Qiagen Endofree Kit,
Qiagen, Leusden,The Netherlands).The plasmid DNA was shown to be absent of RNA or
bacterial DNA as analyzed by gel electrophoresis and absent of endotoxins as determined by the
limulus amebocyte lysate (LAL) assay. Purity of the plasmid was determined by UV spectroscopy
giving a A260/A280 ratio of 1.84. Furthermore, gel electrophoresis and anion exchange
chromatography showed that the plasmid DNA was in the supercoiled and open circular form in
a ratio of about 1:1 [16].
CELL CULTURE
The human ovarian carcinoma cell line NIH:OVCAR-3 originated from the laboratory of Dr.
Hamilton (National Cancer Institute, Bethesda, MD, USA) [17]. OVCAR-3 cells were cultured in
DMEM containing 3.7 g/l sodium bicarbonate, 4.5 g/l L-glucose and supplemented with L-
glutamine (2 mM), HEPES (10 mM), 10% (v/v) FCS, penicillin (100 IU /ml), streptomycin
(100 µg/ml) and amphotericin B (0.25 µg/ml).
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POLYPLEX FORMATION AND CHARACTERIZATION
For condensation of the pCMVLacZ plasmid DNA the polymer poly(2-
dimethylamino)ethylmethacrylate (p(DMAEMA)) synthesized at our laboratory was used [8].The
weight average molecular weight (Mw) and number average molecular weight (Mn) of
p(DMAEMA) were determined by gel permeation chromatography (GPC).The used batch of
p(DMAEMA) had a Mw of 2.1x106 and a Mn of 4.1x104.
Stock solutions of p(DMAEMA) at a concentration of 37.5 µg/ml were prepared in HEPES-
buffer (5 mM HEPES, pH 7.0).Two and a half µg of pCMVLacZ plasmid DNA at a final
concentration of 10 µg/ml in HEPES-buffer (5 mM HEPES, pH 7.4) was condensed by adding
the p(DMAEMA) at a 3:1 (w/w) ratio to the DNA, followed by vigorously shaking for 5 seconds
on a vortex.This ratio was chosen as at this ratio small-sized particles were obtained without the
presence of free polymer [18]. After 30 minutes of maturation at room temperature, the formed
polyplexes were analyzed for size distribution by dynamic light scattering and ζ-potential as
previously described [8].The polyplexes had a mean diameter of approximately 80 nm with a ζ-
potential of +25-30 mV (in 5 mM HEPES; pH 7.0).
LIPID SOLUBILIZATION WITH OG: TURBIDITY ASSAY
Lipid films (3 µmol of total lipid) of different compositions were prepared from lipid stocks in a
mixture of chloroform/methanol (2:1) by solvent evaporation under low pressure using a
rotavapor device. A series of lipid films were hydrated in 1 ml of HEPES-buffer (5 mM HEPES,
pH 7.0) at increasing concentrations of OG (0-30 mM) for 30 min at room temperature under
gentle agitation. Hereafter, the turbidity of all solutions was measured (OD400)
spectrophotometrically. As liposomes have a much higher turbidity than mixed micelles [19],
turbidity determination can be used to assess the minimum OG concentration required to
achieve complete lipid solubilization into mixed micelles.The stability of polyplexes in the
presence of OG detergent at a concentration just high enough to completely solubilize the lipids
was evaluated by monitoring the change in particle size in time with dynamic light scattering.The
size of polyplexes was measured every 15 min for 2 hrs. Polyplexes were considered to be stable
if particle size did not increase with more than 10% after 2 hrs incubation in the presence of
detergent.
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PREPARATION OF LIPOPOLYPLEXES (LPP)
AND IMMUNO-LIPOPOLYPLEXES (ILPP) 
Lipid films containing 3 µmol of total lipid (EPC:EPG:CHOL molar ratio 2:2:1, unless
mentioned otherwise) were formed from lipid stocks in a mixture of chloroform/methanol (2:1)
by solvent evaporation under low pressure using a rotavapor device.The lipid films were further
dried under a stream of nitrogen for one h. Lipid films were solubilized by adding 1 ml of 18
mM OG in HEPES-buffer (5 mM HEPES, pH 7.0). Subsequently, p(DMAEMA)-based polyplexes
prepared as described above were added to the solubilized lipid films in an amount corresponding
with 2.5 µg of plasmid DNA.Twenty five mg of BioBeads were added and the polyplex/lipid
micelle mixtures were shaken for 1 h at 1400 rpm using a IKA MTS2 shaker. Hereafter, 200 mg
of BioBeads were added and again the samples were shaken for 1 h, then samples were separated
from the BioBeads and final traces of detergent were removed by overnight dialyisis at 4ºC
against 1 l of HEPES-buffered salt solution (HBS; 5 mM HEPES, 150 mM NaCl, pH 7.4).
For coupling antibody Fab’-fragments to the lipid surface of LPP, 2.5 mol% (of total lipid) of N-
[4-(p-maleimidophenyl)butyryl] phosphatidylethanolamine (MPB-PE) was added to the lipids
before solvent evaporation. MPB-PE is an anchor molecule commonly used to couple antibodies
or enzymes to liposomes and is thiol reactive [14,20].Three mg of (Fab)2 fragments of mAb
323/A3 were reduced with 20 mM DTT in a total volume of 1 ml of 100 mM NaCl, 35 mM
sodium phosphate, 20 mM citric acid, and 1 mM EDTA, pH 5.5 for 90 min at room temperature
under nitrogen atmosphere. Reduced Fab’ fragments containing free thiol groups were separated
from DTT by column chromatography using a PD-10 column (Pharmacia Biotech, Uppsala,
Sweden) equilibrated with deoxigenated PIPES-buffer (20 mM PIPES, 140 mM NaCl, pH 6.5)
and added to freshly prepared LPP containing the MPB-PE functionalized phospholipid in a Slide-
A-Lyzer dialysis slide (MWCO 10,000; Pierce, Rockford, IL, USA).The coupling reaction was
proceeded overnight at 4ºC while dialysis against 0.8 liter of Pipes-buffer (20 mM PIPES, 140 mM
NaCl, pH 6.5) was continued.The formed immunolipopolyplex particles (ILPP particles) were
separated from unconjugated Fab’-fragments by ultracentrifugation (40 min at 60,000 rpm).
LPP and ILPP were characterized for phospholipid and protein amount, size distribution and
surface charge. Phospholipid amount was determined by the colorimetric method of Fiske and
Subbarow [21].The contribution of DNA to the total phosphate amount of LPP particles was
negligible as determined with phosphate determination after phospholipid extraction according
to Bligh and Dyer [22].The amount of conjugated Fab’ on the surface of the ILPP was determined
with the Bio-Rad DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA) with mouse
IgG as standard (obtained from Sigma). Size distribution and surface charge properties of LPP and
ILPP were determined by DLS and ζ-potential measurements, respectively.
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ELECTRON MICROSCOPY 
Polyplexes and LPP were adsorbed to glow-discharged carbon-stabilized formvar-coated grids,
negatively stained using 2.0% potassium phosphotungstate (pH 5,2) and analyzed in a Philips
TEM 400 electron microscope at an operating voltage of 80 kV. Images were digitally stored and
analyzed using analySIS (Soft-imaging software, Germany). Images were printed after grey value
modification.
NUCLEASE RESISTANCE ASSAY
Freshly prepared LPP and a mixture of polyplexes and empty anionic liposomes were exposed to
a large excess of p(Asp) (1 mg/ml final concentration in HEPES buffer pH 7.0) to liberate DNA
from polyplexes [9,23]. Subsequently, 1/10 volume of 10x DNase I reaction buffer (1 M sodium
acetate, 50 mM MgCl2) and 4U of DNase I were added and samples were incubated for 3 hrs at
37ºC. Hereafter, DNase I was inactivated by adding EDTA (40 mM final concentration) and lipid
vesicles (LPP or empty liposomes) were disrupted by the addition of OG (50 mM final
concentration). An additional amount of p(Asp) was added before analyzing the samples by gel
electrophoresis on a 0.7% agarose gel containing 0.5 µg/ml ethidium bromide, in TAE buffer
(pH 7.4).
QUANTITATIVE DETERMINATION OF PLASMID DNA IN LPP 
Poly(aspartic acid) (p(Asp)) is able to dissociate polyplexes but not LPP as they possess a
protective lipid coat.This feature of p(Asp) is utilized to determine indirectly the amount of
DNA present in LPP.The LPP dispersion was incubated for 3.5 hrs at 40ºC either with p(Asp) (1
mg/ml) to liberate the DNA from polyplexes present in the LPP dispersion or with p(Asp) (1
mg/ml) and 1% (v/v) Triton X-100 to liberate DNA from LPP.Triton X-100 disrupts the lipid
coat of LPP allowing p(Asp) to liberate the DNA from polyplexes inside LPP.The amount of
liberated DNA was quantified with the PicoGreen dsDNA detection kit (Molecular Probes,
Eugene, USA) according to the manufacturer’s protocol. PicoGreen fluorescence was measured
with a LS50B fluorometer (Perkin Elmer), set at an excitation wavelength of 480 nm and an
emission wavelength of 520 nm. By subtracting the amount of non-LPP associated DNA
determined by incubation with p(Asp) from the total amount of DNA determined by incubation
with p(Asp) and Triton X-100 the amount of DNA inside LPP could be derived.
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TRANSFECTION STUDIES
Cells were plated in 96-wells plates at 1.1x104 cells/well and cultured for 24 h prior to
transfection, by which time the adherent cells were ~60-80% confluent. Cells were overlaid with
100 µl of prewarmed culture medium containing 10% FCS before the addition of polyplexes,
LPP or ILPP particles (corresponding to 1 µg of DNA) in triplicates. From here, three different
methods were followed:The ‘short-term exposure’ method cells were exposed to the DNA-
particles for 1 h at 37ºC after which the transfection medium containing the DNA-particles was
replaced by fresh culture medium containing 10% FCS and incubation was continued for another
47 hrs. In the ‘prolonged exposure’ method DNA-particles were not removed from the cells but
cells remained exposed for the total 48 h incubation time.The third method is the same as the
‘short-term exposure’ method with the difference that hyaluronic acid (2.5 mg/ml) is
additionally present in the wells during DNA-particle exposure.This concentration is sufficient
to block the transfection capability of p(DMAEMA)-based polyplexes [11]. Cells were evaluated
for β-galactosidase expression and viability using a slightly modified ONPG-assay and the XTT-
assay, essentially as described before [9].
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RESULTS
SIZE STABILITY OF P(DMAEMA)-BASED POLYPLEXES
IN THE PRESENCE OF DETERGENT 
In this study a procedure was developed to coat small-sized, cationic polyplexes with lipids using
a detergent removal method (Figure 1). Initially, lipid-coated polyplexes (further referred to as
lipopolyplexes (LPP)) were formed by adding p(DMAEMA)-based polyplexes (3:1 w/w ratio of
polymer:DNA) to 3 µmol of lipids solubilized in 150 mM octyl glucoside (OG) and subsequent
slow removal of the detergent by adsorption to hydrophobic polystyrene BioBeads.The used OG
concentration is far above the critical micelle concentration (14.5 mM according to
manufacturer) and it turned out that this high concentration of detergent had a negative influence
on the stability of the formed polyplexes as a substantial increase in size of polyplexes occurred
in time (results not shown).Therefore, in an attempt to avoid this problem, the minimal
concentration of OG necessary to completely solubilize the lipids was determined and size
stability of polyplexes at this concentration was monitored.
Lipid films (3 µmol of total lipid) of different compositions were prepared: EPG:EPC:CHOL at
 
 
 
Cationic polymer
p(DMAEMA)
Figure 1 — Schematic representation of lipopolyplex formation. (1) Plasmid DNA is condensed by adding the cationic
polymer p(DMAEMA) to the DNA at a weight/weight ratio of 3:1, respectively. The formed polyplexes (2) are added to mixed
micelles containing the detergent OG and a total amount of 3 µmol detergent-solubilized lipids (3). Upon slow removal of
detergent by adsorption to hydrophobic BioBeads, lipid coats are preferentially formed around positively charged polyplexes
due to electrostatic interactions (4).
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the molar ratios of 2:2:1 (40% EPG), 1:7:2 (10% EPG) and 0:4:1 (0% EPG). For each
composition lipids were hydrated at increasing concentrations of OG. Figure 2 shows that the
amount of PG included in the lipid film influences the solubilization capacity of OG for the lipids.
At decreasing amounts of PG in the lipid film, increasing concentrations of OG are needed in
order to totally solubilize the lipids into mixed micelles.Table 1 shows that, at the different
amounts of PG tested, polyplexes do not change in size within the OG concentration range of 18-
32 mM (stable for at least 2 hrs).Thus, low OG concentrations can be used to solubilize anionic
lipid compositions into mixed micelles with preservation of the size stability of the polyplexes.
Figure 2 — Assessment of the minimal amount of OG necessary for complete lipid solubilization. Lipid films containing 3
µmol TL were hydrated with OG in the concentration range of 0-30 mM in HEPES, pH 7.0. After 30 min incubation at room
temperature the turbidity of samples was spectrophotometrically determined at 400 nm. , EPC:CHOL (2:1) lipids ; 
S, EPC:EPG:CHOL (6:1:3) lipids; T, EPC:EPG:CHOL (2:2:1) lipids.
Table 1 — Size stability of polyplexes at OG concentrations necessary for lipid solubilization.
Amount of lipid (µmol)
0
3
3
3
% of PG in lipid coat
—
0
10
40
[0G] (for total solubilization
into mixed micelles (mM))
—
32
22.5
18
Size of polyplexes in nm
(after 2 hrs at required OG
concentration)
91±0.4
101±1.2
104±0.8
113±1.6
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EFFECT OF LIPID/POLYPLEX RATIO ON THE SIZE OF LPP
The influence of the total amount of lipid on the size of formed LPP was determined. LPP were
prepared at a fixed polyplex concentration (corresponding to 2 µg/ml of DNA and 6 µg/ml
p(DMAEMA)) and increasing concentrations of OG-solubilized lipids (0-4 µmol/ml of TL;
PC:PG:CHOL molar ratio 2:2:1). After slow removal of the detergent by adsorption to BioBeads
and exhaustive dialysis against HBS, the mean size of the LPP was determined (Figure 3). It can
be seen that the apparent mean size of LPP varied with the lipid/polyplex ratio. At lipid amounts
> 1 µmol TL, small LPP were obtained with an average size of ~100-200 nm. LPP prepared at
lipid amounts < 1 µmol TL showed larger particle sizes. In the experiments described below,
LPP prepared at 3 µmol of lipids were used.
Figure 3 — Effect of lipid/polyplex ratio on the size of LPP. LPP were prepared at a fixed amount of polyplexes
(corresponding to 2.5 µg DNA) with increasing amounts of lipids. Mean size was determined by dynamic light scattering. 
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CHARACTERIZATION OF LPP
LPP prepared with the detergent removal method were characterized for mean particle size, ζ-
potential, and morphology. At 3 µmol TL, the formed LPP had an average size of 125 nm and a
ζ-potential between –50 and –60 mV. Both parameters did not change during storage at 4ºC for
at least 2 weeks.The morphology of LPP was compared with that of polyplexes by negative-stain
electron microscopy. As shown in Figure 4A, polyplexes are small, spherical particles with an
average diameter of 80 ± 9 nm. Most of these particles are roundish of shape. Due to the
negative staining technique, they show a mark halo of stain and appear as moderately electron
dense as they attract much of the negative stain onto their positive charged surface. In contrast,
LPP appear as electron light particles in a background of stain. Due to their negative surface
charge there is a general failure of PTA to penetrate into these particles resulting in the presence
of a white halo (Figure 4B). Besides small particles with a size variable from 50 to 70 nm (most
likely empty liposomes) also larger (100-150 nm) polymorphic structures can be observed,
which consist of condensed structures surrounded by a lipid coat (LPP; marked with arrows in
Figure 4B).The presence of these polymorph structures probably accounts for the large size
distribution range of LPP as indicated by the polydispersity index of 0.3-0.4.
Figure 4 — Electron microscopic images of negatively stained polyplexes and LPP. Polyplexes (A) are seen as roundish
spherical structures with a mark halo of stain and LPP (B) are seen as electron light particles within a stained
background.These differences in staining characteristics reflect the differences in surface electrostatic forces of these particles.
The arrows point at polyplexes surrounded by a phospholipid bilayer. Indicated bar represents 100 nm.
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LPP ARE PROTECTED AGAINST POLYANION DESTABILIZATION
Previous work from our group has demonstrated that p(DMAEMA)-based polyplexes are
destabilized when exposed to p(Asp), which liberates the DNA from the polyplexes and making it
susceptible to DNase I induced degradation [9]. Here, we investigated whether polyplexes present
in LPP are protected against destabilization with p(Asp). LPP and polyplexes admixed with empty
anionic liposomes were incubated with DNase I in the presence of a large excess of p(Asp). Before
and after the addition of DNase I samples were analyzed by gel electrophoresis for the presence of
non-degraded plasmid DNA (Figure 5). It is demonstrated that there is no difference in DNA
staining intensity between LPP before (lane 2) and after (lane 1) treatment with DNase I, indicating
that a large amount (if not all) of the polyplexes within LPP is protected from destabilization with
p(Asp). In contrast, polyplexes that were admixed with empty preformed liposomes with the same
lipid composition as in the LPP coat appeared very sensitive to destabilization with p(Asp), as
DNase I completely degraded complexed DNA (lanes 3 and 4).These results indicate that coating
of polyplexes with lipids protects the polyplexes from destabilization by p(Asp).
Figure 5 — Nuclease resistance assay of DNA in polyplexes and in LPP in the presence of p(Asp). LPP (lanes 1 and 2) and
polyplexes admixed with empty liposomes (lanes 3 and 4) were incubated with DNase I in the presence (lanes 1 and 3) or
absence (lanes 2 and 4) of p(Asp) (1 mg/ml) for 30 min at 37°C and subsequently analysed by gel electrophoresis to visualize
the presence of intact plasmid DNA. Image colors have been inverted for clarity.
QUANTITATIVE DETERMINATION OF DNA IN LPP
To quantify the efficiency of the lipid coating procedure, the amount of polyplexes effectively
coated with lipids (LPP) was determined with an assay which is based on the observation that
polyplexes in LPP are protected from dissociation in the presence of a large excess of p(Asp).
Figure 6 shows that the degree of protection conferred by the lipid coating is positively
correlated with the amount of negatively charged PG used for the coating. Complete protection
of polyplexes was obtained when the lipid coat of LPP contained 40 mol% PG, 70% protection
was obtained when the coat contained 10 mol% PG and 50% protection when the coat lacked
negatively charged PG.These results suggest that electrostatic interactions between the cationic
polyplexes and negatively charged phospholipids promote the coating of polyplexes with lipids
occurring during the slow removal of detergent from the detergent-solubilized lipids.
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Figure 6 — Effect of anionic lipids on the efficiency of lipid coating in protecting cationic polyplexes. The coating efficiency of
polyplexes with lipid compositions containing different amounts of PG (0,10 and 40%) was determined by comparing the total
amount of DNA present in the sample and the amount of DNA inside polyplexes not protected against destabilization with
p(Asp) (=outside LPP). The amount of DNA was determined with the Picogreen dsDNA detection assay (see materials &
methods section).
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CONJUGATION OF FAB’-FRAGMENTS TO LPP (ILPP)
As our aim is to target genes to ovarian carcinoma cells, we have conjugated Fab’-fragments of
mAb 323/A3 to the surface of LPP.This mAb binds specifically to the epithelial glycoprotein-2
(EGP-2, EPCAM), which is expressed at high levels on the surface of OVCAR-3 cells [24,25].
After conjugation, the amount of Fab’-molecules coupled to the surface of LPP was determined.
These antibody-targeted LPP (further referred to as immunolipopolyplexes, ILPP) contained an
average of 20-30 conjugated Fab’-molecules per vesicle.
COMPARATIVE TRANSFECTION CAPABILITY OF POLYPLEXES, 
LPP AND ILPP 
The capability of polyplexes, LPP and ILPP (both LPP and ILPP both contained 40mol % PG) to
transfect cultured OVCAR-3 cells was investigated under three different transfection conditions.
Cells were exposed to the DNA formulations for (1) 1h, (2) 48 h and (3) 1 h in the presence of
hyaluronic acid (2.5 mg/ml). Hyaluronic acid was used as this component has been shown to
have an adverse effect on the transfection capability of plain polyplexes [11]. However, it is
Figure 7 — Transfection of OVCAR-3 cells (EGP-2 +) and COS-7 cells (EGP-2 -) after short term (1h) exposure to
polyplexes, LPP or ILPP. Cells (1.1x104 cells/well) were exposed for 1 h at 37°C to either polyplexes, LPP or ILPP (at 1 µg of
plasmid DNA). Gene carriers were removed by washing and cell culture was continued for another 47 h prior to evaluation of
β-galactosidase expression.
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hypothesized that hyaluronic acid will not adversely affect the transfection capability of LPP and
ILPP due to the protective lipid layer.
Figure 7 shows the transfection results obtained when cells were exposed for 1 h to the different
DNA formulations. It is clear that both negatively charged LPP and ILPP are much less efficient
in transfecting OVCAR-3 cells compared to positively charged polyplexes under the tested
conditions. Nevertheless, the antibody-targeted ILPP are 10-fold more efficient than LPP in
transfecting OVCAR-3 cells. In addition, the efficiency of ILPP to transfect COS-7 cells (lacking
EGP-2 expression) is not enhanced compared to non-targeted LPP indicating that antibody-
mediated targeting to OVCAR-3 cells can be achieved. No cytotoxicity was observed with all
DNA formulations used (polyplexes, LPP and ILPP) in the short-term exposure setting (results
not shown).
Figure 8 shows the results of transfection of OVCAR-3 cells after long-term exposure (=48 hrs)
Figure 8 — Transfection and cell viability of OVCAR-3 cells after long term exposure (48h) to polyplexes, LPP or ILPP.
OVCAR-3 cells (1.1x104 cells/well) were exposed for 48 hrs at 37°C to either polyplexes, LPP or ILPP (at 1 µg of plasmid
DNA), and subsequently evaluated for β-galactosidase expression and cell viability using the ONPG and XTT assay,
respectively.
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to polyplexes, LPP or ILPP. It can be seen that long-term exposure of cells to the polyplexes was
detrimental for the transfection efficiency of this transfection system (compare with effect in
Figure. 7).The reason for this negative effect lies in increased cytotoxicity: the cell viability was
only about 5%. Cytotoxicity was not observed when cells are exposed for 48 hrs to LPP and
ILPP. In this long-term exposure setting, the transfection efficiency of ILPP was about 2.5 times
higher than that of plain polyplexes. LPP hardly gave any transfection in contrast to the ILPP,
indicating that antibody-mediated binding of the LPP to OVCAR-3 cells is critical for achieving
transfection of OVCAR-3 cells.
As we have shown that coating of polyplexes with lipids protects the polyplexes from polyanion-
induced destabilization, we have compared transfection results obtained with polyplexes and ILPP
in the absence and presence of the polyanion hyaluronic acid, which is abundantly present in
tumor ascitic fluid (Figure 9).Whereas the transfection efficiency of polyplexes is drastically
reduced in the presence of hyaluronic acid (Figure 9A), this reduction is not observed with ILPP
(Figure 9B), indicating that hyaluronic acid does not negatively affect the transfection efficiency
of ILPP.
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Figure 9 — Influence of hyaluronic acid on the transfection efficiency of polyplexes vs ILPP. OVCAR-3 cells (1.1x104
cells/well) were exposed for 1 h at 37°C to (A) polyplexes or (B) ILPP in the absence (-HyAc) or presence (+HyAc) of 2.5
mg/ml hyaluronic acid. Gene carriers were removed by washing and cell culture was continued for another 47 hrs prior to
evaluation for β-galactosidase expression. 
DISCUSSION
Local delivery of therapeutic genes into ovarian carcinoma cells is an attractive strategy for the
treatment of ovarian carcinoma [1]. As naked DNA is very unstable in the biological
environment, is poorly taken up by target cells and lacks cell specificity, a gene delivery carrier is
needed to fulfill the requirements of stability and cellular uptake. For this purpose, the cationic
polymer p(DMAEMA) has been developed in our laboratory. p(DMAEMA) can condense large-
sized DNA into small and stable complexes of approximately 100 nm in size and which are
protected from DNA degradation by DNase in vitro [8,9]. Despite encouraging transfection
results obtained with p(DMAEMA)-based polyplexes in vitro, in vivo transfection of ovarian
carcinoma cells growing in the peritoneal cavity of nude mice is negligible [11]. Evidence exists
that one of the components of the peritoneal ascitic fluid, hyaluronic acid, induced a detrimental
effect on the in vivo transfection capability of p(DMAEMA)-based polyplexes.
To address the problem of low in vivo transfection activity of p(DMAEMA)-based polyplexes we
present here a method of coating the p(DMAEMA)-based cationic polyplexes with anionic lipids
and show that the anionic lipid coating confers protection against destabilization of polyplexes by
polyanionic molecules such as p(Asp) and hyaluronic acid. However, the LPP lack significant
transfection capability likely due to the loss of cationic charge-mediated electrostatic interaction
with the cells.This problem can be overcome by coupling specific antibody fragments to the LPP
surface thus restoring cellular uptake and transfection. Both aspects, i.e. protection and targeting,
will be discussed below.
The first requirement to meet was to create protection against polyanion-induced destabilization
or inactivation. Previous transfection studies with plain p(DMAEMA)-based polyplexes have
shown that hyaluronic acid, which is present at high levels in tumor ascitic fluid, has a dose-
dependent negative effect on the transfection efficiency of plain polyplexes (see Figure 9A and
van de Wetering et al.[11]).With the detergent removal method used in this study it is possible to
coat polyplexes with lipids with efficiencies of up to 100% as reflected by complete protection
against polyanion-induced destabilization. Moreover, this method yields stable particles with a
small mean size (~120 nm) and a net negative surface charge.The degree of protection conferred
by the lipid coating is positively correlated with the amount of negatively charged lipids present
in the coat, which indicates that electrostatic interactions promote the lipid coating process.
Similarly, Lee et al. [26,27] took advantage of electrostatic interactions for coating polylysine-
condensed DNA complexes with pre-formed anionic liposomes. Although analysis by negative
stain electron microscopy revealed anionic lipid-coated particles, it was not shown whether the
lipid coat really caused protection of the condensed DNA against degradation or destabilization.
Here, we show that LPP prepared with the detergent removal method are protected from
destabilization by polyanions such as p(Asp) and hyaluronic acid. In addition, the transfection
efficiency of ILPP is not negatively influenced by the presence of high concentrations of
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hyaluronic acid, in contrast to the transfection efficiency of plain, unprotected polyplexes (Figure
9).
Unfortunately, besides the positive effect of conferring protection, the presence of a negatively
charged lipid coat around LPP has a negative impact on cellular uptake of LPP. Cationic
polyplexes are thought to electrostatically interact with cell membranes thereby triggering
cellular uptake mechanisms [13].The observed lack of transfection capability and cytotoxicity of
LPP is most likely due to absence of cellular association. Indeed, this is confirmed by our
observation that targeting of LPP, which promotes specific cellular uptake of LPP is a
prerequisite to obtain transfection of ovarian carcinoma cells.Targeting of LPP to ovarian
carcinoma cells (OVCAR-3) was realized by coupling Fab’-fragments of mAb 323/A3 (anti-EGP-
2) to the surface of LPP (ILPP). However, despite the targeting effect the transfection efficiency
of ILPP is 20-fold lower than obtained with plain polyplexes in case of ‘short term’ exposure 
(1 h) of cells to the gene carriers.This may well be explained by the quantitative difference in
degree of cellular uptake between polyplexes and ILPP.The mechanism of nonspecific cellular
uptake of plain polyplexes may be much more efficient than the mechanism of specific cellular
uptake of ILPP (antibody-mediated binding and internalization), the latter being dependent on
antigen-density and kinetics of internalization of the target surface antigen EGP-2.The EGP-2
surface receptor is slowly internalized (50% after 48 hrs) [28].
However, it should be realized that the 1 h exposure period does by far not reflect the in vivo
conditions in which peritoneal tumor cells are expected to be exposed to i.p.-injected ILPP for
much longer periods of time. For this reason we have compared the transfection levels of ovarian
carcinoma cells after 48 h exposure to either plain polyplexes, LPP or ILPP. Under these ‘long-
term exposure’ conditions the transfection efficiency of the antibody-targeted ILPP, which were
20 times less efficient in transfection ovarian cancer cells under ‘short term exposure’ are now
2.5-fold more efficient in transfecting ovarian carcinoma cells compared to plain polyplexes.
Moreover, even under ‘long-term exposure’ conditions non-targeted LPP does not show any
transfection, which illustrates the necessity of achieving target receptor-mediated internalization.
Apparently, the presence of the targeting ligand mediates cellular binding and uptake of the
coated particles and compensates for the loss of electrostatic interaction with the cell membrane
caused by the introduction of the lipid coating on the polyplex surface. It is noteworthy that 
— in sharp contrast with the plain polyplexes — ILPP did not induce any cytotoxicity to the
cells (Figure 8).These findings indicate that antibody-targeted ILPP are better suited for
intraperitoneal transfection of ovarian carcinoma cells than plain polyplexes.
In conclusion, the ILPP system introduced in this study features colloidal stability and
transfection capability under conditions mimicking the in vivo situation and therefore shows
promise for use in plasmid-based approaches to gene therapy of ovarian cancer. At present, the
ILPP system is being investigated in our laboratory for its efficiency to deliver genes to ovarian
carcinoma cells for the purpose of gene-dependent enzyme prodrug therapy [29].
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SUMMARIZING DISCUSSION
Advances in molecular and cellular biology have led to the development of a new class of
biotherapeutic macromolecules (i.e. proteins, (poly)peptides and nucleic acids) that can be
designed de novo to modulate functions of target cells. As many of these new biotherapeutics
have intrinsically unfavorable properties for accessing targets within the cytoplasm or nucleus,
achieving their full potential ultimately requires drug carriers that can efficiently deliver these
agents across cellular membrane barriers into the cytosol of target cells.
This thesis describes the optimization of immunoliposomes (IL) for cytosolic delivery of
biotherapeutic macromolecules to tumor cells, in particular ovarian carcinoma cells, via the
route of receptor-mediated endocytosis.Two important requirements to be met for efficient
cytosolic delivery via this route that are investigated in this thesis are (1) specific interaction with
target cells leading to receptor-mediated uptake of the immunoliposomes and (2) release of IL-
entrapped drug into the cytosol of target cells by endosomal membrane destabilization. Although
there are several critical steps involved in the transport of immunoliposomes from the site of
injection to the target site (see chapter 1), this thesis primarily focuses on the delivery of the
macromolecular drug into the cytosol of target cells after immunoliposomes have reached their
target cells.
RECEPTOR-MEDIATED ENDOCYTOSIS OF IMMUNOLIPOSOMES
As reviewed in chapter 1, a variety of receptor-specific monoclonal antibodies have been
conjugated to the surface of liposomes to achieve site-specific delivery. Dependent on the type of
target receptor and size of the IL particles, receptor binding can result in internalization of the
receptor/IL complexes by receptor-mediated endocytosis. Although numerous receptors with
internalizing capacity have been identified, the liposome-internalizing capacity of most of the
tumor-associated receptors used for tumor cell-directed IL targeting is unknown.Therefore, in
pursuing cytosolic drug delivery with IL via the route of receptor-mediated endocytosis, target
receptors need to be identified that enable not only selective binding to tumor cells but also
sufficient internalization of the cell surface-bound IL. In Chapter 2 and the Appendix to
Chapter 2 we have explored three target receptors expressed on OVCAR-3 cells that may be
used to deliver IL into the endocytic pathway.These receptors are the intercellular adhesion
molecule-1 (ICAM-1), the epithelial glycoprotein-2 (EGP-2) and the epidermal growth factor
receptor (EGFR).
It is well established that the expression of ICAM-1 is up-regulated on endothelial and epithelial
cells at sites of inflammation.Thus, targeting liposomes to ICAM-1 may have potential for
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specific drug delivery to sites of inflammation. In previous work from our group it was
demonstrated that liposomes could be specifically targeted to cells expressing ICAM-1 by
conjugating the monoclonal antibody F10.2 to their surface.These F10.2-IL were shown to
strongly bind to different cell types expressing ICAM-1 on their surface and binding was
positively correlated with the expression level of ICAM-1 [1]. In Chapter 2 of this thesis it was
demonstrated that F10.2-IL were efficiently internalized by bronchial epithelial cells. Sixty
percent of cell-bound IL were internalized within 1 h of incubation at 37ºC. As ICAM-1
expression is up-regulated at sites of inflammation, selective drug delivery with ICAM-1-directed
IL to sites of inflammation has been proposed. ICAM-1 not only plays a role in localization of
immune cells into inflamed tissue but is also involved in the pathogenesis and metastatic spread of
many types of tumor cells [2-6]. For this reason we have also investigated the possibility to target
F10.2-IL to ovarian carcinoma cells (OVCAR-3) (Appendix to Chapter 2). Flow cytometry
analysis confirmed the presence of ICAM-1 on the surface of OVCAR-3 cells. Unfortunately,
binding of F10.2-IL to OVCAR-3 cells was not observed. As the flow cytometry analysis of
ICAM-1 expression on OVCAR-3 cells was performed with the same mAb as used for IL
targeting, lack of IL binding is likely related to loss of binding capacity of the F10.2 mAb during
the chemical modification step necessary to conjugate the mAb to the surface of liposomes.
An important aspect in selecting a suitable target receptor for tumor targeting is not only tumor-
selective expression but also accessibility for the targeted drug carriers. EGP-2, also referred to
as epithelial cell adhesion molecule (Ep-CAM), mediates Ca2+-independent homotypic cell-cell
adhesions and has been found to be expressed on the basolateral cell membrane of normal
epithelial cells and a variety of adenomas and adenocarcinomas [7-10]. Similarly, we observed in
vitro that 323/A3-IL targeted to EGP-2 on OVCAR-3 cells efficiently bound to these cells when
cells were in suspension but when grown as a monolayer adhered to plastic culture flasks binding
of the IL was restricted to the edges of the monolayer (Appendix to Chapter 2). Clearly,
under these in vitro growing conditions the accessibility of EGP-2 for IL binding is poor.
Consequently, the accessibility of target receptors should be taken into consideration when
targeted drug delivery systems are tested in vitro and in vivo. Besides poor accessibility, the rate of
IL internalization bound to EGP-2 on OVCAR-3 cells is slow: only 15% of cell surface-bound
323/A3-IL were internalized by OVCAR-3 cells grown in suspension after 2 hrs incubation.
The third receptor expressed on OVCAR-3 cells which has been tested for IL internalization is
the EGFR.The EGFR is a receptor tyrosine kinase that is over-expressed in a wide variety of
solid human cancers, including non-small cell lung, breast, head and neck, bladder and ovarium
carcinomas [11-13]. For this reason the EGFR and other members of the EGFR-family have often
been used as targets for site-specific drug delivery [11,12,14-16]. As demonstrated in the
Appendix to Chapter 2, the EGFR appears to be a suitable candidate to achieve IL
internalization.The EGFR is readily accessible for IL binding both on OVCAR-3 cells grown in
suspension and grown as a monolayer. In addition, 425-IL binding to OVCAR-3 cells resulted in
approximately 40% internalization of surface-bound IL within 2 hrs. Based on the in vitro results
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on IL targeting to OVCAR-3 cells we can conclude that, under the conditions tested, the EGFR
is the most suitable receptor to deliver immunoliposomes into the endocytic pathway of
OVCAR-3 cells.
Clearly, the choice of the target receptor able to shuttle drug-laden IL into the endocytic pathway
of tumor cells is critically important.The target receptor has to meet several requirements. First,
its expression level on the surface of target cells must be high enough to allow binding of a
sufficient amount of drug-laden IL. Second, the target receptors must be accessible for the IL.
Third, the target receptor should be tumor specific or at least overexpressed on malignant cells
in order to obtain tumor-selectivity. Finally, the target receptor should mediate internalization of
receptor-bound liposomes. As screening of existing mAb that specifically bind to receptors for
aforementioned requirements is time-consuming and laborious, the availability of a selection
system that allows rapid selection of antibodies recognizing tumor cell-selective internalizing
cell-surface receptors is highly needed. Recently, it was demonstrated that scFv molecules
displayed on bacteriophage particles could be selected for both tumor cell-specific binding and
internalization properties by selecting and enriching internalized phagemids [17,18].This system
may prove useful in rapidly selecting antibody molecules that can deliver large drug carriers like
liposomes into the endocytic pathway of tumor cells as a first step in cytosolic drug delivery.
ENDOSOMAL ESCAPE BY LOW PH-INDUCED MEMBRANE FUSION
As immunoliposomes with the entrapped biotherapeutic macromolecules are liable to
degradation inside lysosomes after receptor-mediated endocytosis, enormous gains in therapeutic
efficacy can be anticipated when this degradative pathway is circumvented. Hence, we have
exploited the low pH-induced fusion mechanism of the human influenza virus in two different
ways. In the first approach reconstituted envelopes of influenza virus particles (virosomes) were
used as basis to construct a targeted fusogenic liposome by conjugating antibody fragments via a
PEG-spacer to their surface. In the second approach, synthetic fusion peptides that resemble the
influenza virus HA2 N-terminal fusion domain were encapsulated in IL to induce membrane
destabilization or membrane fusion upon release from IL exposed to the acidic environment
within the endosomes.
The use of influenza virosomes (i.e. reconstituted envelopes of the influenza virus containing the
viral fusion protein HA) guarantees efficient membrane fusion similar to the native virus, which
by no means can be equaled with synthetic fusion peptides. However, as HA also contains the
sialic acid binding pocket, the use of unmodified virosomes will result in undesired binding to the
ubiquitous sialic acid residues present on glycoproteins and glycolipids on the surface of many
cell types.To circumvent HA-mediated sialic acid binding without losing fusogenic activity, we
have coupled PEG molecules to the surface of influenza virosomes, which, at high
concentrations, were able to prevent binding to sialic acid residues on cells (Chapter 3). In
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addition to a ‘steric shielding effect’ provided by the PEG chains, the PEG chains served as a
spacer to which antibody molecules were conjugated. In this way, influenza virosomes could be
re-directed towards EGP-2 expressed on the surface of OVCAR-3 cells with preservation of
fusogenic activity.This chapter represents the first report on successful antibody-mediated
virosome targeting and may be used for target-cell specific delivery of drugs or antigens.
A major impediment to the use of influenza virosomes as drug carrier is that the presence of viral
HA will induce immunogenic reactions, which will adversely affect the in vivo targeting capacity
of these carriers upon repeated injection [19,20]. One option to circumvent the problem of
immunogenicity may be the use of different strains of influenza virus for preparing the virosomes
for separate injections. Alternatively, the presence of high amounts of PEG-molecules on the
surface of virosomes may effectively prevent immune recognition by a sterical shielding effect as
was recently demonstrated for PEGylated adenoviruses [21,22].
Although not the focus of this thesis, antibody-targeted influenza virosomes may be of great value
in tumor vaccination protocols. In the case of vaccination, the immunogenicity of HA is highly
useful for raising an immune response against the antigenic peptides of interest incorporated in
the virosomal carriers. Due to their fusogenic capacity, influenza virosomes are able to introduce
antigen into the MHC class I presentation pathway of antigen presenting cells [23]. Active
targeting of influenza virosomes may therefore enhance antigen delivery to specific subsets of
antigen presenting cells (e.g. dendritic cells) in vivo.
In an attempt to demonstrate their cytosolic delivery capacity we have encapsulated the bacterial
toxin DTA inside antibody-targeted virosomes. No increased cytotoxicity of virosomal DTA over
free DTA was observed (results not shown).This can be ascribed to a poor encapsulation
efficiency of DTA into virosomes, which is inherent to the method of virosome preparation
(detergent removal at low lipid concentrations). In addition, loss of biological activity of DTA has
been reported when exposed to hydrophobic beads used to remove detergent during the
preparation of virosomes [24]. Due to the low amounts of virosome-associated DTA it was
impossible to determine the exact amount of incorporated DTA. It was estimated that
approximately 0.1% of the bacterial toxin was associated with targeted influenza virosomes.
Furthermore, as the influenza virosomes are prepared with a detergent with a low critical micelle
concentration (CMC) value, a relatively high amount of residual detergent monomers can be
expected to be present in the virosome membranes, which makes them permeable for DTA
leakage [25].
To circumvent the problems of low encapsulation efficiency and membrane instability a novel
method of virosome preparation was explored: HA proteins solubilized with short-chain PC
molecules (DCPC) were post-inserted into preformed liposomes (Chapter 4).The potential
advantage of this ‘post-insertion method’ is that liposome preparation techniques can be used that
allow high efficiency entrapment of water-soluble substances into stable liposomes. HA could be
functionally post-inserted in liposomes. However, the insertion process resulted in excessive
leakage of both small (calcein) as well as large (DNA) molecules from the liposomes. Hence,
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with this alternative method of virosome preparation the encapsulation of water-soluble
substances in virosomes was not improved. Nonetheless, efficient entrapment of drug molecules
inside virosomes prepared by the post-insertion method may be obtained by a remote loaded
procedure after removal of the short-chain PC molecules by dialysis.The high CMC value of
DCPC used for solubilization of HA in the post-insertion method allows efficient removal of
bilayer-associated detergent by dialysis in contrast to C12E8 used in the traditional method of
virosome preparation. As a result, the bilayers of virosomes prepared by the post-insertion
method are expected to be more stable and therefore better to sustain transbilayer gradients,
which may allow remote loading of these virosomes with drug molecules [26].
The use of pH-dependent fusion peptides represents another approach to obtain cytosolic
delivery of biotherapeutic molecules with IL. Synthetic peptides derived from viral fusion
proteins are expected to be less immunogenic than whole viral fusion proteins as they lack the
major antigenic determinants.This will be particularly true when these peptides are entrapped
inside liposomes. In addition to reduced immunogenicity, peptides have the advantage that they
can be readily synthesized at large scale without the need for laborious purification procedures.
Based on previously reported results [27], a dimerized synthetic peptide (diINF-7) resembling the
N-terminal fusion domain of the influenza virus hemagglutinin HA2 subunit was used to enhance
the endosomal escape of IL-entrapped compounds after endocytosis (Chapter 5). Liposome-
encapsulated diINF-7 peptides were able to induce release of co-encapsulated calcein from
liposomes upon exposure to pH 5.2. Likely, due to the hydrophobic nature of the peptide, part of
the encapsulated peptide is associated with the bilayer, which has induced the release of calcein
upon membrane destabilization at low pH. A more relevant observation was that liposome-
encapsulated diINF-7 peptides were able to induce release of calcein encapsulated in another set
of liposomes (devoid of peptide) at low pH.This suggests that the encapsulated diINF-7 peptides
destabilized the bilayers such that they facilitated their own release. Subsequently, released
peptides were able to destabilize the separate calcein-containing liposomes, resulting in the
observed calcein leakage. In line with these results, co-encapsulation of the fusion peptide
together with diphtheria toxin A chain into immunoliposomes resulted in specific cytotoxicity
towards OVCAR-3 cells whereas DTA-containing IL without co-encapsulated fusion peptides
were negligibly toxic. As DTA –which lacks the cell binding domain and membrane-translocation
domain– is only toxic to cells when delivered into the cytosol, the results indicate that co-
encapsulation of diINF-7 into IL can mediate endosomal escape of DTA after receptor-mediated
endocytosis. In conclusion, the results in chapter 5 clearly indicate that co-encapsulation of the
diINF-7 fusion peptide is a good strategy to obtain cytosolic delivery of drug molecules from
internalized immunoliposomes.
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CELL-SPECIFIC GENE DELIVERY
Chapter 6 demonstrates that cell-specific gene delivery to ovarian carcinoma cells can be
obtained by coating p(DMAEMA)-based polyplexes with an anionic lipid layer bearing conjugated
antibody fragments. As the lipid coat around these so-called lipopolyplexes (LPP) efficiently
shields the positive charge of polyplexes, the predominant electrostatic interaction with cell
membranes, which is unwanted for cell type-specific gene delivery, could be avoided. As LPP
without antibody did not show transfection, it can be concluded that the presence of a targeting
ligand on the immunolipopolyplexes (ILPP) is essential. In addition, the lipid coat around the
LPP provided protection of the polyplexes against destabilization by polyanions such as
poly(aspartic acid) and hyaluronic acid.This is expected to be essential for in vivo application of
LPP as naturally occurring polyanions have been shown to have detrimental effects on plain
polyplexes [28]. Preliminary in vivo testing of the ILPP yielded results, which are in good
agreement with this expectation.
The transfection efficiency of ILPP is relatively low compared to plain polyplexes under in vitro
transfection conditions.This can be ascribed to less efficient cellular uptake of ILPP via receptor-
mediated endocytosis compared to adsorption-mediated cellular uptake of plain polyplexes. Flow
cytometry analysis of fluorescently labeled polyplexes and ILPP has shown that cellular
association of polyplexes was much higher than ILPP. Moreover, the presence of the lipid-coat
around ILPP may hamper the release of DNA into the cytosol and subsequently the nucleus of
target cells. It is not well understood how DNA from p(DMAEMA)-based polyplexes can escape
from the endocytic vesicles after cellular uptake. In vitro experiments have demonstrated that
neither free p(DMAEMA) polymers nor p(DMAEMA)-based polyplexes were able to induce
erythrocyte hemolysis at low pH, indicating that polymer-induced endosomal membrane
disruption probably does not occur [29]. For another polymer used in non-viral gene delivery,
poly(ethyleneimine) (PEI), a proton sponge mechanism has been proposed: PEI buffers the
acidification in the endosomal/lysosomal vesicles resulting in osmotic swelling and subsequent
burst of endosomes/lysosomes [30]. In analogy with PEI, the proton sponge hypothesis may also
hold for p(DMAEMA)-based polyplexes, although no experimental evidence is available. Anyway,
intracellular release of the DNA from LPP is required either in the endocytic compartment or
after arrival in the cytosol. Disassembly of the lipid coat of LPP upon arrival in the acidic
endosomal compartment may be improved by incorporating non-bilayer forming lipids such as
dioleoylphosphatidylethanolamine (DOPE) into the lipid coat. Alternatively, synthetic fusion
peptides such as those discussed in chapter 5 may be co-encapsulated into the LPP to obtain low-
pH induced membrane destabilization. Clearly, additional research is needed to identify and
improve the rate-limiting step in non-viral gene delivery with LPP.
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CONCLUSION
In this thesis, a Trojan horse strategy with antibody-targeted liposomes has been followed to
obtain cytosolic delivery of biotherapeutics to tumor cells in vitro.This strategy involves targeting
of immunoliposomes to specific receptors on tumor cells that result in receptor-mediated uptake
of the immunoliposomes. Escape of immunoliposome-entrapped biotherapeutics from within the
endocytic compartment was realized by incorporating either influenza virus hemagglutinin
proteins or synthetic dimeric fusion peptides resembling the fusion peptide domain of influenza
virus HA into the immunoliposomes/virosomes.These molecules have membrane destabilizing
and fusion activity at low pH allowing passage of liposome-entrapped drug over the endosomal
membrane into the cytosol.Via the same cellular uptake route cationic polymer-condensed DNA
could be specifically delivered into ovarian carcinoma cells by encapsulating polyplexes into
antibody-targeted liposomes.The results demonstrate in vitro that liposomal delivery of
biotherapeutics into the cytosol of target cells via the route of receptor-mediated endocytosis and
subsequent endosomal escape is feasible and provide exciting new avenues to be explored in the
future.
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“Leuk zo’n boekje, maar wat heeft die jongen nou eigenlijk gedaan?”
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HET INFLUENZA VIRUS: VAN ZIEKTEVERWEKKER
TOT FARMACON TRANSPORTEUR 
Het influenza virus, de verwekker van de griep, teistert de mensheid al eeuwenlang.Tijdens de
grote ‘Spaanse griep’ pandemie van 1918 waren naar schatting wereldwijd 1 miljard mensen
besmet met het virus en stierven er binnen een periode van een jaar meer dan 20 miljoen
mensen aan influenza.Ter vergelijking: het aantal slachtoffers van de Eerste Wereldoorlog van
1914-1918 is geschat op 7 miljoen. Ook tegenwoordig veroorzaken influenza virussen nog bijna
jaarlijks epidemieën, ten gevolge waarvan aanzienlijk wat mensen overlijden.
Veel onderzoek is gedaan naar de manier waarop het influenza virus in staat is cellen van de
gastheer binnen te dringen en te infecteren. Dit proces is uitgebeeld in Figuur 1. Het virus is
Figure 1 — Schematische weergave van de infectiecyclus van het humane influenza virus. Virusdeeltjes komen via kleine
waterdruppeltjes in de luchtwegen terecht (a) waar ze kunnen binden aan het oppervlak van cellen die de luchtwegen bekleden (b).
Na binding aan siaalzuur worden de virusdeeltjes opgenomen in kleine blaasjes die afsnoeren van de celmembraan, de
zogenaamde endosomen (c). Doordat het milieu in de endosomen langzaam verzuurt, wordt het eiwit hemagglutinine van het virus
geactiveerd waardoor het het virusmembraan laat fuseren met het membraan van het endosoom (d). Het genetische materiaal van
het virus komt nu vrij in het cytoplasma van de cel (e). Via een ingewikkeld proces wordt de cel nu gedwongen aan de hand van
deze genetische code nieuwe virale eiwitten te gaan aanmaken (f,g,h). Deze virale eiwitten worden getransporteerd naar de
celmembraan (i), waar nieuwe virusdeeltjes afsnoeren van de celmembraan (j). Deze nieuwe virusdeeltjes kunnen vervolgens weer
andere cellen infecteren (k).
omgeven door een membraan die is opgebouwd uit lipiden (vetten) waarin eiwitten zijn
verankerd. Deze langwerpige eiwitten spelen een belangrijke rol bij het binnendringen van 
het virusdeeltje in het hart van de gastheercel, het cytoplasma. Eén van deze eiwitten, het
hemagglutinine, zorgt ervoor dat het virusdeeltje na verspreiding via kleine waterdruppeltjes in
lucht en na inademing kan hechten aan cellen die de luchtwegen bekleden (epitheelcellen).
Het hemagglutinine bindt aan suikerstructuren (siaalzuren) die voorkomen op het oppervlak van
epitheelcellen. Binding van virusdeeltjes aan deze suikerstructuren op de celmembraan resulteert
in instulping van de celmembraan en vervolgens afsnoering van een membraan-omgeven blaasje
met de virusdeeltjes daarin opgesloten. De zuurgraad binnenin deze blaasjes, de zogenaamde
endosomen, neemt toe naarmate de blaasjes verder de cel in getransporteerd worden. Het zure
milieu binnenin de endosomen zorgt ervoor dat het hemagglutinine van het influenza virus van
vorm verandert en daardoor in staat is het virusmembraan met het endosomale membraan te
laten versmelten (fuseren). Door deze membraanfusie komt het genetische materiaal (blauw-
druk) van het virus vrij in het cytoplasma van de gastheercel.Via een ingewikkeld proces wordt
nu de cel gedwongen de genetische code van het virus af te lezen en aan de hand van deze code
viruseiwitten te gaan aanmaken. De viruseiwitten worden naar de celmembraan getransporteerd
wat uiteindelijk resulteert in de afsnoering van nieuwe met membraan omgeven influenza virus-
deeltjes, die vervolgens weer andere cellen kunnen infecteren. Een cel die op deze manier
belaagd wordt is niet meer in staat zijn eigen functie naar behoren te vervullen en kan daardoor
zelfs afsterven. Deze celdood, samen met de uitwerkingen van het afweermechanisme van de
gastheer op de virusinfectie zorgen ervoor dat de geïnfecteerde persoon ziek wordt.
De manier waarop het influenza virus haar genetische materiaal met grote efficiëntie aflevert aan
epitheelcellen van de gastheer kan als voorbeeld dienen voor de gerichte afgifte van genees-
krachtige stoffen (farmaca) aan kankercellen met behulp van zogenaamde dragersystemen. Het
gebruik van dragersystemen voor de afgifte van farmaca in het cytoplasma van kankercellen is
vaak een noodzaak: veel farmaca, met name de nieuwe generatie van door de biotechnologische
industrie geproduceerde stoffen zoals eiwitten en DNA, kunnen niet uit zichzelf de celmembraan
passeren om zo het cytoplasma of andere compartimenten in de cel te bereiken waar ze hun
werking hebben. Deze farmaca zijn daarom afhankelijk van dragersystemen die, net als het
influenza virus, in staat zijn hun inhoud te legen in het cytoplasma van een bepaalde populatie
cellen (in dit geval kankercellen). Een veel gebruikt dragersysteem is het liposoom.
Liposomen zijn minuscuul kleine blaasjes gevuld met water die omgeven zijn door een membraan
bestaande uit een dubbele laag (bilaag) van fosfolipiden (Figuur 2). Fosfolipiden zijn moleculen
bestaande uit een hydrofiel gedeelte dat zich graag in water bevindt en een hydrofoob gedeelte
dat letterlijk vertaald ‘bang is voor water’.Wanneer zulke fosfolipiden in water worden gebracht
zullen deze moleculen zich zo rangschikken dat de hydrofobe gedeeltes zo min mogelijk in
aanraking zullen komen met water: ze vormen bilagen waarin de hydrofobe gedeeltes van de
fosfolipiden naar binnen steken. Aangezien de randen van deze bilagen ook niet graag
blootgesteld worden aan water zullen deze membranen van fosfolipide bilagen blaasjes vormen
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en zie hier, het liposoom is gevormd. Liposomen bevatten een waterige ruimte die afgesloten is
van de grote ruimte waarin zij zich bevinden. In deze waterige kern kunnen wateroplosbare
farmaca ingesloten worden terwijl vetoplosbare farmaca goed in de fosfolipide bilaag ingebouwd
kunnen worden. De grootte van liposomen kan variëren van 40 nanometer (er passen dan 25000
liposomen in rij op één millimeter) tot enkele micrometers (500-1000 liposomen op één
millimeter). Hoewel dit erg klein lijkt, zijn liposomen vergeleken met eiwitten relatief groot
waardoor ze niet in staat zijn na inspuiting de bloedbaan te verlaten. Echter, op plaatsen waar de
bloedvaatwand van nature gaten vertoont of beschadigd is, zijn kleine liposomen (<150
nanometer) in staat uit de bloedbaan te treden en het betreffende weefsel binnen te dringen.
Aangezien tumoren vaak van bloed voorzien worden door vaten die vele gaten vertonen, kunnen
deze liposomen daar uit de bloedbaan treden en ophopen in het tumorbevattende weefsel. Deze
eigenschap van liposomen wordt vaak gebruikt om celdodende stoffen selectief af te leveren aan
tumoren. Door bepaalde moleculen (antilichamen) die in staat zijn zeer specifieke structuren
(antigenen) op het oppervlak van kankercellen te herkennen te koppelen aan de liposomen
(Figuur 2) zijn deze antilichaamgestuurde liposomen, ook wel immunoliposomen genoemd, in
staat specifiek te binden aan kankercellen. De antilichaam-antigeen binding is zeer specifiek, net
zoals maar één type sleutel past op een slot. Op deze manier kan een grote hoeveelheid farmacon
Figure 2 — Schematische weergave van een liposoom als dragersysteem van farmaca. De membraan van liposomen bestaan uit
fosfolipiden die een bilaag vormen doordat ze hun hydrofiele kop naar de waterfase toe richten. De lipide membraan van
liposomen omsluit een waterig compartiment waarin water-oplosbare farmaca ingesloten kunnen worden. Tevens kunnen
vetoplosbare farmaca in de lipide membraan ingebouwd worden. Aan de bilaag kunnen vervolgens antilichamen gekoppeld worden
die bepaalde receptoren op kankercellen herkennen en hieraan kunnen binden.
ingesloten in liposomen in de buurt van kankercellen worden gebracht. Een overzicht van de
literatuur die het gebruik van immunoliposomen voor de specifieke afgifte van celdodende
stoffen aan kankercellen beschrijft, is gegeven in hoofdstuk 1 van dit proefschrift.
Het in de buurt brengen van farmaca bij kankercellen wil echter nog niet zeggen dat deze
farmaca daadwerkelijk beschikbaar zijn voor de kankercellen.Ter verduidelijking: het bezorgen
van de post door de postbode wil ook niet zeggen dat de geadresseerde de post meteen kan
lezen. Hiervoor moet de post eerst door de geadresseerde vanuit de postbus of brievenbus
binnengehaald worden, en vervolgens moet de envelop waarin de brief zich bevindt geopend
worden, voordat de informatie in de brief door de geadresseerde gelezen kan worden. Net zoals
de post moeten immunoliposomen met ingesloten farmaca, die met behulp van gekoppelde
antilichamen ‘geadresseerd’ zijn aan kankercellen voor efficiënte bezorging aan het juiste adres,
na binding door de desbetreffende kankercellen opgenomen worden.
Of een kankercel immunoliposomen opneemt is afhankelijk van het type kankercel en de
receptor waaraan het antilichaam van het liposoom bindt. Aangezien bij de behandeling van
kanker het ‘farmacon’ vaak bestaat uit een celdodende stof, wil men immunoliposomen die deze
celdodende stof bevatten alleen laten binden aan kankercellen en niet aan gezonde cellen.Vandaar
dat de keuze van receptoren op het oppervlak van kankercellen voor binding van
immunoliposomen beperkt blijft tot die receptoren die uitsluitend of voornamelijk vóórkomen
op het oppervlak van kankercellen.Tevens moeten de receptoren in staat zijn de gebonden
immunoliposomen op te nemen. In hoofdstuk 2 en de appendix bij hoofdstuk 2 wordt
gekeken naar 3 verschillende receptoren op kankercellen van de eierstokken en de long die
mogelijkerwijs in staat zijn immunoliposomen naar binnen te sluizen. Aangetoond wordt dat een
receptor die normaalgesproken groeihormonen de cel binnen brengt uitermate geschikt is om
immunoliposomen de cel in te transporteren.
Opname van farmacon bevattende liposomen door kankercellen alleen is echter niet genoeg: na
opname in de cel moet het liposoom zich ‘openen’ om zo het farmacon op de juiste plaats in de
cel (in veel gevallen het cytoplasma) af te leveren, waar het zijn werking kan uitoefenen. Helaas
is vaak gebleken dat cellen de immunoliposomen gebonden op het oppervlak van de cel wel
binnenhalen in endosoomblaasjes, maar vervolgens de liposomen met inhoud doorsluizen naar
andere blaasjes in de cel die stoffen (enzymen) bevatten welke in staat zijn de liposomen en het
ingesloten farmacon af te breken. Dit is natuurlijk ongewenst omdat zo het ingesloten farmacon
niet zijn werk kan uitoefenen.Terugkomend op het influenza virus zou het inbouwen van het
virale eiwit hemagglutinine in farmacon bevattende immunoliposomen een oplossing zijn om de
afbraak van het farmacon na opname van immunoliposomen in kankercellen te voorkomen.
Hoofdstuk 3 laat zien dat het mogelijk is liposomale dragersystemen te maken die zowel
gekoppelde antilichamen (nodig voor binding en opname van de liposomen) als functionele
hemagglutinine eiwitten (nodig voor membraanfusie na opname van de liposomen) bevatten.
Deze zogenaamde ‘fusogene’ immunoliposomen zijn gemaakt door membranen van het influenza
virus met daarin de hemagglutinine eiwitten op te lossen met zeep. Hierdoor wordt het virus
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geïnactiveerd en kan het genetische materiaal van het influenza virus verwijderd worden zodat
het zichzelf niet meer kan vermenigvuldigen. Aan de zeepoplossing, waarin zich de
virusmembranen en hemagglutinine eiwitten bevinden, worden antilichamen die gekoppeld zijn
aan fosfolipiden toegevoegd. Door op een speciale manier het zeep langzaam te verwijderen
vormen zich automatisch liposomen omdat de fosfolipiden zich nu weer gaan rangschikken in
bilagen. Deze liposomen bevatten zowel het hemagglutinine membraaneiwit als de antilichamen.
Omdat deze liposomen virale eiwitten bevatten worden ze ook wel virosomen genoemd.
Aangezien de methode van bereiding van het virosoom met behulp van zeep niet toelaat dat grote
hoeveelheden farmaca ingebouwd kunnen worden in de waterige kern van de virosomen is in
hoofdstuk 4 gekeken naar een andere manier van virosoombereiding. Hierbij wordt getracht
het eiwit hemagglutinine in te bouwen in voorgevormde liposomen waarin grote hoeveelheden
farmaca zijn ingesloten. Ons onderzoek toont aan dat de hemagglutinine eiwitten inderdaad
ingebouwd kunnen worden in de voorgevormde liposomen. De ingebouwde hemagglutinine
eiwitten zijn tevens functioneel: ze zijn in staat in een zuur milieu de membranen van virosomen
te laten fuseren met celmembranen. Echter, tijdens het inbrengen van de hemagglutinine eiwitten
in voorgevormde liposomen lekt de ingesloten wateroplosbare stof (in dit geval was dit geen
farmacon maar een fluorescerend stofje wat makkelijk te detecteren valt), uit de liposomen.
Ondanks dit ongewenste effect zijn de gevormde liposomen fusieactief en kunnen daarom goed
gebruikt worden voor de afgifte van bijvoorbeeld vetoplosbare farmaca (die wel in de liposomen
blijven) aan het cytoplasma van tumorcellen.
Door het inbrengen van hele hemagglutinine eiwitten in liposomen is men eigenlijk bezig
kunstmatig een virus na te bouwen met alle negatieve gevolgen van dien.Virussen worden
namelijk in meer of mindere mate herkend door het afweersysteem van de gastheer. Dit
zogenaamde immuunsysteem is in staat vreemde indringers (bijvoorbeeld bacteriën, virussen en
vreemde cellen) in het lichaam te herkennen en deze te vernietigen. Zo worden ook de
hemagglutinine eiwitten van het influenza virus herkend door het immuunsysteem waardoor het
virus na verloop van tijd door het immuunsysteem kan worden vernietigd. Aangezien de
dragersystemen ontwikkeld in hoofdstuk 3 en 4 hemagglutinine eiwitten bevatten, zullen ook
deze dragersystemen na inspuiting in de bloedbaan uiteindelijk herkend worden door het
immuunsysteem en afgebroken worden.Vandaar dat in hoofdstuk 5 gebruik is gemaakt van een
klein gedeelte van het hemagglutinine eiwit waarvan bekend is dat het membraanfusie in zuur
milieu kan induceren, maar waarvan verwacht wordt dat het veel minder goed (of helemaal niet)
door het immuunsysteem van de mens herkend zal worden. Deze zogenaamde influenza
fusiepeptiden zijn ingesloten in immunoliposomen samen met een celdodende stof (DTA). DTA
moet in het cytoplasma van de kankercellen worden afgegeven om werkzaam te zijn.Toevoeging
van DTA aan de buitenkant van de cel heeft geen enkel effect. Na binding en opname van de
immunoliposomen aan eierstokkanker cellen, komen de immunoliposomen in de endosoom-
blaasjes van de cel terecht. In het zure milieu van de endosoomblaasjes worden de ingesloten
fusiepeptiden geactiveerd waardoor de membranen van de opgenomen liposomen fuseren met 
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de membranen van de endosomen om zo de DTA moleculen af te geven in het cytoplasma van 
de kankercellen. Aangetoond is dat alleen immunoliposomen die zowel de fusiepeptiden als de
celdodende stof bevatten in staat zijn de kankercellen te doden, terwijl immunoliposomen die
alleen de celdodende stof bevatten daartoe niet in staat zijn.
Het laatste hoofdstuk van dit proefschrift, hoofdstuk 6, gaat over de afgifte van genetisch
materiaal aan kankercellen. Informatie over hoe de cel een eiwit moet bouwen (de
blauwdrukken) is opgeslagen in genen. Ieder gen codeert voor een ander eiwit. In plaats van het
inbrengen van geneeskrachtige eiwitten in zieke cellen om zo de cel te genezen, is het ook
mogelijk het gen coderend voor deze geneeskrachtige eiwitten in te brengen. Het voordeel
hiervan is dat de zieke cel die dit gen opneemt zelf in staat wordt gesteld over een lange periode
het geneeskrachtige eiwit aan te maken.Wanneer men genen (DNA) met therapeutische werking
in zieke cellen brengt is men bezig met gentherapie. Net als vele eiwitten is DNA door zijn
omvang en lading zelf niet in staat de zieke cellen binnen te dringen.Tevens is DNA buiten en in
de cel erg gevoelig voor afbraak door speciale enzymen. Het DNA moet dus beschermd en in
staat gesteld worden cellen binnen te dringen. In ons laboratorium is een polymeer ontwikkeld
dat in staat is het DNA te verkleinen tot een bolletje. Een polymeer is een keten van repeterende
moleculen. Dit is te vergelijken met een kralenketting die is opgebouwd uit dezelfde kralen
(parelketting). Het DNA vormt een complex met het polymeer aangezien de negatieve ladingen
van het DNA aangetrokken worden door de positieve ladingen van het polymeer, waardoor
kleine positief geladen deeltjes ontstaan, de zogenaamde polyplexen. Het DNA gecomplexeerd in
deze polyplexen is goed beschermd tegen afbraak door enzymen.Tevens hechten deze polyplexen
goed aan negatief geladen celmembranen doordat ze positief geladen zijn. Door deze hechting
worden de polyplexen opgenomen door de cellen.Vervolgens komt het DNA vrij in de cel op
een manier die niet geheel bekend is. Dit DNA kan door de zieke cel afgelezen worden om zo
het therapeutische eiwit aan te maken. Het probleem van deze opname is echter dat het niet
specifiek is. Alle cellen hebben negatief geladen celmembranen waardoor de polyplexen door vele
cellen opgenomen zullen worden. Dit is ongewenst omdat alleen de zieke cellen de genen dienen
op te nemen.Vandaar dat wij in hoofdstuk 6 deze polyplexen hebben ingebouwd in
immunoliposomen. Door polyplexen in te bouwen wordt de positieve lading van de polyplexen
afgeschermd zodat ze niet meer aspecifiek aan de celmembranen kunnen ‘kleven’.Vervolgens
kan, met behulp van specifieke antilichamen op het oppervlak van deze immunoliposomen,
specifieke binding aan kankercellen van de eierstokken bewerkstelligd worden. Aangetoond is dat
op deze manier de genen gecomplexeerd in de polyplexen en ingebouwd in immunoliposomen
aan kankercellen van de eierstokken worden afgegeven en niet aan andere cellen.Tevens zijn de
polyplexen ingebouwd in liposomen (ook wel lipopolyplexen genoemd) beter bestand tegen
ongewenste destabilisatie door negatief geladen eiwitten.
Concluderend kunnen we zeggen dat immunoliposomen met ingebouwde virale fusie-eiwitten of
fusiepeptiden kunnen dienen als dragersystemen voor de bezorging van biotechnologische
eiwitten en DNA in het cytoplasma van kankercellen. Deze cytoplasmatische dragersystemen zijn
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echter alleen nog getest op losse cellen in kweekbakjes in het laboratorium.Toekomstig
onderzoek zal moeten uitwijzen of deze dragersystemen ook hun werk kunnen doen in
proefdieren en in een nog later stadium de mens.
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ABBREVIATIONS
BSA Bovine serum albumin
CD circular dichroism
CHOL cholesterol
CLSM confocal laser scanning microscopy
DiD 1,1’-dioctadecyl-3,3,3’,3’- tetramethylindodicarbocyanine perchlorate 
diINF-7 dimerized synthetic influenza virus fusion peptide
DNA deoxyribonucleic acid
DSPE distearoyl phosphatidylethanolamine
DT diphtheria toxin
DTA diphtheria toxin A chain
DTT dithiothreitol
EGFR epidermal growth factor receptor
EGP-2 epithelial glycoprotein-2
EPC egg phosphatidylcholine
EPE egg phosphatidylethanolamine
EPG egg phosphatidylglycerol
Fab’ Antigen binding antibody fragment
FCS fetal calf serum
FIL fusogenic immunoliposomes
FITC fluorescein isothiocyanate
FL fusogenic liposomes
HA hemagglutinin
HBS HEPES-buffered salt solution
HEPES 4-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid]
HyAc hyaluronic acid
i.p. intraperitoneal
i.v. intravenous
ICAM-1 intercellular cell adhesion molecule-1
IF immunofluorescence
IgG immunoglobulin type G
IL immunoliposomes
ILPP immunolipopolyplexes
LM light microscopy
LPP lipopolyplexes
mAb monoclonal antibody
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MES 2-[N-morpholino]ethanesulfonic acid
MPB-PE maleimide-4-(p-phenylbutyryl)-phosphatidylethanolamine
MWCO molecular weight cut-off
NA neuraminidase
OG octyl glucoside
ONPG o-nitrophenyl-b-D-galactopyranoside
p(Asp) poly(aspartic acid)
p(DMAEMA) poly(2-dimethylamino)ethylmethacrylate
PBS phosphate-buffered salt solution
pCMVLacZ plasmid vector containing the gene encoding for ?-galactosidase under
the control of the CMV promoter
pDNA plasmid DNA
PEG poly(ethylene glycol)
PHEPC partially hydrogenated egg phosphatidylcholine
PI-virosomes Post-insertion virosomes
PL phospholipid
PyrPC (1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphocholine)
Rho-PE L-a-phosphatidylethanolamine–N-(lissamine rhodamine B sulfonyl)
SATA N-succinimidyl-S-acetylthioacetate 
SDS-PAGE sodium dodecyl sulphate –poly(acrylamide) gel elecrophoresis
TL total lipid
XTT sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-
nitro)benzene sulfonic acid hydrate
∆ε difference in molar absorbance
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